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 1INTRODUCTION
The gastrointestinal (GI) tract is a unique organ which requires coordinated movements 
of its neuromuscular apparatus, as well as fluid secretion for the mixing and propulsion of 
food, for breaking down complex food particles during digestion, and for absorption and 
excretion. It consists of many specialised regions, which all must remain connected and 
function optimally. Over the last several decades, significant advances have been made in 
our understanding towards normal development and physiology of the GI tract (Huizinga, 
Thuneberg et al. 1995, Silberg, Swain et al. 2000, Burns, Pasricha et al. 2004, He, Zhang 
et al. 2004, Sancho, Batlle et al. 2004). 
 For example, we currently know that this sophisticated system is made of cells 
that are derived from all three different embryonic germ layers, the ectoderm, mesoderm 
and endoderm. The epithelial lining of the GI tract is derived from the endoderm, while the 
smooth muscle cells are derivatives of the mesoderm. Enteric neurons and glia are formed 
from neural crest cells, derivatives of the ectoderm (de Santa Barbara, van den Brink et 
al. 2003, McLin, Henning et al. 2009, Goldstein, Hofstra et al. 2013). The epithelial lining 
of the intestine mainly functions in nutrient absorption. Meanwhile, coordination between 
muscular and neuronal structures of the intestine underlies intestinal contractility. Collective 
and continuous works from all of these cell types are pivotal to maintain normal physiology. 
Thus, failure in any of the developmental processes necessary for the formation of the GI 
tract can result in life-threatening congenital diseases. 
 Although recent advances in medical care and diagnostics have offered 
significant improvements in the prognosis of patients with GI disorders/diseases, some 
of these, such as megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS), 
hereditary multiple intestinal atresia (HMIA) and congenital short bowel syndrome (CSBS), 
remained lethal for the majority of patients or are even universally fatal. Thus, improvement 
in diagnostics and therapy of these diseases are urgently needed to provide a better 
prognosis for the patients and their family. Nonetheless, efforts to advance therapy for 
patients with these diseases have been hampered primarily by our limited understanding 
of their pathogenesis and the intrinsic morbidity related to potential treatment options. 
 Based on the lethality of these congenital diseases of the intestine, and the lack 
of knowledge towards their pathogenesis, we focused our research on MMIHS, CSBS and 
HMIA. Since these diseases are inherited a better understanding might start by identifying 
their genetic cause. Currently, finding disease-causing genes has been greatly facilitated 
by the rapid progress in technologies such as next generation sequencing (NGS). 
Moreover, further testing of identified candidate genes by genome editing techniques (in 
animal models) is currently making forward genetic studies possible. Thus, by utilizing 
these state-of-art methodologies in genetics, we can unravel the pathogenesis of these 
diseases. Moreover, since all three are diseases of the newborn, our research may also 
enlighten our knowledge towards the development and physiology of the intestine. 
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MEGACYSTIS MICROCOLON INTESTINAL HYPOPERISTALSIS SYNDROME
Clinical Presentation
Megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS) is arguably the most 
severe cause of intestinal and bladder obstruction in neonates, characterized by severely 
reduced contractility of these visceral organs (White, Chamberlain et al. 2000, Puri and 
Shinkai 2005). Berdon et al. first reported the disease in 5 newborns, including 2 sibs 
(Berdon, Baker et al. 1976), indicating genetic abnormality as a probable cause of this 
devastating syndrome. 
 In majority of the cases, the bladder abnormality starts to manifest in the prenatal 
period, hence a routine 20-week ultrasonography examination often reveals bladder 
distension. Another MMIHS-related prenatal complication often reported is polyhydramnios 
(Vintzileos, Eisenfeld et al. 1986, Garber, Shohat et al. 1990, Hsu, Craig et al. 2003, 
Cuillier, Cartault et al. 2004, Hellmeyer, Herz et al. 2013, Tuzovic, Anyane-Yeboa et al. 
2014). At birth, MMIHS patients usually present with abdominal distension due to bladder 
hypocontractility, inability to urinate, and signs of intestinal obstruction, such as bilious 
vomiting. The presence of microcolon can be identified through barium enema test and/or 
surgery (Clark and O’Connor 2007) (Fig. 1). 
Fig.1: Prenatal USG and neonatal barium enema test in patient with MMIHS. showing a distended 
bladder and bilateral hydronephrosis. Barium enema test in the same patient identifies microcolon.
In addition to the main characteristics of MMIHS, a list of associated symptoms has been 
reported, including hydronephrosis, malrotation, Meckel’s diverticulum, duodenal web and 
lax abdominal wall (Patel and Carty 1980, Lorenzo, Twickler et al. 2003, Levin, Soghier 
et al. 2004, Puri and Shinkai 2005, Akhtar, Alladi et al. 2012). Hydronephrosis might be 
secondary to the inability of the bladder to excrete urine, but the explanation for most of 
the other associated symptoms is not yet available. Aganglionic megacolon has also been 
reported in one case (Chamyan, Debich-Spicer et al. 2001). All these reports show a wide 
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 1range of clinical anomalies that might be featured in patients with MMIHS.
 Overall, diagnosing MMIHS, in clinical practice, is challenging, especially since 
several other diseases have similar clinical signs, such as visceral myopathy, intestinal 
pseudo-obstruction, posterior urethral valve (PUV) obstruction, and prune belly (Schuffler, 
Pagon et al. 1988, Peters, Bolkier et al. 1990, Ghavamian, Wilcox et al. 1997). Even with 
the revelation of microcolon, it is still possible that the intestinal and bladder symptoms 
are separate entities that are caused by different etiologies. Thus, elucidating the genetic 
etiology of this syndrome is important to provide a reliable parameter that will help clinicians 
to confirm the diagnosis of MMIHS.    
Histopathology
As contraction of the bladder and the intestine requires the coordinated action of smooth 
muscle cells, neurons and interstitial cells of Cajal (al-Rayess and Ambler 1992, Rolle, 
O’Briain et al. 2002, Piotrowska, Rolle et al. 2003, Piaseczna Piotrowska, Rolle et al. 
2004, Szigeti, Chumpitazi et al. 2010), it is logical to think that failure of contraction is the 
result of alterations in any (or a combination) of these three cell types. Therefore, it is not 
surprising that initial histopathology analyses in specimens from MMIHS patients came 
up with various conclusions that could fit the pathogenesis of MMIHS. In many patients, 
a neuropathy was excluded (Puri and Shinkai 2005). However, some reports identified 
decreased to absence of ganglia (Vezina, Morin et al. 1979, Young, Yunis et al. 1981), 
while others reported increased number of ganglia (Berdon, Baker et al. 1976), and one 
report suggested axonal dystrophy as the cause of MMIHS in one patient (al-Rayess and 
Ambler 1992). Abnormal interstitial cells of Cajal has also been reported (Piotrowska, Rolle 
et al. 2003, Piaseczna Piotrowska, Rolle et al. 2004), while some reported MMIHS as a 
congenital myopathy of the visceral organs (Rolle, O’Briain et al. 2002). These differences 
in the interpretation of the histological findings may indicate that different factors can lead 
to the clinical symptomology of MMIHS. 
Treatments and Prognosis
Until now, all treatments for patients with MMIHS can be categorized as symptomatic. 
Surgery to remove the defective intestine, catheterization and total parenteral nutrition 
(TPN) to feed the patient are the main potential treatment modalities. Despite numerous 
efforts and reports of long term survival, most MMIHS patients do not survive their early 
years of life (Gosemann and Puri 2011). Furthermore, in cases where patients survive, 
morbidities related to long-term use of parenteral nutrition and catheterization have been 
reported (Hirato, Nakazato et al. 2003). Multivisceral transplantation is the last line of 
treatment for MMIHS patients (Masetti, Rodriguez et al. 1999, Loinaz, Mittal et al. 2004), 
although not every patient will have the opportunity to become the multi organ recipient, 
and the patients who have the transplantation have a grave risk of immune rejection (Wu, 
Selvaggi et al. 2011).
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Genetics
Since the first publication from Berdon et al., more than 250 MMIHS cases have been 
reported. Most of these were sporadic, however some were considered familial, as they 
were born from consanguineous parents. Therefore, MMIHS has been suggested to be 
an inherited disease with an autosomal recessive pattern of inheritance. In the beginning 
of our study on MMIHS (2012), only a deletion of chromosome 15 (15q11) (Szigeti, 
Chumpitazi et al. 2010) and a trisomy of chromosome 18 (Chamyan, Debich-Spicer et al. 
2001) had been reported in two separate cases. No other DNA aberrations were described. 
Besides these chromosomal abnormalities, one candidate gene was reported, α3 nAChR. 
Knockout of the α3 nicotinic acethylcoline receptor (α3 nAChR) subunit in mice resulted in 
a MMIHS like phenotype. Richardson et al. performed immunostaining on specimens from 
10 patients with MMIHS using an antibody against the α3 nAChR subunit, and observed a 
significant decrease in protein expression (Xu, Gelber et al. 1999, Richardson, Morgan et 
al. 2001). Nonetheless, no disease-causing variants in the gene that encodes α3 nAChR 
have been reported in MMIHS patients to date.   
CONGENITAL SHORT BOWEL SYNDROME
Clinical Presentation
Congenital short bowel syndrome (CSBS) is a very rare congenital disease, characterized 
by an extremely short small intestine (Hamilton, Reilly et al. 1969). Comparing the intestines 
of normal and CSBS neonates, delivered at term (>35 weeks), the small intestine in the 
normal neonate is approximately 250 cm in length, while the length of small intestine 
in CSBS neonates is approximately 50 cm. Despite this obvious anatomical defect, the 
intestine in most CSBS patients is not obstructed. Thus, the abnormality may remain 
undetected for several days or weeks. 
 The length of small intestine correlates with the available area for digestion 
and absorption (Cheng, O’Grady et al. 2010), hence this severe shortening results in a 
failure of these functions. Consequently, patients with CSBS usually present with chronic 
dehydration, chronic diarrhea, malnutrition and failure to thrive. The diagnosis can be 
confirmed by a barium enema test, or by exploratory laparotomy (Kern, Leece et al. 1990, 
Schalamon, Schober et al. 1999, Sabharwal, Strouse et al. 2004, Hasosah, Lemberg et al. 
2008).    
 In all CSBS cases, the intestine is malrotated. Volvulus has been identified in 
four patients (Tanner, Smith et al. 1976, Kern, Leece et al. 1990), while the appendix 
was absent in three (Iwai, Yanagihara et al. 1985, Sarimurat, Celayir et al. 1998). In most 
cases, no additional intestinal phenotypes were identified. However, minor dysmorphic 
features and patent ductus arteriosus coexisted in a few patients (Royer, Ricour et al. 
1974, Sansaricq, Chen et al. 1984).
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 1Histopathology
Histology from the intestine of CSBS patients is not always available. However, a few 
cases were reported and no abnormal histological findings were described. In three CSBS 
patients, who also suffered from functional intestinal obstruction, histopathology analyses 
revealed decreased numbers of argyrophilic neurons in the ganglia of the intestine (Tanner, 
Smith et al. 1976). In line with these early findings, neuronal dysplasia was found in one 
other CSBS patient.
Treatments and Prognosis  
As a consequence of the failure to digest and absorb nutrients, TPN is an imperative 
treatment for CSBS patients. Ideally, TPN is temporarily prescribed until the intestinal 
length and function are retained/improved sufficiently. However, 75% of CSBS patients die 
of starvation or sepsis in their first few days of life. Nonetheless, the survival rates of CSBS 
patients has increased in the last two decades, arguably due to the recent developments 
in TPN. The oldest patient we are aware of is currently approximately 30 years of age 
(patient 4 in van der Werf, Wabbersen et al. 2012) 
Genetics
Familial cases make up around 60% of all CSBS cases. Within these familial cases both 
sexes are equally affected, and consanguinity is described, hence, an autosomal recessive 
pattern of inheritance has long been suggested. Besides the presumed recessive forms of 
CSBS, an X-linked form of CSBS was also suggested. Recently, these hypotheses were 
confirmed by the discovery of disease-causing variants in CLMP as the cause of recessive 
CSBS and variants in FLNA as the cause of the X-linked form of CSBS (Van Der Werf, 
Wabbersen et al. 2012, van der Werf, Sribudiani et al. 2013).   
HEREDITARY MULTIPLE INTESTINAL ATRESIA
Clinical Presentation
Intestinal atresia (IA) makes up approximately thirty percent of the causes of intestinal 
obstruction in neonates (Hajivassiliou 2003). IA is characterized by a discontinued lumen 
of the intestine at one or multiple sites. As a consequence, patients with IA are not able to 
digest food, hence lethality is the definitive outcome unless corrections of the atretic sites 
are performed in the newborn period (Dalla Vecchia, Grosfeld et al. 1998).
 Based on the number of the atretic sites and the type of the discontinuity itself, IA 
can be categorized into 4 different types. In IA type I, although the intestinal tube seems 
to be connected, the lumen inside of it is disrupted. IA type II refers to a disconnected 
intestinal tube, without any mesenteric defect. Based on the size of the mesenteric defect 
and the existence of intestinal malrotation, IA type III can be divided into 2 subtypes. The 
mesenteric defect is restricted to the atretic site in type IIIa, while most of the mesentery 
is absent in type IIIb. Since the mesentery also functions as a supporting structure for the 
16
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intestine, the intestine in IA type IIIb is often malrotated, causing an appearance often 
referred to apple-peel-like. Lastly, IA type IV consists of atresia of any type I, II, III or a 
combination of these, at multiple sites of the intestine, referred to as multiple intestinal 
atresia (MIA) (Fig. 2).
 Compared to the other types of IA, MIA is the rarest, yet the most lethal type of IA. 
During pregnancy, ultrasonography (USG) on MIA can identify abdominal distension, with 
multiple dilated intestinal loops. At the postnatal period, a characteristic X-ray, a so-called 
double-bubble sign, can be indicative, in which the first larger bubble is the stomach, and 
the second smaller bubble is the dilated proximal duodenum (Ali, Rahman et al. 2011). 
Nonetheless, it is difficult to distinguish this from classical duodenal atresia cases. Thus, 
the information cannot differentiate the different types of IA, and the exact diagnosis can 
only be confirmed during surgery. 
Fig.2: Illustration of different types of intestinal atresia. In type I and II, the lumen of the intestine 
is disrupted, but there is no defect in the mesentery. Meanwhile, defect in the mesentery is identified 
in type IIIa, while larger mesentery defect is found in type IIIb, causing volvulus of the intestine. Type 
IV consists of atretic intestine in more than 1 site.
 Many familial cases of MIA have been reported, hence they are often referred 
to as hereditary multiple intestinal atresia (HMIA). In addition to the intestinal phenotype, 
many HMIA patients have been described to also have a severe immune deficiency 
(Gahukamble and Gahukamble 2002, Bilodeau, Prasil et al. 2004, Gilroy, Coccia et al. 
2004, Ali, Rahman et al. 2011). The prevalence of this unique combination of comorbidities 
in hereditary MIA highlights the possibility that the two entities are caused by one common 
genetic aberration. Hence, unraveling the genetic etiology of this disease might be an 
entry point in understanding the pathogenesis of HMIA.  
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 1Histopathology
In patients diagnosed with HMIA combined with severe immune deficiency, multiple 
separate lumens, that are lined up with separate mucosa, were described. This is often 
described as a sieve-like appearance. Many of the lumens from this atretic site are 
filled with calcified substances and cell debris, while the mucosal villi appear shorter or 
flattened. Although these individual lumens are lined/connected by separate mucosa and 
its muscularis mucosa, they are all surrounded by common layers of submucosal and 
mucularis propria of the intestine (Fig. 3). At the time we initiated this project, there were 
no descriptions about the histopathology of immune-related organs probably due the low 
prevalence of this combination of anomalies.
Fig.3: H&E staining in intestinal specimens from control and HMIA patient. Multiple lumen in the 
atretic site of the intestine is a common feature found in HMIA.
Treatments and Prognosis
Surgical resection of the affected intestinal sites is a mandatory treatment for HMIA. 
After surgery, patients are usually dependent on long term TPN until intestinal function 
is restored sufficiently. The general conditions of HMIA patients, who also have severe 
immune deficiency, usually deteriorate due to the many infections they suffer from. 
Therefore, intestinal transplantation is considered as an alternative treatment to restore 
intestinal function. Despite all efforts, mortality rates of HMIA remain close to 100%, with 
only one reported patient surviving long term (Fischer, Friend et al. 2014).     
Genetics
Consanguinity was described in many of the familial cases. This strongly suggests that 
HMIA is an inherited disease with an autosomal recessive pattern of inheritance. No genes 
were reported at the start of this project (2012).
 
18
Chapter 1
Overall aim 
All research described in this thesis is focused on understanding the pathophysiology 
of these three rare congenital diseases of the intestine. For MMIHS and IA, we follow 
a comparable path, starting a search for the genetic cause of the disease by SNP 
arrays and or exome sequencing. Subsequently, after identifying the candidate genes, 
we performed both in vitro and in vivo assays to prove causality and to determine the 
mechanism underlying disease development. For CSBS we performed mutation analysis 
of the already known gene and perform functional work to unravel disease mechanism.  
THESIS AIM AND OUTLINE
The prevalence of MMIHS, HMIA and CSBS in siblings, and the fact that most of the 
familial cases are from consanguineous families, strongly suggest that these congenital 
intestinal diseases have a genetic origin. The aim of the studies described in this thesis is 
to identify the genetic etiologies of these lethal diseases, and use these findings to unravel 
the disease pathogenesis.
Outline
Most cases of MMIHS are sporadic. In the study described in Chapter 2, we performed 
a genetic screening in 8 patients with sporadic MMIHS, and identified disease-causing 
heterozygous missense variants in all patients in the gene for enteric smooth muscle actin 
γ-2 (ACTG2). Using intestinal specimens from controls and three patients, we assessed 
the gene expression patterns during normal development of the human intestine, and 
determined the effect of the variants on the pathology of patients’ intestines. Molecular 
modeling and a series of in vitro studies, using cell lines, were performed to investigate the 
mechanisms underlying how the identified variants could lead to sporadic MMIHS.
 In Chapter 3, we present a genetic study on one MMIHS patient from a 
consanguineous family. To do so, homozygosity mapping and whole exome sequencing 
were utilized. A nonsense mutation in Leiomodin-1 (LMOD1) was identified in the patient. 
To confirm the involvement of LMOD1 in MMIHS our collaborators created a Lmod1 
knockout mouse model. Similar phenotypes in the KO mice, resembling MMIHS in human, 
were revealed. To investigate the molecular pathogenesis of this disease, primary human 
intestinal smooth muscle cells were used in a series of in vitro assays.
 Despite our findings in both sporadic and familial MMIHS cases, the genetic 
etiology in three MMIHS patients from two separate consanguineous families are yet to be 
identified. In Chapter 4, we describe the identification of two disease-causing-variants in 
myosin light chain kinase (MYLK) as the cause of MMIHS in the two remaining families. 
In one family, a duplication of 7-bp in exon 22 led to an out-frame-mutation that resulted 
in loss of MYLK expression in the patient’s intestine and bladder specimens. In the other 
family, a splice-site variant in intron 22 was identified. Mini-gene analysis showed that the 
variant identified disturbed the splice site in such a way that exon 21 was not recognized 
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 1by the splice machinery. Immunohistochemistry was performed to study the effect of the 
out-of-frame mutation on the pathology of the patient’s intestine and bladder specimens.
 An overview of the literature on CSBS is given in Chapter 5. This overview 
particularly focuses on the recent genetics findings, in which mutations in Coxsackie- 
And Adenovirus Receptor-Like Membrane Protein (CLMP) and Filamin A (FLNA) were 
identified in CSBS patients. We speculate on how the protein products from these two 
genes are involved in the tight junction complex. Additionally, a summary of knockout 
mouse models with a CSBS phenotype is included.
 In Chapter 6, we describe the identification of a homozygous nonsense variant 
and compound heterozygous variants in two CSBS families. These findings validate CLMP 
as the disease-causing gene of CSBS, as previously reported.
 FLNA was previously reported as the disease-causing gene for the X-linked 
form of CSBS. Based on this recent finding, we generated a flna knockout zebrafish 
model. Characterization and functional studies on this zebrafish model are presented in 
Chapter 7.
 HMIA is the familial form of MIA, and an autosomal recessive pattern of 
inheritance has been suggested. In Chapter 8, a homozygous deletion of the entire exon 
2 in tetratricopeptide-7A (TTC7A) was identified in two patients from a consanguineous 
family. Immunohistochemistry was performed to assess the effect of this mutation on the 
intestinal pathology from both patients. In addition, a ttc7a knockout zebrafish model was 
generated to study the effect of the loss of ttc7a on the structure and function of the 
zebrafish intestine.
 A general discussion, including future perspectives, is presented in Chapter 9.
Together, the work in this thesis provides new information that extend our knowledge on 
the nature and pathogenesis of these congenital diseases of the intestine. Our data can 
be used in genetic counseling, and also in further research to design therapies for the 
patients.
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ABSTRACT 
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS) is a rare congenital 
disorder, in which heterozygous missense variants in the Enteric Smooth Muscle actin 
γ-2 (ACTG2) gene have been recently identified. To investigate the mechanism by which 
ACTG2 variants lead to MMIHS, we screened a cohort of eleven MMIHS patients, eight 
sporadic and three familial cases, and performed immunohistochemistry, molecular 
modelling and molecular dynamics (MD) simulations, and in vitro assays. In all sporadic 
cases, a heterozygous missense variant in ACTG2 was identified. ACTG2 expression was 
detected in all intestinal layers where smooth muscle cells are present in different stages 
of human development. No histopathological abnormalities were found in the patients. 
Using molecular modelling and MD simulations, we predicted that ACTG2 variants lead 
to significant changes to the protein function. This was confirmed by in vitro studies, 
which showed that the identified variants not only impair ACTG2 polymerization, but also 
contribute to reduced cell contractility. Taken together, our results confirm the involvement 
of ACTG2 in sporadic MMIHS, and bring new insights to MMIHS pathogenesis.        
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INTRODUCTION
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS) (OMIM 249210) is 
the most severe form of intestinal obstruction in neonates. It was first reported by Berdon 
et al in 1976, and is characterized by non-obstructive bladder distension, microcolon, 
and decreased or absent intestinal peristalsis (Berdon, Baker et al. 1976). MMIHS is a 
rare congenital disorder for which surgical intervention is normally required. However, 
this frequently results in futile therapy without improvement of the clinical symptoms. 
Pathological evaluation of intestinal biopsies collected from patients have resulted in 
different theories regarding the underlying cause of MMIHS. Some reports suggested a 
muscular problem (Ciftci, Cook et al. 1996, Rolle, O'Briain et al. 2002, Szigeti, Chumpitazi 
et al. 2010), while others stated that the main defect was neuronal with both increased 
and decreased number of neurons being detected (Kubota, Ikeda et al. 1989, Richardson, 
Morgan et al. 2001, Narayanan, Murphy et al. 2007). Abnormalities of the interstitial cells of 
Cajal have also been associated with MMIHS pathogenesis (Piotrowska, Rolle et al. 2003, 
Piaseczna Piotrowska, Rolle et al. 2004). However, most of these findings were obtained 
in one or a few number of patients using different methods and consensus regarding 
pathogenesis does not exist. 
 Familial appearance and parental consanguinity have been previously reported 
for MMIHS suggesting that it is an autosomal recessive disorder (Anneren, Meurling et al. 
1991, McLaughlin, Gooch et al. 1993). However, since most MMIHS cases are sporadic, 
it seems reasonable to hypothesize that locus heterogeneity exists, and that the genetic 
etiology of sporadic and familial MMIHS cases may differ. Recently, this hypothesis has 
been confirmed by the identification of pathogenic variants in two genes: the Enteric 
Smooth Muscle Actin γ-2 (ACTG2) gene, and the smooth muscle myosin heavy chain 
(MYH11) gene. Heterozygous missense variants in ACTG2 were identified as the cause of 
sporadic MMIHS in three independent studies (Thorson, Diaz-Horta et al. 2014, Tuzovic, 
Anyane-Yeboa et al. 2014, Wangler, Gonzaga-Jauregui et al. 2014), while a homozygous 
missense variant in MYH11 was identified in a newborn patient of consanguineous 
descent (Gauthier, Ouled Amar Bencheikh et al. 2014). ACTG2 encodes one of the six 
actin isoforms present in humans and is specifically expressed in smooth muscle cells of 
the intestinal and urogenital tracts (Miwa, Manabe et al. 1991, Szucsik and Lessard 1995, 
Thorson, Diaz-Horta et al. 2014). MYH11 encodes for the myosin heavy chain protein, one 
of the components required for smooth muscle contraction. Loss of Myh11 in mice has 
been reported to result in a bladder and intestinal phenotype reminiscent to the one seen 
in MMIHS patients (Morano, Chai et al. 2000), supporting the involvement of this gene in 
MMIHS pathogenesis. 
 Interestingly, heterozygous missense variants in ACTG2 have also been 
described to cause another intestinal disorder, i.e. Visceral Myopathy (VM; OMIM 155310). 
Four families were reported with heterozygous ACTG2 variants affecting three different 
residues: R40 (missense), R148 (missense), and G269 (tandem base substitution) 
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(Lehtonen, Sipponen et al. 2012, Wangler, Gonzaga-Jauregui et al. 2014, Klar, Raykova 
et al. 2015). Since MMIHS and VM are mainly characterized by inadequate contractility 
of the intestine and variable levels of bladder dysfunction (severe in MMIHS and often 
mild in VM), it is not surprising that the same gene is involved in the pathogenesis of both 
disorders. However, it raised the hypothesis that MMIHS and VM are one disease entity 
with different spectrums of severity. 
 Despite the identification of ACTG2 as a disease-causing gene for MMIHS, it is 
still unclear how variants in ACTG2 lead to its development. In this study, we confirm the 
involvement of ACTG2 in MMIHS, and bring new molecular insights into the mechanism 
associated with the pathogenesis of this disease. 
MATERIALS AND METHODS
Patient information
In this study, a cohort of eleven MMIHS patients was analyzed. Eight of these patients 
were sporadic cases (S1-S8), two patients were siblings of consanguineous descent (F1 
and F2), and one patient was derived from an isolated Dutch community where inbreeding 
was suspected, and was thus, considered as a familial case (F3). Patient S1 has been 
previously reported (Talisetti, Longacre et al. 2009). Prenatal ultrasounds showed the 
presence of a distended bladder in the majority of the patients included in this study. A 
final MMIHS diagnosis was confirmed in all of them, due to the presence of a microcolon 
and distended bladder. All patients included in this study were Caucasian, except for 
patients F1, F2 and F3 of North African ancestry. Written informed consent was given 
by the families, and ethical approval was obtained from the Erasmus Medical Center 
ethical committee (Medische Ethische Toetsings commissie - METc 2011/148, ABR form: 
NL35920.042.11).
Sanger sequencing 
Genomic DNA was isolated from peripheral blood lymphocytes using standard methods. 
DNA obtained from amniotic fluid was extracted using standard DNA isolation protocols for 
prenatal material (Chemagic DNA Blood Kit Special, Chemagen, Perkin Elmer). Exons 1-10 
of ACTG2 were amplified using 15 ng of genomic DNA and the set of primers described 
in Supplementary Table 1. PCR products were purified (ExoSap it – GE Healthcare), 
and Sanger sequencing was performed with dye labelled primers (forward and reverse; 
Big Dye Terminator v3.1 Sequencing Kit, Applied Biosystems) on a ABI 3130XL genetic 
analyzer. Sanger reads were analysed using SeqScape software.
Immunohistochemistry
Fetal human gut tissues were obtained from the MRC-Wellcome Trust Human 
Developmental Biology Resource (HDBR), in collaboration with UCL Institute of Child 
Health in London, UK. Paraffin-embedded intestinal tissues from neonatal controls and 
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patients S3 and S5, were obtained from the Pathology Department repository of the 
Erasmus University Medical Center. Intestinal paraffin-embedded material from patient 
S1 was obtained from Stanford Histology/EM Laboratory of the Stanford University 
Medical Center. All human embryonic and neonatal intestinal tissues used as control 
were obtained from elective abortions, or from patients in which the cause of death was 
not intestinal related. Immunostainings were performed using specific antibodies against 
ACTG2 (1:100; Novus Biologicals), neurofilament (1:600; Monosan), smooth muscle actin 
α2 (ACTA2; ready to use; Dako), tyrosin protein kinase Kit (c-Kit/CD117) (1:200; Cell 
Marque), tryptase (1:1600; Dako), and synaptophysin (SP11) (ready to use; Ventana). 
3,3’-diaminobenzidine (DAB) chromogen (Ventana) was used for protein visualization, 
and sections were counterstained with hematoxylin. All images were taken with the 
Nanozoomer 2.0-HT (Hamamatsu Photonics), and analyzed with the Nanozoomer Digital 
Pathology viewer software (Hamamatsu Photonics). Negative controls performed with 
depletion of primary antibody were included for each staining, and showed no signal in 
any of the material tested (data not shown).
Molecular modelling and molecular dynamics simulations 
Molecular dynamics (MD) simulations of ACTG2 were performed using the structure of the 
chicken actin gamma monomer in complex with Dnase1 (PDB ID: 3W3D) (Sakabe, Sakabe 
et al. 1983). In order to obtain only the actin subunit for subsequent MD simulations, removal 
of Dnase1, N-acetyl-D-glucosamine and alpha/beta-D-mannose structures was performed 
using the VMD software, version 1.9.1 (Humphrey, Dalke et al. 1996). Different ACTG2 
mutants were produced using the in-built VMD plugin “mutate residue”. Each mutant was 
then checked for chirality errors and cis peptide bonds to ensure proper geometry via 
dedicated VMD plugins. An explicit 15 Å -padding TIP3P water box was used to solvate the 
protein, and the system was neutralized with KCl. All-atom MD simulations were performed 
with the NAMD software on a 32-core Intel®Xeon(R) CPU E5-2665 (Phillips, Braun et al. 
2005). Integration steps of 2 fs were used for minimization, equilibration and productive 
run in an isothermal-isobaric ensemble with constant number of particles, pressure and 
temperature (NPT ensemble), in the presence of periodic boundary conditions (PBC) and 
Particle Mesh Ewalds (PME) for full electrostatics. Temperature of 310 K was ensured 
by Langevin dynamics with a damping coefficient of 2 ps, and pressure was maintained 
constant at 1.013 bar by a Langevin Piston. Minimization was performed for 20 ps and 
productive run for 10 ns. Simulations were performed using the same parameters for 
mutants and wild-type. Analysis was carried out with standard VMD Analysis tools. Root-
mean square deviation (RMSD) was calculated over the alpha-carbon traces every 50 ps. 
Expression vectors
pCMV6-Myc-ACTG2 wild-type (WT) was purchased from Origene. All the mutants 
described were generated by site-directed mutagenesis on pCMV6-Myc-ACTG2 WT 
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according to the manufacturer’s instructions (QuickChange II site-directed mutagenesis 
kit, Agilent technologies). Primers used are listed in supplementary Table 2. Following 
mutagenesis, the entire ACTG2 insert was checked by Sanger sequencing.
Cell culture and transfection
The U2OS cell line was cultured in DMEM with high glucose content (Lonza), supplemented 
with 10% fetal calf serum (Sigma-Aldrich) and 1% penicillin/streptomycin (Gibco). Cells 
were maintained at 37oC and 5% CO2. For transient transfection, 300,000 cells were 
seeded in 6 well plates. Transfection was performed 24 hours after using GeneJuice 
transfection reagent (Millipore) according to the manufacturer’s instructions. 
Cell lysates and Western blot analysis
Cells were washed with PBS and incubated with lysis buffer [m-PER (Thermo Scientific) 
containing protease inhibitors (Roche)], for 30 minutes on ice. Cell lysates were collected 
by scraping and cleared by centrifugation at 14000 rpm for 10 minutes in a pre-cooled 
(4oC) centrifuge. Lysates were stored at -80oC before being processed further for SDS-
PAGE and immunoblotting. Protein quantification was performed using a BCA kit (Thermo 
Scientific), and 30 µg of protein was loaded into a criterion TGX precast gel (Bio-Rad). The 
following antibodies were used: Myc (Cell Signaling) and GAPDH (Millipore). Secondary 
antibodies used were IRDye 800CW Goat anti-mouse and IRDye 680RD Goat anti-Rabbit 
(Li-Cor). 
Microscopy and image analysis
For immunofluorescence cells were cultured on cover slips. Four percent paraformaldehyde 
was used as a fixative and cells were permeabilised with 1% BSA and 0.1% Triton X-100 in 
PBS. Myc antibody (Cell Signaling) was used at a concentration of 1:100, and Phalloidin-
rhodamin (Santa Cruz Biotechnology) was used at a concentration of 1:500. Images 
were taken using a Leica (AOBS) microscope, and analysed with the Leica LAS AF Lite 
software.
Actin Binding assays
U2OS cells transfected with ACTG2 expressing constructs (WT and mutants) were lysed 
in an actin buffer (Cytoskeleton) containing 0.1% Triton X-100 (Sigma) and protease 
inhibitors (Roche). Lysates were centrifuged for 15 min at 14000 rpm in a pre-cooled 
centrifuge (4oC), and supernatant fractions were incubated with polymerized actin 
(F-actin), generated according to the manufacturer's instructions (Cytoskeleton™). 
Polymerized actin was pelleted by centrifugation (100,000 G for 1 h) using the Airfuge, Air-
driven Ultracentrifuge (Beckman-Coulter). Supernatant and pellet fractions were further 
analyzed by Western blotting.
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Contractility assays
Twenty-four hours after transfection with ACTG2 expressing constructs (WT and mutants), 
U2OS cells were trypsinised, and analysed for their ability to contract. A cell contraction kit 
(Cell Biolabs) was used according to the manufacturer’s instructions.
RESULTS
Heterozygous missense variants in ACTG2 are present in sporadic MMIHS patients 
Since previous studies have implicated ACTG2 in MMIHS development, we screened our 
cohort of eleven patients for the presence of variants in this gene (Fig.1A). All patients 
presented with typical MMIHS features, including a microcolon and an enlarged bladder 
(Table 1). In all sporadic MMIHS cases a heterozygous missense variant in ACTG2 was 
identified (Table 2). 
Fig.1: Analysis of ACTG2 variants in MMIHS patients. A) Pedigrees of the ten families included in 
this study. B) Overview of the ten exons of ACTG2 with all the variants identified to date. The F110L 
variant is not represented, as it affects an alternate exon 4 of a predicted ACTG2 short isoform [14] 
(Black – in this study; Red – previously reported MMIHS cases; Blue – identified in VM patients).
In three of these cases we were able to confirm the de novo status of the variants. How-
ever, for the remaining five patients this was not possible due to unavailability of parental 
DNA. The missense variants identified in our patient cohort are located in three different 
exons of ACTG2, exons 3, 4 and 7 (Fig.1B), and are all predicted to be pathogenic by at 
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least two of three prediction programs (PolyPhen, MutationTaster, and Provean) (Table 2). 
None of these variants is present in the 1000 Genomes project database or in the Exome 
Sequencing project, but all of them have been reported before in MMIHS patients (Table 
2) [12-14]. No variant in ACTG2 was identified in the three familial cases (F1, F2 and F3).
Fig.2: Expression of ACTG2 in human intestinal material. A) Immunohistochemistry analysis 
shows that ACTG2 is expressed in the human intestine during different stages of development. B) 
Immunohistochemistry performed in intestinal material obtained from three MMIHS patients, S1, S3 
and S5, and an age matched control shows a diffuse cellular distribution of ACTG2 in the cytoplasm 
of smooth muscle cells of the muscularis mucosa, blood vessels and, the circular and longitudinal 
muscle of muscularis propria in patients and control. No significant changes were detected in any 
cellular constituents of the intestine of MMIHS patients, shown by hematoxylin and eosin (HE) stain-
ing and immunohistochemistry for c-Kit/CD117, Tryptase, Neurofilament and ACTA2. Legends: m: 
mucosa, mm: muscularis mucosa, sm: submucosa, cm: circular muscle, lm: longitudinal muscle, mp: 
muscularis propria.
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Chapter 2
ACTG2 
(376 residues)
ACTG2 Average (Å) STDEV
WT 2.856 0.288
R178C 3.476 0.448
R178L 2.779 0.361
R178H 3.168 0.363
R40C 2.536 0.343
R63Q 2.815 0.255
R148S 3.079 0.429
D-loop 
(residues 41-53)
ACTG2 Average (Å) STDEV
WT 7.061 1.077
R178C 8.405 1.697
R178L 6.376 1.447
R178H 8.012 1.488
R40C 4.955 1.998
R63Q 8.055 1.180
R148S 9.455 2.320
ADP-ribosylation site
(residues 174-182)
ACTG2 Average (Å) STDEV
WT 1.820 0.545
R178C 2.106 0.454
R178L 1.996 0.545
R178H 1.712 0.340
R40C 1.260 0.338
R63Q 1.856 0.381
R148S 1.350 0.240
Myosin binding site
(residues 357-376)
ACTG2 Average (Å) STDEV
WT 2.383 0.636
R178C 2.564 0.361
R178L 2.328 0.407
R178H 2.630 0.517
R40C 3.557 0.506
R63Q 2.560 0.716
R148S 2.827 0.440
Table 5. RMSD value for the ADP-rybosilation site 
in the ACTG2 WT and mutant proteins
Table 6. RMSD value for the the myosin binding 
site in the ACTG2 WT and mutant proteins
Table 3. RMSD value for ACTG2 WT and mutant 
proteins
Table 4. RMSD value for the D-loop in ACTG2 WT 
and mutant proteins
ACTG2 is expressed in all smooth muscle cells during human intestinal development 
Since MMIHS is an intestinal congenital anomaly, we assessed the expression of ACTG2 
in the human intestine (jejunum/ileum) at weeks 9, 11, and 22 of embryonic development, 
and at neonatal stage. At all developmental stages ACTG2 was abundantly expressed in 
the cytoplasm of smooth muscle cells, including smooth muscle cells of the muscularis 
mucosa, inner circular layer and outer longitudinal layer of the muscularis propria (Fig.2A). 
 ACTG2 expression was also detected in vascular smooth muscle cells of the 
intestine, and surprisingly, in myofibroblast cells of the mucosal layer. Since myofibroblasts 
have been described to only express the smooth muscle actin α 2 (ACTA2) (Arnoldi, 
Hiltbrunner et al. 2013), we cannot exclude the possibility that the antibody used recognizes 
both the α and γ smooth muscle actin isoforms, and could therefore, be unspecific for 
ACTG2.
MMIHS patients with ACTG2 variants do not show abnormal expression of ACTG2, 
or primary defects in any cellular constituents of the intestine
To define the histopathological findings in MMIHS patients with a ACTG2 variant, we 
investigated the expression of ACTG2, neurofilaments, ACTA2, c-Kit/CD117, and tryptase
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by immunohistochemistry, in intestinal material obtained from three MMIHS patients (S1, 
S3 and S5). Intestinal specimens collected during autopsy from an age-matched control 
were used for comparison. In the three patients analysed we were unable to detect any 
difference in the expression levels of ACTG2 when compared to the control (Fig.2B). 
The same result was obtained for neurofilaments and ACTA2 (Fig.2B, Supplementary 
Fig.1). An increased expression of c-Kit/CD117, a marker for interstitial cells of Cajal, was 
observed in the intestinal mucosa of patients S1 and S3 (Fig.2B, Supplementary Fig.1), 
but no change was observed in patient S5. Considering that c-Kit/CD117 is also a marker 
for mast cells, a tryptase staining was performed, confirming that the increased expression 
of c-Kit/CD117 in these two patients was due to an increased number of mast cells. 
Missense variants in ACTG2 lead to significant changes to the protein structure 
To gain a better understanding of the possible mechanisms underlying the development of 
MMIHS, we performed molecular modelling and molecular dynamics (MD) simulations for 
ACTG2. Molecular modelling involves editing protein structures by, for instance, introducing 
amino acid substitutions into a known crystal structure of a protein. However, since 
molecular modelling is often insufficient to infer the functional role of such substitutions, 
MD simulations are often performed. Using this approach, the atoms of the (modeled) 
crystal structures are allowed to move according to the forces exerted by the surrounding 
environment (temperature, pressure, water, ions, nearby atoms, electrostatic interactions, 
hydrophobic interactions, etc). Their motion can be measured at each time-point of the 
simulation and followed for the entire duration of the movement. In the end, these motions 
are plotted as the root mean square displacement (RMSD) from the initial crystal structure, 
over time. Therefore, higher RMSD values at a given time correspond to more structural 
differences in respect to the starting crystal structure, allowing prediction of the behavior 
of a (mutated) protein over time.  
 Since they represent the “skeleton” of the protein, their motion is more restricted 
than the side chains, which are more likely to suffer irrelevant high deviations associated 
to their intrinsic flexibility. Up to date, there is no statistical test that can be performed on 
RMSDs to assess significant differences. However, the persistence and the extent of the 
differences in RMSD, coupled with visual inspection of the simulated trajectories, are used 
to determine the relevance of such differences.
 Since the human ACTG2 structure was not available, we used in this study the 
chicken actin gamma monomer, which is 99.2% homologous in primary sequence (they 
differ only by three residue). We systematically compared the structure of the entire ACTG2 
protein or its main relevant sites, for wild type (WT) and mutants during 10 nanoseconds 
(ns) (Tables 3-6). All mutants displayed structural differences to some extent with respect 
to WT ACTG2 (Fig.3A, 3B). However, the most striking observations were associated with 
the R178C mutant, which showed the highest RMSD of the alpha-carbon trace throughout 
the whole simulation time for the entire protein (Fig.3B, Table 3). 
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Fig.3: Molecular modelling and MD simulations of ACTG2 WT and mutant proteins. A) Ribbon 
representation of the secondary structure of ACTG2. Residues of interest have been depicted as Van 
der Waals spheres. The representation on the bottom has been obtained by 180° rotation around the 
vertical axis. (B) Root-mean square deviation (RMSD) of ACTG2 alpha-carbon trace (376 residues) 
for WT and mutant proteins plotted as a function of time every 0.5 ns. The behavior of each protein 
was analysed every 50 ps. (C) Distance between subdomains II and IV for ACTG2 WT and the R178C 
mutant shows significant differences over time. Distances were calculated between alpha-carbons of 
Thr67 (on subdomain II) and Ala205 (on subdomain IV).
 We also noticed that subdomains II and IV behaved differently from WT, since 
they moved closer to each other over time, instead of moving slightly apart (Fig.3A). The 
average distance during the majority of the simulation time was about half compared to the 
WT (Fig.3C). Distances were computed between the alpha-carbons of Thr 67 (subdomain 
II) and of Ala 205 (subdomain IV), with an average of 7.3±1.5 Å for R178C and 14.2±1.5 
Å for the WT (Fig.3C). The R40C mutant showed the lowest average RMSD value for 
the entire protein (2.536 Å compared to 2.856 Å for the WT), reflecting a less dynamic 
structure with respect to WT ACTG2, as well as for the ADP ribosylation site (residues 174 
to 182), with an average RMSD of 1.26 Å (compared to 1.82 Å for the WT) (Fig.3B, Tables 
3 and 5). An exception to the generally lower structural deviations of the R40C mutant was 
observed for the region spanning residues 357-376, which belongs to the myosin-binding 
site. This region showed a significant displacement, having an average RMSD of 3.557 
Å in contrast with 2.383 Å for the WT (Table 6). Moreover, the region spanning residues 
41 to 53, belonging to the D-loop, resulted in lower RMSD values for the R40C mutant 
(4.995±1.998Å) when compared to the WT (7.061±1.077Å, Table 4).
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Fig.4: Cellular distribution and function of ACTG2 WT and mutant proteins. A) Confocal im-
ages of U2OS cells stained for Phalloidin (a F-actin marker), and expressing a Myc-tagged version 
of ACTG2 WT and mutant proteins show reduced incorporation of the mutant proteins into the actin 
filaments. B) In vitro actin binding assays show that ACTG2 mutant proteins do not precipitate with 
polymerized actin when subjected to high-speed centrifugation. C) Contractility assays performed for 
ACTG2 WT and mutant proteins show a reduction of cellular contractility for all the mutants studied. 
D) Quantification of the difference between the initial (0 hours) and final (24 hours) area occupied 
by a collagen matrix confirms reduced cellular contractility for the mutant proteins. *(p<0.05); Scale 
bars: 20 μm.
ACTG2 polymerization is impaired by the presence of a missense variant
To further investigate the effect of the missense variants found in MMIHS patients on the 
overall function of ACTG2, we determined the localization of WT and mutant proteins with 
phalloidin, a known marker of filamentous actin (F-actin). We over-expressed a tagged 
version of ACTG2 WT and mutant proteins in a human osteosarcoma cell line (U2OS), 
and specifically looked for co-localization between ACTG2 and actin fibers. While the WT 
protein could incorporate into the actin filaments, no co-localization was observed for any 
of the mutants analyzed (Fig.4A). We further confirmed this finding by performing in vitro 
actin binding assays. In these assays, polymerized actin is pelleted by high-speed cen-
trifugation and the binding of ACTG2 to the actin filaments is determined by co-sedimen-
tation. We found that while ACTG2 WT was able to pellet in the presence of F-actin, all 
the mutants analyzed remained in the supernatant both in the absence and presence of 
polymerized actin (Fig.4B). 
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ACTG2 missense variants reduce cellular contractility 
Contraction and relaxation of smooth muscles occur in an involuntary manner and are 
critical processes for the normal functioning of the vascular, digestive, respiratory and 
urogenital systems (Lehtonen, Sipponen et al. 2012). ACTG2 is the main actin isoform 
present in visceral smooth muscle and previous studies showed that its presence is 
necessary for the controlled dilatation of various muscular structures within the body 
(Arnoldi, Hiltbrunner et al. 2013). Recent in vitro studies have also reported that ACTG2 
is involved in cellular contractility, and that variants in ACTG2 lead to reduced cellular 
contraction (Lehtonen, Sipponen et al. 2012, Thorson, Diaz-Horta et al. 2014). Therefore, 
we decided to investigate if the missense variants identified in our cohort of patients 
also affect cellular contractility. For that, U2OS cells were transfected with ACTG2 WT 
and mutant vectors, and cell contraction assays were performed in vitro based on the 
contraction of a collagen matrix. Our results showed that all missense variants analyzed 
affected cellular contractility (Fig.4C), but this effect was only significant (p<0,05) for the 
variants affecting codon 178 (R178H; R178C; R178L; Fig.4D).
The ACTG2 variant R148S identified in Visceral Myopathy leads to similar in vitro 
changes as the ones described for MMIHS 
Since heterozygous ACTG2 missense variants are also known to cause Visceral Myopa-
thy (VM) [13,19-21], we investigated the effect of one of these variants (R148S) on the 
structure and function of ACTG2. We performed molecular modelling and MD simulations, 
and the same set of in vitro assays described above for the MMIHS associated variants. 
Our MD simulations showed that the R148S mutant protein behaved similarly to the WT, 
and we could only detect an increasing RMSD (for the entire protein trace) towards the 
end of the simulation (Fig.5A). However, this increasing RMSD is likely due to the high 
RMSD values for the residues belonging to the D-loop (9.455 Å for the R148S variant in 
comparison to 7.061 Å for the WT, Table 4), an intrinsically flexible region. Exclusion of the 
D-loop from the analysis gave RMSD values for the entire R148S mutant protein compa-
rable to the ones obtained for the WT and the R40C mutant (data not shown). The analysis 
of the 10 ns simulation also showed that the R148S variant led to specific structural modifi-
cations of the ACTG2 protein that are comparable to the R40C variant. Both these mutant 
proteins showed the lowest RMSD average values at the ADP-ribosylation site (1.260 Å 
and 1.350 Å for the R40C and R148S variants respectively), which reflect a less dynamic 
structure when compared to the WT (1.820 Å) (Table 5). They also presented the highest 
alpha-carbon trace displacements at the myosin-binding site (3.557 Å and 2.827 Å for the 
R40C and R148S respectively) when compared to the WT (2.383 Å, Table 6), suggestive 
of structural differences at this site that could possible translate into suboptimal interac-
tions with myosin. 
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Fig.5: Effect of the R148S to the structure and function of ACTG2. A) Molecular modelling and 
MD simulations of ACTG2 WT and the R148S mutant show moderate structural differences. B) Con-
focal images of U2OS cells stained for Phalloidin (a F-actin marker), and expressing a Myc-tagged 
version of ACTG2 WT and of the R148S protein show reduced incorporation of the mutant into the 
actin filaments. C) In vitro actin binding assays show that the R148S mutant protein does not pre-
cipitate with polymerized actin when subjected to high-speed centrifugation. D) Contractility assays 
performed for ACTG2 WT and the R148S mutant protein show a reduction of cellular contractility for 
the mutant. E) Quantification of the difference between the initial (0 hours) and final (24 hours) area 
occupied by a collagen matrix confirms a reduced cell contractility for the R148S variant. However, 
this difference is not significant (p>0.05). Scale bars: 20 μm.
 Our in vitro assays also showed that, similarly to what we observed for the MMI-
HS variants, the cellular localization of ACTG2 is disrupted by the presence of the R148S 
variant, as well as its ability to bind to actin filaments (Fig.5B, 5C). Moreover, a reduction 
in cell contractility was detected in the presence of this variant, as previously described 
(Fig.5D, 5E) [19]. 
DISCUSSION
ACTG2 is the main actin isoform expressed in intestinal smooth muscle cells, and it is 
therefore, not surprising that changes affecting its structure lead to severe disruption of 
normal intestinal development and function. Recently, heterozygous ACTG2 variants have 
been identified as the cause of MMIHS (Thorson, Diaz-Horta et al. 2014, Tuzovic, Any-
ane-Yeboa et al. 2014, Wangler, Gonzaga-Jauregui et al. 2014). In this manuscript we 
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confirm the involvement of ACTG2 in this disorder, and show that the heterozygous mis-
sense variants associated with MMIHS are pathogenic, disrupting actin polymerization. 
As a consequence, cellular contractility is affected which could account for the pheno-
typic abnormalities seen in MMIHS patients. Surprisingly, no differences in the expres-
sion levels of ACTG2, or any other major histological abnormalities was detected in the 
intestinal biopsies of MMIHS patients, despite previous studies have reported pathological 
abnormalities associated with this disorder (Kubota, Ikeda et al. 1989, Ciftci, Cook et al. 
1996, Richardson, Morgan et al. 2001, Rolle, O'Briain et al. 2002, Piotrowska, Rolle et al. 
2003, Piaseczna Piotrowska, Rolle et al. 2004, Narayanan, Murphy et al. 2007, Szigeti, 
Chumpitazi et al. 2010). However, since most of these studies did not provide a genetic 
etiology for the patients reported, and some abnormal findings, such as increased number 
of mast cells, can be a secondary effect due to reactive changes normally associated with 
bowel obstruction, the use of histological analysis for diagnostic purposes still needs to be 
carefully evaluated. Of particular notice is a recent report describing differences in ACTG2 
expression between one MMIHS patient carrying a R178H variant and a control (Tuzovic, 
Anyane-Yeboa et al. 2014). In our study two patients with a variant on the same codon 
were also analyzed immunohistochemically (Fig.2B, patients S3 and S5), but we were 
unable to find any differences when compared with the control. Although we find this dis-
crepancy difficult to explain, we believe that the sample size in both cases is rather small 
and thus, any inferences must be treated with caution.
 To date, all of the ACTG2 variants associated with MMIHS affect specific resi-
dues strongly conserved among different species (Table 2) (Thorson, Diaz-Horta et al. 
2014, Tuzovic, Anyane-Yeboa et al. 2014, Wangler, Gonzaga-Jauregui et al. 2014). There 
also seems to be an over-representation of variants associated with residue 178 in MMIHS 
(Fig.1B, Table 2), which is suggestive of a possible mutational hot-spot in this region. Since 
no clear loss of function variants (early stop codons or out of frame insertions/deletions) 
have been identified in any of the MMIHS patients reported, and no difference in ACTG2 
expression levels has been found in patients and controls (Fig.2B), we hypothesize that 
the variants identified in ACTG2 are likely to have a dominant negative effect. Based on 
our functional studies we cannot establish a genotype-phenotype correlation, since all the 
variants seem to behave in a similar way. However, considering that in our cohort, patients 
with a variant in residue 178 died a few days after birth, and the only patient alive has a 
R40 variant (S6), it is tempting to speculate that variants affecting residue 178 have a 
stronger dominant effect leading to a more severe phenotype. Interestingly, residue 178 of 
ACTG2 corresponds to residue 179 of ACTA2, which has been reported to be mutated in 
patients diagnosed with early-onset vascular disease associated with smooth muscle cell 
dysfunction (Milewicz, Ostergaard et al. 2010), and in a patient with prune belly syndrome 
(Richer, Milewicz et al. 2012), supporting a stronger effect of this variant on the overall 
phenotype. Our molecular dynamics (MD) simulations also corroborate this idea, since the 
structural changes assessed from visual inspection of the MD trajectories, were generally 
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more predominant for the R178 mutants when compared to the others. However, since 
our analysis focused only on the whole protein or specific regions (as described in Tables 
3-6), it is possible that we have missed subtle changes involving smaller sub-regions that 
might lead to significant local structural differences in functionally important domains. To 
further investigate and understand such changes, the crystal structure for each mutant 
protein should be determined and longer MD simulations (on the µs- to ms-scale) should 
be performed. 
 From our cohort of eleven MMIHS patients, three of them did not carry a variant 
in ACTG2 (F1, F2 and F3). These patients were considered to be familial cases. Since a 
homozygous variant in MYH11 (L1200T) has been recently identified in a patient of con-
sanguineous descent diagnosed with MMIHS and prune belly syndrome (Gauthier, Ouled 
Amar Bencheikh et al. 2014), we screened this gene in our familial cases. However, no 
variant was found in any of them (data not shown). The absence of ACTG2 and MYH11 
variants in these patients strengthens the idea of locus heterogeneity, and suggests the 
involvement of other genes in MMIHS pathogenesis. These genes would be associated 
to the familial cases, in which an autosomal recessive pattern of inheritance is expected. 
Since our immunohistochemistry data shows that ACTG2 localizes to the intestinal smooth 
muscle, and myosin and actin are two major proteins involved in muscle contractility, MMI-
HS can be considered to result from a myopathic defect. Therefore, we believe that par-
ticular attention should be given to other proteins involved in the contractile apparatus, as 
impaired function of any of these proteins could also possibly lead to the same syndrome 
or overlapping clinical entities. Alternately, Filamin A (FLNA), an actin binding protein with 
a well characterized role in the cytoplasm, could also be considered to be another suitable 
candidate for MMIHS, especially because of its known involvement in other intestinal mo-
tility disorders (Gargiulo, Auricchio et al. 2007, Clayton-Smith, Walters et al. 2009, Kapur, 
Robertson et al. 2010). 
 VM and MMIHS are clinically two separate disorders with overlapping features. 
The main differences rely on the age of onset, MMIHS can be diagnosed prenatally due 
to a recognizable bladder distension while VM occurs during adolescence, and disease 
severity with most MMIHS patients surviving only a few days or months after birth. The 
identification of ACTG2 missense variants as the cause of both disorders led to their re-
cent classification as ACTG2-related disorders, and suggested that MMIHS and VM could 
be one entity with a continuum of symptoms that vary in severity (Wangler, Gonzaga-
Jauregui et al. 2014). To investigate this possibility, we included one of the VM missense 
variants previously described (R148S) (Lehtonen, Sipponen et al. 2012), in our study, and 
analyzed its effect on the structure and function of ACTG2. Our MD simulations and in 
vitro results corroborated this idea, as the R148S variant affected ACTG2 structure and 
function in a similar way as the MMIHS variants. However, contradictory to what has been 
previously reported for VM patients carrying a R148S variant (Lehtonen, Sipponen et al. 
2012), we were unable to detect the presence of ACTG2 positive inclusions in any of the 
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MMIHS patients analyzed by immunohistochemistry. We found instead a diffuse cytoplas-
mic distribution of ACTG2 (Fig.2B). Considering that we were unable to obtain material 
from a VM patient carrying the R148S variant, we cannot rule out the possibility that the 
R148S variant leads to specific localization changes of ACTG2 that do not occur in the 
presence of the MMIHS associated variants. However, based on our results, we have no 
indication that MMIHS and VM are pathophysiologically different disorders. We can only 
hypothesize that variants identified in MMIHS cause specific conformational changes that 
do not occur in VM, but disrupt binding of ACTG2 to key interactors required for intestinal 
and bladder development, accounting for a more severe phenotype in MMIHS. 
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Supplementary table 1:  ACTG2 sequencing primers.
Primer name Sequence (5’-3’)
ACTG2 1F CGTCAGCTGGCCTTTTTAGG
ACTG2 1R CAAAGGACATCAGGGTGTGG
ACTG2 2F GGTTTCTGGCCACCTTTGG
ACTG2 2R TAGGGTCCCCTCAGCAACC
ACTG2 3F TTCACATTTCAGGGCAGAGG
ACTG2 3R CACAGTGCAGCGCTTACTCC
ACTG2 4F TGTTTCTGGGGGAAGAAAGG
ACTG2 4R CAGCCTAGGTTGGAGAAATGG
ACTG2 5F GAGGAGGGAAGGTCAAATGG
ACTG2 5R GGCATGGACCACAGACATAGC
ACTG2 6F TAAATCCCAAGGCCAACAGG
ACTG2 6R GACCCCAGCTTTTCCCTACC
ACTG2 7F TCAGAGCTCATTGGTAACAGTCC
ACTG2 7R AGCTGGTCTCTGGGGAAGG
ACTG2 8F AGCTACTTGGGAGGCTGAGG
ACTG2 8R GAGATTGGCAGGGACTGTGG
ACTG2 9F AACCAGGGATCAGAGGTTGC
ACTG2 9R GGAGACAACTGAGGCAAGACC
ACTG2 10F GATTCACCACATTTGTTCTTTGC
ACTG2 10R TGACACAGTAGAAGGAGCACTAGC
Supplementary table 2: Primers for site-directed mutagenesis of ACTG2 WT. The affected nucleo-
tide is underlined in each sequence.
Primer name Sequence (5’-3’)
ACTG2(R40C)F GTGGGCCGCCCTTGCCACCAGGGTGTGATGG 
ACTG2(R40C)R CCATCACACCCTGGTGGCAAGGGCGGCCCAC
ACTG2(R63Q)F TGAGGCTCAGAGCAAGCAAGGGATCCTAACTCTC
ACTG2(R63Q)R GAGAGTTAGGATCCCTTGCTTGCTCTGAGCCTCA
ACTG2 (R148S)F CTCTATGCCTCTGGCAGCACGACAGGCATCG
ACTG2(R148S)R CGATGCCTGTCGTGCTGCCAGAGGCATAGAG
ACTG2(R178H)F CCATGCCATCATGCACCTGGACTTGGCTGGC
ACTG2(R178H)R GCCAGCCAAGTCCAGGTGCATGATGGCATGG 
ACTG2 (R178C)F CCATGCCATCATGTGCCTGGACTTGGCTGGC
ACTG2(R178C)R GCCAGCCAAGTCCAGGCACATGATGGCATGG
ACTG2(R178L)F CCATGCCATCATGCTCCTGGACTTGGCTGGC
ACTG2(R178L)R GCCAGCCAAGTCCAGGAGCATGATGGCATGG
Supplementary table 3: RMSD value for ACTG2 WT and mutant proteins.
ACTG2 
(376 residues)
ACTG2 Average (Å) STDEV
WT 2.856 0.288
R178C 3.476 0.448
R178L 2.779 0.361
R178H 3.168 0.363
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R40C 2.536 0.343
R63Q 2.815 0.255
R148S 3.079 0.429
Supplementary Table 4: RMSD value for the D-loop in ACTG2 WT and mutant proteins.
D-loop 
(residues 41-53)
ACTG2 Average (Å) STDEV
WT 7.061 1.077
R178C 8.405 1.697
R178L 6.376 1.447
R178H 8.012 1.488
R40C 4.955 1.998
R63Q 8.055 1.180
R148S 9.455 2.320
Supplementary table 5: RMSD value for the ADP- ribosylation site in the ACTG2 WT and mutant 
proteins.
ADP-ribosylation site
(residues 174-182)
ACTG2 Average (Å) STDEV
WT 1.820 0.545
R178C 2.106 0.454
R178L 1.996 0.545
R178H 1.712 0.340
R40C 1.260 0.338
R63Q 1.856 0.381
R148S 1.350 0.240
    
Supplementary table 6: RMSD value for the myosin binding site in the ACTG2 WT and mutant 
proteins.
Myosin binding site
(residues 357-376)
ACTG2 Average (Å) STDEV
WT 2.383 0.636
R178C 2.564 0.361
R178L 2.328 0.407
R178H 2.630 0.517
R40C 3.557 0.506
R63Q 2.560 0.716
R148S 2.827 0.440
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ABSTRACT
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS) is a congenital 
myopathy characterized by severe obstruction of the bladder and the intestine. Elucidating 
the etiology of this disease will extend our understanding of the networks crucial for proper 
functioning of muscle cells in visceral organs. Using a combined strategy of homozygosity 
mapping and whole exome sequencing, we aimed to identify the deleterious recessive 
variation responsible for MMIHS in a child from consanguineous parents. We identified 
a homozygous Leiomodin-1 (LMOD1) nonsense mutation in a newborn child. LMOD1 
expression in patient’s fibroblasts was reduced. We utilized CRISPR genome editing 
to engineer a knockout mouse. Western blotting, qRT-PCR, and immunofluorescence 
microscopy were performed to define expression of the identified gene. Actin filament 
formation and contractility assays were performed to gain mechanistic insights. Analysis 
of actin filaments by G-Actin/F-Actin assay indicated that deficiency of LMOD1 caused 
severely reduced formation of actin filaments and impaired contractility. Characterization of 
Lmod1 knockout mice carrying a similar nonsense mutation revealed phenotypes featured 
in patients with MMIHS. Thus, we conclude that LMOD1 is a new disease gene for MMIHS. 
Adding to the previously known MMIHS disease-causing-genes, ACTG2 and MYH11, 
this study confirms that MMIHS is a heterogeneous disease of the visceral organs, with 
multiple patterns of inheritance. The striking similarities in pathology in human and mice 
support the latter as a powerful model to further investigate the underlying mechanistic 
role of LMOD1 in MMIHS as well as potential therapeutic interventions.
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INTRODUCTION
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS) (OMIM 249210) is a 
rare congenital malformation characterized by a severe obstruction of the intestine and the 
urinary bladder in neonates. More than 250 cases of MMIHS have been reported since its 
first description in 1976, (Berdon, Baker et al. 1976, Mc Laughlin and Puri 2013, Wangler 
and Beaudet 2015). Until now, parenteral nutrition and multivisceral organ transplantation 
are the only available treatments for this disease.  Fatal outcomes were reported in most 
cases, while morbidities caused by long term administration of parenteral nutrition or 
catheterization were manifest in surviving patients (Lopez-Munoz, Hernandez-Zarco et 
al. 2013).
 Although most MMIHS cases are considered sporadic, several familial cases 
with multiple affected sibs from consanguineous families have been reported, suggesting 
that MMIHS has a genetic cause with two distinct modes of inheritance: de novo mutations 
in sporadic patients and a recessive mode of inheritance in familial patients (Mc Laughlin 
and Puri 2013). This hypothesis is now partially confirmed as we and other groups 
identified de novo mutations in the enteric smooth muscle gamma actin gene (ACTG2) 
(Thorson, Diaz-Horta et al. 2014, Wangler, Gonzaga-Jauregui et al. 2014, Halim, Hofstra 
et al. 2016). These mutations were found mainly in sporadic cases of MMIHS, leading to 
the assumption that other loci are responsible for the presumed recessive form of MMIHS. 
This notion is strengthened by the recent identification of a homozygous loss-of-function 
variant in smooth muscle myosin heavy chain-11 (MYH11) in an MMIHS patient from a 
consanguineous family (Gauthier, Ouled Amar Bencheikh et al. 2015). To date, no other 
reports of MMIHS patients with MYH11 variants have been published, suggesting more 
genes may lead to the same phenotypes represented by this syndrome.
 In this study, we investigated an MMIHS patient from a consanguineous family 
in whom no rare variants in ACTG2 or MYH11 were found. We describe the identification 
of a homozygous nonsense mutation in Leiomodin-1 (LMOD1), an ill-defined gene that 
is expressed preferentially in smooth muscle lineages (Nanda and Miano 2012). At the 
same time, a CRISPR-generated nonsense mutation in exon 1 of murine Lmod1 yielded 
an MMIHS-like phenotype. Functional studies support a previously unrecognized role for 
LMOD1 in visceral smooth muscle function. LMOD1 is a new MMIHS disease gene that 
expands the genetic heterogeneity of this devastating visceral smooth muscle disease.
MATERIALS AND METHODS
Recruitment of the Study Subject
An MMIHS patient from consanguineous parents was included. Ethical approval for this 
study was granted by the Erasmus Medical Center ethical committee (Medisch Ethische 
Toetsings commissie - METc 2011/148, ABR form: NL35920.042.11), and written informed 
consent was given by the family. 
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SNP-array analysis
To determine chromosomal abnormalities in the patient and to identify the presence of Runs 
of Homozygosity (ROH), we processed 250 ng of DNA on the Illumina HumanOmniExpress 
BeadChip v1 array (Illumina, Inc., San Diego, USA) using standard protocols. Normalized 
output was generated using Genome Studio version 2011.1 (Illumina, San Diego, CA, 
USA), ROH and Copy Number variations were analyzed and visualized in Nexus CN8.0 
(Biodiscovery Inc, El Segundo, CA, USA). CNV was profiled according to previously 
described prioritization methods (Brosens, Marsch et al. 2016). As a minimum cut-off for 
homozygosity mapping, ROH regions had to contain at least 50 probes and be larger than 
1 Mb in size in line with criteria described elsewhere (Yu, Zhao et al. 2001, Auton, Bryc et 
al. 2009). To determine the consanguinity coefficient (f ) and the inbreeding coefficient (F) 
we used the the genomic oligoarray and SNP-array evaluation tool v3.0 (Wierenga, Jiang 
et al. 2013), and a 50 probe minimum for ROH region.
 
Whole Exome Sequencing
Genomic DNA was fragmented using acoustic technologies (Covaris, Inc. Woburn, 
Massachusetts, USA). Exome capture was performed with the SureSelect Human All 
Exon 50 Mb Targeted exome enrichment kit v4 (Agilent Technologies, Inc., Santa Clara, 
California) and the library was paired-end sequenced (2x101 bp) using the Illumina 
TruSeq version 4 procedure. (Illumina, Inc., San Diego, USA). More than 5 Gigabases 
of raw sequence data was processed using the NARWHAL pipeline and aligned to the 
hg19 reference genome with Burrows-Wheeler Aligner version 0.6.2. Variants determined 
using the Bayesian genotyper incorporated in the genome analysis toolkit version 1.2.9 
were uploaded to Cartagenia Bench NGS version 4.1.8 (Cartagenia Inc, Boston, MA, 
USA) for filtering and prioritization. Copy Number Variants (CNV) and ROH regions were 
exported from Biodiscovery Nexus CN8.0. to Cartagenia Bench CNV and NGS to inspect 
for overlap between the identified ROH regions with the rare variants. 
 We excluded variants with a high frequency in our in-house control cohort 
(n=200, with similar capture, alignment and variant calling procedures), variants with an 
allele frequency above 0.1% in public databases (ExAC release 0.3, ESP6500SI-V2; 1000 
Genomes Phase 3 release v5.20130502 and GoNL SNPs and Indels release 5). Next, we 
annotated variants using the framework described by Kircher and colleagues (Kircher, 
Witten et al. 2014) and retained all the variants predicted to affect splicing, nonsense 
variants, and all coding and non-coding variants, with a CADD score above 20 representing 
the top 1% ranked variants in the framework. The higher this Phred-base-calling score is, 
the more likely the variant has a deleterious effect (http://cadd.gs.washington.edu/home, 
CADD v1.3). Deleterious variant is deposited in the ClinVar database (http://www.ncbi.
nlm.nih.gov/clinvar/) using the submission name “Loss of LMOD1 in MMIHS” and using 
identifiers as described in this manuscript.
 Genes harboring candidate variants are inspected for their mRNA and protein 
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expression patterns in the Human Integrated Protein Expression Database and the 
Genotype Tissue Expression project database (Consortium 2013), incorporated in 
Genecards (Fishilevich, Zimmerman et al. 2016) and overlapped with smooth muscle 
functioning in the Reactome database (Croft, Mundo et al. 2014).   
Sanger sequencing 
Genomic DNA was isolated from peripheral blood lymphocytes using standard methods 
(Chemagic DNA Blood Kit Special, Chemagen, Perkin Elmer, Waltham, Massachusetts, 
USA). Sanger sequencing across exon 2 of LMOD1 was performed to confirm the 
nonsense mutation using sets of primers described in Supplemental table 1. 15 ng of 
genomic DNA was used to amplify exon 2 of LMOD1 using a standard PCR protocol. 
PCR products were purified (ExoSap it – GE Healthcare, Little Chalfont, UK) and Sanger 
sequencing was performed by using dye labelled primers (forward and reverse; Big Dye 
Terminator v3.1 Sequencing Kit, Applied Biosystems, Foster City, California, USA) on an 
ABI 3130XL genetic analyzer. Sequencing reads were analyzed using SeqScape® v2.5 
software.
Animal Work
All animal experiments were approved by the Institutional Animal Care and Use Committee 
of the University of Rochester in Rochester, NY. All animals were housed in a temperature- 
and humidity-controlled facility under the supervision of the Department of Laboratory 
Animal Medicine, University of Rochester Medical Center, Rochester, NY. 
CRISPR-Cas9 Editing of Lmod1 
Three guide-RNAs (gRNAs; Supplementary table 1) targeted to mouse Lmod1 exon 1 
were designed and cloned into the BbsI site of pX330-U6-Chimeric_BB-CBh-hSpCas9 
(Addgene #42230). The gRNAs were synthesized by in vitro transcription using the 
HiScribe T7 mRNA synthesis kit (New England Biolabs, Ipswich, Massachusetts, USA) 
and microinjections were carried out as previously described (Oliver, Yuan et al. 2015). 
Briefly, fertilized zygotes were microinjected with a mixture of Cas9 mRNA from Trilink 
Biotechnologies (200 ng/µl) and each individual in vitro transcribed gRNA (100ng/µl each; 
300 ng/µl in total). Following injection, zygotes were cultured in KSOM+AA medium for 1 
hour before transfer into the oviductal ampullae (10-15 zygotes per oviduct) of CD1 mice 
that had been mated with vasectomized CD1 males the previous night. 
 Genomic DNA was isolated from mouse tail-snips by overnight proteinase K 
digestion. PCR was used to detect the deletion on Lmod1 exon 1 (Supplemental table 
1) using AccuStart II Supermix (Quanta, Houston, Texas, USA) at the following cycling 
conditions: 3 minute incubation at 95˚C, followed by 35 cycles of 30 seconds at 95˚C, 30 
seconds at 58 ˚C, and 30 seconds at 72 ˚C, and lastly a 5 minute incubation at 72 ˚C. PCR 
reactions were analyzed on a 2% agarose gel. 
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PCR Screening for CRISPR-Cas9 Off-targeting
A gRNA design tool based on an algorithm designed by Feng Zhang’s lab (http://crispr.
mit.edu/) was used to calculate the ten most highly ranked off-targets for each of the 
three gRNAs used to develop the Lmod1KO allele. PCR primers flanking each off-target 
sequence were designed and are listed in supplemental table 3. Adapter sequences were 
added onto the 5’ ends of each primer (5’-ACACTGACGACATGGTTCTACA-3’ for forward 
primers, 5’-TACGGTAGCAGAGACTTGGTCT-3’ for reverse primers). PCR amplification 
was carried out for 28 cycles (95˚C for 30 seconds, 53˚C for 30 seconds, 72˚C for 30 
seconds) using AccuStart II Supermix (Quanta, Houston, Texas, USA). All 30 PCR 
reactions were pooled and sent for sequencing to a DNA Services Facility (Research 
Resources Center at the University of Illinois at Chicago). Sequence analysis was done 
using CRISPresso (Pinello, Canver et al. 2016).
Quantitative Real Time (qRT)-PCR
RNA extraction from patient’s and controls’ fibroblasts was performed using a RNA 
extraction kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. 1 
µg of RNA was converted into cDNA using iScript cDNA synthesis kit (Bio-Rad, Hercules, 
California, USA). Mix of cDNA and primers (Supplementary table 1) were used with 
KAPA SYBR Fast qPCR kit (Kapa Biosystems, Wilmington, Massachusetts, USA), and 
qRT-PCR was performed using a IQ5 cycler PCR machine (Bio-Rad). Expression levels 
were corrected with the expression of two housekeeping genes, COPS5 and CLK2, 
averaged and presented as fold changes. Total RNA was isolated from mouse tissues 
using miRNeasy Mini kit (Qiagen, Hilden, Germany), and cDNA was synthesized with an 
iScript cDNA Synthesis kit (Bio-Rad, Hercules, California, USA). qPCR was performed 
using PerfeCTa SYBR Green SuperMix (Quanta, Houston, Texas, USA) and PCR primer 
pairs (Supplemental table 1). 
Protein isolation and Western blot analysis
Fibroblasts were washed with PBS and incubated with standard lysis buffer and protease 
inhibitors (Roche) for 30 minutes on ice. Cell lysates were collected by scraping and 
cleared by centrifugation at 13.000 rpm for 15 minutes at 4oC. 
 When using human intestinal SMC, protein isolation was performed based on 
the manufacturer’s instruction. Protein lysates were kept at -80oC before being processed 
further for SDS-PAGE and immunoblotting. Protein was quantified using a BCA kit (Thermo 
Scientific), and 30 µg of protein from each sample were loaded into a TGX precast gel (Bio-
Rad). The following primary antibodies and their dilutions were used: LMOD1 (Proteintech; 
1:200), Actin (Cytoskeleton; 1:250) and GAPDH (Millipore 1:1000). Secondary antibodies 
used were IRDye 800CW Goat anti-mouse and IRDye 680RD Goat anti-Rabbit (Li-Cor). 
 When using mouse tissue, whole protein was extracted in Cell Lysis Buffer 
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(Cell Signaling) supplemented with complete Mini EDTA-free protease inhibitor cocktail 
tablets (Roche) by mechanical homogenization. Cleared protein lysates were subjected 
to Western blotting as previously described.3we describe a new SRF/MYOCD-dependent, 
SMC-restricted gene known as Leiomodin 1 (Lmod1 Antibodies used were LMOD1 
(Proteintech 15117-1-AP, 1:800), SM22α (Abcam ab14106, 1:5000), and Beta-Tubulin 
(Cell Signaling 2128, 1:1000). 
Immunohistochemistry and Immunofluorescence
Formalin-fixed paraffin-embedded human small intestinal tissues from controls were 
obtained from the repository of the department of Pathology, Erasmus University Medical 
Center. Immunostaining was performed using specific antibody directed against LMOD1 
(dilution 1:1000; Proteintech). After the addition of the primary antibody, the biotinylated 
multilink secondary antibody and the avidin-biotin-complex with peroxidase were applied, 
followed by the addition of 3,3’-diaminobenzidine (DAB) chromogen (Ventana, Tucson, 
Arizona, USA), and then slides were counterstained with hematoxylin. All images were 
taken with a Nanozoomer 2.0-HT (Hamamatsu Photonics, Hamamatsu City, Shizuoka, 
Japan), and analyzed using the Nanozoomer Digital Pathology (NDP) viewer software 
(Hamamatsu Photonics, Hamamatsu City, Shizuoka, Japan).  
 Mouse tissues were fixed in methanol/H2O/acetic acid (60:30:10, v/v) solution 
overnight, embedded in paraffin, and sectioned at 5-micron thickness. Following 
deparaffinization, antigen retrieval was performed using a pressure cooker set at high 
pressure for 5 minutes in a pH 9 solution (Dako S2367) for LMOD1 primary antibody. For 
TUNEL and Ki-67 staining, slides were similarly subjected to high pressure steam in a pH 6 
solution (Dako S1699) for 5 and 10 minutes, respectively. For LMOD1 staining set (LMOD1 
Proteintech 15117-1-AP, 1:100; SM actin-Cy3, Sigma #C6198) and Ki-67 staining set (Ki-
67 antibody: BioLegend #652402, 1:100; smooth muscle myosin, Biomedical Tech BT-562, 
1:100), cells were washed in 1X PBS prior to overnight incubation with primary antibody 
(antibody diluent: Dako S0809) at 4˚C. The next day, slides were washed in 1X PBS prior 
to incubation with secondary antibody (AF-488 anti-rabbit (Thermo Scientific #A11008), 
AF-488 anti-mouse (Thermo Scientific #A11001), or AF-594 anti-rabbit (Thermo Scientific 
#A11012)) for 1 hour at room temperature. Cells were washed again before being mounted 
using ProLong Gold Antifade (Molecular Probes P36935). TUNEL staining was carried out 
using the In Situ Cell Death Detection Kit, Fluorescein (Sigma #11684795910) according 
to manufacturer’s instructions, followed by staining with smooth muscle alpha actin-Cy3 
conjugated antibody. All images were taken with a confocal microscope (Olympus FV 
1000, Olympus, Tokyo, Japan) with voltages set using wild type controls for each tissue, 
such that wild type and experimental samples were imaged with the same parameters 
within each tissue group. 
 For immunofluorescence of hISMC, hISMC were cultured on cover slips. 
Seventy-two hours after being transfected with either scrambled siRNA or siLMOD1, cells 
54
Chapter 3
were fixed with four percent paraformaldehyde (PFA) and permeabilized with 1% BSA and 
0.1% Triton X-100 in PBS. LMOD1 antibody (Proteintech, 1:25) and Phalloidin-rhodamine 
(Santa Cruz Biotechnology, 1:500) Images were taken using a Leica (AOBS) microscope, 
and analyzed with the Leica LAS AF Lite software.
Cell culture and transfections
Primary human intestinal smooth muscle cells (hISMC) were obtained from the Sciencell 
research laboratories, and cultured in smooth muscle cell (SMC) medium mixed with 1% 
smooth muscle growth supplement and 1% penicillin/streptomycin (Sciencell, Carlsbad, 
California, USA). Cells were maintained at 37oC and 5% CO2. 24 hours before the 
transfection, 300,000 cells were seeded in 6 well plates. Cells were transfected with either 
Scrambled siRNA or siLMOD1 (Ambion, 100 nM per well) using Lipofectamine® 2000 
transfection reagent (Thermo Fisher Scientific, Waltham, Massachusetts, USA). After 6 
hours, the medium was refreshed with a normal SMC medium, and cells were allowed to 
grow for 72 hours before analysis.  
G-actin/F-actin analysis
Seventy-two hours after hISMC were transfected with scrambled siRNA or siLMOD1, 
the cells were harvested and lysed in a detergent-bases lysis buffer that preserves 
the monomeric (G-) and filamentous (F-) forms of actin. F-actin was pelleted by 
ultracentrifugation, while G-actin remained in supernatant. Samples of supernatant and 
pellet were loaded into an SDS-PAGE system and underwent Western blot analysis 
(Cytoskeleton, Denver, Connecticut, USA).  
Contractility assays
Twenty-four hours after transfection with scrambled siRNA or siLMOD1, hISMC were 
trypsinized, and used for collagen contractility assay. A cell contraction kit (Cell Biolabs, 
San Diego, California, USA) was used according to the manufacturer’s instruction.
Myography Assay
Primary jejunum was isolated from mice and placed in ice-cold PSS buffer (130 mM NaCl, 
4.7 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 14.9 mM NaHCO3, 5.5 mM dextrose, 0.026 
mM EDTA, 2.5 mM CaCl2). Jejunum ring segments were mounted on a 610m myograph 
(DMT) in PSS buffer with oxygenation, and the temperature was brought up to 37˚C for 
approximately 30 minutes. Passive tension was applied and buffer was exchanged before 
tissues were allowed to equilibrate for an additional 20 minutes. Tissues were treated 
with K-PSS buffer (PSS with 60 mM KCl, 74.7 mM NaCl) or 100 µM carbachol in order 
to induce contraction. For KCl treatment, the mean peak contractile force was taken for 
several independent rounds of contraction. N = 6 animals for KCl treatment and n = 4 for 
carbachol treatment. 
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RESULTS
Clinical information of the patient
The proband was a female child from a consanguineous couple of Dutch origin. During 
a routine ultrasound sonography (USG) examination at 20 weeks of pregnancy, bilateral 
hydronephrosis and a distended bladder were detected (Fig. 1A). Polyhydramnios was 
later acknowledged, and delivery was medically induced at 34-weeks due to mechanical 
problems of the mother. 
Fig.1: Identification of loss-of-function mutation in LMOD1 gene in MMIHS patient. (A) Barium 
enema test confirmed the clinical diagnosis of MMIHS in patient. (B) Pedigree of the studied family, with 
their Sanger Sequencing results showing heterozygous variant in parents and homozygous variant 
in proband. (C) Quantitative real time (qRT) PCR analysis using RNA from controls and patients’ 
fibroblasts showed severely reduced expression of LMOD1 at RNA level. (D) Protein expression 
study by Western blot using control’s and patient’s fibroblasts confirmed the reduced expression of 
LMOD1 in patient at protein level.
Physical examination at the neonatal period noted distended and lax abdominal wall, 
causing the intestine to be externally palpable. Further USG investigation did not 
reveal abnormalities of the brain and the heart. Bilateral hydronephrosis was noted, 
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along with bilateral distension of proximal ureter and distended bladder. No intestinal 
peristaltic movement was acknowledged. Barium enema testing indicated the presence 
of a microcolon (Fig. 1A). Conventional treatments given included parenteral nutrition, 
gut feeding, stomach suction and catheterization for the atonic bladder. As the patient 
succumbed at 5-days-old due to sepsis, there were no further clinical measures or 
interventions.
Although the patient was the first child in the family diagnosed with MMIHS, the parents 
acknowledged a previous intrauterine fetal death (IUFD) in which routine 20-week USG 
detected abdominal distension of the fetus. Meanwhile, two other siblings in this family are 
healthy and do not show any signs of bladder and intestinal abnormalities.
Copy Number Variation (CNV) profiling and homozygosity mapping
In the parental samples, 24 regions that are larger than 1 Mb, including ROH regions 
and heterozygous regions, were detected. Seven CNVs were present, all common 
polymorphisms inherited from unaffected parents (see supplementary table 4) Two 
homozygous regions were larger than 10 Mb: (hg19 chr2:95,395,757-115,363,347 and 
hg19 chr1:193,573,186-210,528,162). Genotype information derived from the SNP-array 
was indicative of consanguinity with an f of 0.375 and F of 0.1875 with 528 Mb of ROH.
A homozygous nonsense mutation in LMOD1 was identified in the MMIHS patient 
from a consanguineous family  
Whole exome sequencing analysis identified no deleterious variants in the known disease 
genes, ACTG2 and MYH11. In total, 526 variants had a minor allele frequency below 0.1%. 
Prioritization to yield the most likely deleterious variants resulted in 7 nonsense variants, 
10 that were predicted to affect splicing and 53 other variants had a CADD score of twenty 
or higher. (n= 70 variants in total). Only two out of 70 variants were homozygous, one 
nonsense (premature stop mutation) in LMOD1 (NM_012134.2:c.1108C>T; p.Arg370*) 
and an intronic variant predicted to affect splicing in CREG2 (NM_153836.3: c.442-5G>A). 
Of these two genes, the LMOD1 gene has mRNA and protein expression in human bladder 
and intestine (Croft, Mundo et al. 2014, Fishilevich, Zimmerman et al. 2016).
We identified a homozygous mutation in exon 2 of LMOD1, that converted a cytosine 
at the position g.201.897.806 into a thymine, resulting in a premature termination 
codon. Confirmation with Sanger sequencing was obtained, and sequence analyses of 
both parents revealed the heterozygous variant, thus confirming the recessive mode of 
inheritance (Fig. 1B). This genetic finding was registered in ClinVAr (http://www.ncbi.nlm.
nih.gov/clinvar/) under the following accesion number: SCV000299346.
 To assess the effect of this variant, we examined the expression of LMOD1 mRNA 
and protein in patient versus control fibroblasts. qRT-PCR and Western blot analyses 
revealed severe reduction/loss of LMOD1 expression in patient fibroblasts compared with 
that in the control (Fig. 1C-D). 
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LMOD1 is expressed in all SMC throughout the developmental stages of human 
intestine 
SMC are the building blocks of muscle structures in human intestine, including muscularis 
mucosa, the circular and longitudinal muscles that form the muscularis propria, and the 
blood vessels primarily found in submucosa. Immunostaining showed strong LMOD1 
expression within the SMC that constitute these structures. To test the continuity of 
LMOD1 expression, we examined human intestine from prenatal to neonatal stages of 
development. In all stages, LMOD1 is expressed by all SMC of the intestine (Fig. 2A-F).
 
Fig.2: Expression of LMOD1 in embryonic human intestine. (A-E) LMOD1 is expressed in all 
SMC that constitute structures of the intestine, including muscularis mucosa, blood vessels, and 
both muscle layers of the mucularis propria. This expression is constant throughout various stages of 
development that are included in this study. 
CRISPR-Cas9 Mediated generation of a nonsense codon in Lmod1 is neonatal 
lethal in mice. 
In order to determine the importance of LMOD1 in SMC function in an experimental animal 
model, we used two component CRISPR genome editing (Miano, Zhu et al. 2016) to 
target exon 1 of the Lmod1 gene in mice. PCR genotyping around the region of exon 1 
targeted by all three sgRNAs and Sanger sequencing of neonates revealed a 151 base 
pair deletion that created a frameshift and the introduction of a premature termination 
codon (PTC) within exon 1 of Lmod1 (Fig. 3A). This PTC results in a truncated 19-amino 
acid peptide, the first 8 of which are native to the wild type LMOD1 protein (Fig. 3B). We 
used PCR to detect different Lmod1 alleles and found the expected Mendelian frequency 
(Fig. 3C-D) indicating all death due to the nonsense codon was postnatal.
 Western blotting of Lmod1+/- mice showed a 2-fold decrease in expression in 
stomach tissue (Fig. 3E), as well as aorta and bladder (data not shown). Heterozygous 
mice and humans As expected, no detectable LMOD1 protein was observed in any SMC-
rich tissue of Lmod1-/- mice (Fig. 3 and data not shown). To test if the PTC results in 
degradation of the Lmod1 transcript via nonsense mediated decay (Maquat 2004), we 
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analyzed steady-state mRNA using qRT-PCR. Surprisingly, results revealed no significant 
difference between Lmod1+/+Lmod1+/-, Lmod1-/- mice (Fig. 3F). Similar results were 
obtained in qRT-PCR experiments using primers targeted to the 5’ and 3’ regions of the 
Lmod1 transcript (data not shown). These data suggest that the Lmod1 transcript is not 
targeted for nonsense-mediated decay (NMD) in knockout mice.
Fig.3: Cas9-mediated Deletion of Lmod1 exon 1. (A) Schematic of Lmod1 exon 1 deletion 
strategy. Injection of capped Cas9 mRNA and three gRNAs (red arrowheads) resulted in deletion 
of 151 basepairs (pink) within Lmod1 exon 1. PCR primers (blue arrowheads) were used to confirm 
deletion. (B). Deletion of 151 basepair region (pink) results in frameshift mutation and the introduction 
of premature termination codon within Lmod1 exon 1, generating a truncated 19 amino acid peptide. 
(C) Agarose gel analysis of Lmod1 KO mice. PCR products indicating wildtype, heterozygous or 
homozygous deletion of Lmod1 were generated using the primers in Fig1A. (D) Genotyping data 
from a heterozygous Lmod1+/- x Lmod1 +/- mating. (E) Western blot showing complete absence 
of LMOD1 protein in the stomach of Lmod1-/- mice. (F) RT-qPCR analysis reveals no significant 
difference in Lmod1 mRNA expression in knockout mice, indicating that the transcript most likely is 
not targeted for nonsense-medicated decay.  
 While the Lmod1 mutation is transmitted at the expected Mendelian frequency, 
Lmod1-/- neonatal mice display gross distension of the abdominal cavity shortly following 
birth (Fig. 4A). Closer observation and dissection revealed dramatic distension of the 
stomach and urinary bladder (Fig. 4A-B), the latter of which is consistent with clinical 
observations in human MMIHS patients. 
 Hydronephrosis was also noted in some animals, likely due to failed micturition. 
Histopathological analysis revealed thinning and compaction of the visceral smooth muscle 
in both stomach and bladder, along with varied, often severe atrophy of the epithelium (Fig. 
4C). Flattened mucosa and diminished gastric pits were also acknowledged in Lmod1-/- 
stomach.Immunofluorescence microscopy revealed undetectable LMOD1 protein within 
the SMC tissue of knockout stomach and bladder, consistent with earlier Western blotting 
data (Fig. 4C).  
 To further assess the Lmod1-/- phenotype, we conducted histopathological 
analysis on each of the three primary segments of intestine (Fig. 5A). Atrophy of the 
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epithelial layer, while not as dramatic as that observed in stomach and bladder, was 
still noticeable, particularly in the duodenum. However, unlike the bladder and stomach, 
no dramatic architectural changes were detected in the intestinal segments, although 
distension of the duodenum 
Fig.4: LMOD1 deletion results in gross distension of stomach and bladder. (A) Photograph of 
gross Lmod1 knockout pups showing abdominal distension (top), notably the severely distended 
stomach and bladder (bottom panel) present in all Lmod1-/- animals. (B) Gross pathology of distended 
stomach and bladder of Lmod1-/- mice. (C) Histology of Lmod1-/- stomach and bladder compared with 
wt. H&E-stained sections reveal severe atrophy of epithelial cell in stomach and bladder of Lmod1-
/- mice (top row) and immunofluorescence microscopy reveals absence of LMOD1 from visceral 
smooth muscle (bottom three rows) of the same tissues. 
was evident in some animals upon dissection (Fig. 5A). Similar to both the stomach and 
bladder, no LMOD1 protein was visible using immunofluorescence microscopy. 
To assess changes in SMC-specific gene expression following Lmod1 deletion, we 
analyzed protein and mRNA from Lmod1-/- mice; no significant changes in MYH11, CNN1, 
ACTA2, or TAGLN were observed. 
 In order to assess any increase in proliferation following Lmod1 deletion, we 
conducted Ki-67 staining on intestinal segments from Lmod1-/- mice. We found a higher 
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percentage of Ki-67+ cells in the outer SMC layer of the duodenum and jejunum (Fig. 5B-C). 
Collectively, these data indicate that Lmod1 deletion bestows an MMIHS-like phenotype 
in mice, characterized by gastroparesis, megacystis, and hydronephrosis. Interestingly, 
vascular and respiratory function appeared normal. (data not shown).
Fig.5: Loss of LMOD does not cause structural abnormalities of the duodenum, jejunum and 
ileum. (A) Histology of Lmod1- intestinal segments. H&E-stained sections of duodenum, jejunum and 
ileum (left column) and immunofluorescence microscopy reveals absence of LMOD1 from visceral 
smooth muscle of intestinal segments from Lmod1-/- mice. (B) Representative photographs of Ki-67 
staining (green) of inner and outer SMC layers (red; stained with anti-SM actin) of the duodenum and 
ileum of Lmod1 knockout mice. White arrowheads indicate an increase in Ki-67 positive cells in the 
outer SMC layer of Lmod1-/- duodenum and jejunum. C. Quantitation of Ki-67 staining shown in part B.
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Deficiency of LMOD1 impairs the formation of actin filaments in hISMC and mouse 
intestine, and reduced cellular contractility
Fig.6: Knockdown of LMOD1 on hISMC disturb the formation of actin filaments and contractility. 
(A) In vitro G-actin : F-actin assays show that when LMOD1 is knocked down, the amount of actin 
filaments that pelleted by ultracentrifugation are severely reduced. (B) Confocal images of hISMC 
stained for LMOD1 and Phalloidin on cells transfected with Scrambled siRNA or siLMOD1, show that 
reduced expression of LMOD1 cause reduced formation of actin filaments. (C) Collagen contractility 
assays on hISMC transfected with scrambled siRNA or siLMOD1 show impaired contractility when 
LMOD1 is knocked down. 
Since LMOD1 has been described as an actin filament nucleator in SMC (Boczkowska, 
Rebowski et al. 2015), we aimed to test the effect of LMOD1 deficiency in hiSMC. siRNA 
against human LMOD1 was used on cultured hiSMC and Western blot analysis confirmed 
knockdown of LMOD1 protein. Immunoblotting with smooth muscle alpha actin (ACTA2) 
showed that the formation of actin filaments in LMOD1-deficient cells was severely reduced 
compared to controls (Fig. 6A). LMOD1 and Phalloidin staining showed severe reduction 
in the number and size of actin filaments in LMOD1-deficient hiSMC (Fig. 6B). Results 
from G-actin/F-actin and immunofluorescence analyses demonstrated that knockdown of 
LMOD1 in hiSMC impairs actin filament formation.  
 To further investigate the effect of the reduction of actin filaments on the function 
of hISMC, we performed a contractility assay. We revealed reduction of cellular contractility 
by more than 40% in LMOD-1 deficient hiSMC compared to controls (Fig. 6C)
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Lmod1-KO mice exhibit defects in filamentous actin formation and SMC contraction
Our data in hiSMC revealed decreased formation of filamentous actin (F-actin) following 
siRNA knockdown of LMOD1. Therefore, we wished to examine F actin in primary tissues 
from Lmod1-KO mice. Ultracentrifugation of bladder tissue lysates and subsequent G/F 
actin analysis revealed an approximate 2-fold decrease in F actin following LMOD1 
deletion (Fig. 7A-B). These data support the hypothesis that the functional and structural 
defects in LMOD1-/- MMIHS results from a decrease in F actin formation. 
 Since MMIHS is characterized by functional obstruction of the urinary bladder 
and hypoperistalsis in the intestine, we wished to test the hypothesis that Lmod1 deletion 
results in decreased SMC contractility. We conducted myography experiments on primary 
jejunum ring segments; the results revealed significantly reduced contractile force in 
Lmod1-/- mice in response to both KCl and carbachol treatment. Importantly, the Lmod1-/- 
tissues did not exhibit a complete absence of contraction (Fig. 7C-D). 
 Cumulatively, these data suggest that LMOD1 deletion results in decreased 
formation of F actin and impaired contraction in visceral smooth muscle. Together, these 
phenotypes most likely lead to the functional obstruction of the urinary bladder and 
intestine observed in LMOD1-/- MMIHS. 
Fig.7: Deficit of Lmod1 in mice impairs filamentous actin formation and SMC contraction. (A-
B) G-actin : F-actin assays show significant reduction of actin filaments in Lmod1-KO mice. (C-D) 
Myography assays show reduction of SMC contractility in Lmod1-KO mice.
C
ha
pt
er
 3
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome in Human and Mice Deficient of Leiomodin-1
63
DISCUSSION
We identified a single-nucleotide nonsense mutation within exon 2 of LMOD1 in a patient 
with MMIHS, a rare congenital disease of the intestine and urinary bladder. Our study 
revealed that this mutation severely decreased the expression of LMOD1 at both the mRNA 
and the protein level in patient fibroblasts. Moreover, the gross morphology of Lmod1 KO 
mice is strikingly similar with the MMIHS phenotype in human, indicating LMOD1 is a new 
disease gene for MMIHS. Our studies indicate that loss of LMOD1 decreases filamentous 
actin formation and impairs SMC contraction in vivo. 
 LMOD1 is one of three Leiomodins, a family of tandem monomer-actin-binding 
nucleators (Chereau, Boczkowska et al. 2008, Chen, Ni et al. 2015). LMOD1 is preferentially 
expressed in SMC lineages and is regulated by the serum response factor-myocardin 
transcriptional switch (Nanda and Miano 2012). LMOD2 and LMOD3 are preferentially 
expressed by cardiac and skeletal muscle, respectively (Tsukada, Pappas et al. 2010, 
Yuen, Sandaradura et al. 2014). Knockout of Lmod2 in mice resulted in cardiomyopathy 
while disruption of Lmod3 expression mimics nemaline myopathy in human (Yuen, 
Sandaradura et al. 2014, Pappas, Mayfield et al. 2015, Tian, Ding et al. 2015). 
 Despite preferential expression of LMOD1 in SMC has long been known, 
the importance of LMOD1 in SMC of visceral organs remained unclear. Our 
immunohistochemistry results using human intestine from different developmental stages 
showed continuous expression of LMOD1 in all SMC that inhabit the intestine (Fig. 2). 
Since MMIHS is a congenital disease, early expression of LMOD1 may serve an important 
role during the development of human intestine and urinary bladder, therefore any 
disturbances may affect these organs and possibly contribute to MMIHS. This expression 
pattern is similar to previous findings in the intestine of mouse embryo (Nanda and Miano 
2012), hence the necessity to create an Lmod1 knockout mouse in order to investigate 
further.    
 As expected, gross morphology of Lmod1 KO mice is strikingly similar to MMIHS 
in humans. However, significant architectural changes were only observed in the stomach, 
not in the continuing three proximal segments of the intestine, in Lmod1-/- mice. Data from 
Lmod1-/- E18.5 mouse embryo showed none of the structural changes in the stomach, 
confirming that this abnormality is only acquired after birth, and likely due to overdilation of 
the stomach by its contents that could not be efficiently passed through to the continuing 
organs. Interestingly, and entirely consistent with clinical observations of MMIHS, we did 
observe distension of the urinary bladder in e18.5 embryos. These data suggest that in 
principal, loss of LMOD1 is insufficient to alter embryogenesis of the bladder and intestine, 
but may be detrimental to the functional contractility of these organs. Of note, there does 
not appear to be severe pathology in other SMC containing tissues such as blood vessels 
and airways of the lung though further investigation is needed using more restrictive 
means of deleting Lmod1 to vascular or respiratory SMC.
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Fig. 8: Schematic representation of LMOD1’s function in the formation of actin filaments, and 
the predicted effect of LMOD1 mutations on this mechanism. In wild-type, SRF/MYOCD complex 
interacts with CArG regions in LMOD1 gene, leads to LMOD1 expression. Then, as an actin filament 
nucleator, LMOD1 protein initiates the formation of actin filaments. These actin filaments will form 
a cross-bridge interaction with thick myosin filaments, and cause contractions. In mutant LMOD1, 
although SRF/MYOCD complex can bind with CArG regions in its gene, expression of LMOD1 is 
disrupted. Thus, formation of actin filaments is severely impaired. The absent/decreased number of 
actin filaments impair actin-myosin interaction, leading to the failure of contraction in cells. 
 Muscle contraction in visceral organs is the product of coordinated molecular 
processes inside SMC. The center of this elaborate mechanism is the cross-bridge 
interaction between actin thin filaments and myosin thick filaments. Monomer (G-) actin 
molecules polymerize to form an actin filament; to start this process, actin monomers must 
first form actin nuclei, a process referred to as actin nucleation. Although this process can 
occur spontaneously, it is energetically inefficient (Sept and McCammon 2001), and cells 
employ actin nucleator proteins to enhance this reaction. 
 As tandem-monomer-binding nucleator, Leiomodins have actin binding motifs 
that bring G-actins together and create a molecular foundation for actin polymerization to 
form actin thin filaments (Fig. 8) (Qualmann and Kessels 2009). Reports have suggested 
that the process of actin polymerization and depolymerization relates with the continuous 
cycle of contraction and relaxation in SMC. By using actin fractionation assays and 
phalloidin staining, earlier publications have suggested that contraction stimulation on 
SMC induces actin polymerization, hence increases the amount of F-actin. Conversely, 
actin filaments are reduced when relaxation occurs (Hirshman, Zhu et al. 2005, Chen, 
Pavlish et al. 2006).
 Our functional data suggest that loss of LMOD1 decreases of the number of 
actin filaments in hISMC (Fig. 6A-B) and in primary mouse jejunum (Fig. 7A-B). These 
indicate that LMOD1 is indeed an important factor that regulate the actin polymerization 
rates in hISMC. Based on this findings and our current knowledge of the importance of 
actin filament formation in contractility, the decreased actin filaments in LMOD1-deficient 
cells may well be the cause of the impaired cellular contractility in hISMC (Fig. 6C) and in 
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primary mouse jejunum (Fig. 7C-D).       
 Our myography data shows a significant decrease in contractile force in mouse 
intestine lacking LMOD1. Interestingly, we noted a distinct lack of structural integrity in 
mouse tissues during these studies; the intestinal segments were more delicate to the touch 
in KO tissues during dissection, requiring extreme care to handle. Perhaps most striking 
was the inability of the KO jejunum segments to maintain passive tension during the initial 
stages of myography. Whereas control tissues exhibited tensile strength and maintained 
passive tension in response to dilation, KO tissues were unable to do so. Despite this, KO 
tissues were able to undergo repeated cycles of contraction and relaxation, suggesting 
that the distension/dilation observed in stomach, duodenum, and urinary bladder results 
from some combination of defective contraction and decreased structural integrity.     
 In addition to the data we collected on the involvement of LMOD1 in MMIHS, 
indirect evidence on its involvement comes from another mouse model lacking serum 
response factor (SRF), a regulator of LMOD1 transcription. In both cell and mouse model, 
knockdown of SRF result in reduction of LMOD1 expression (Nanda and Miano 2012). As 
expected, smooth muscle-specific inactivation of SRF in mouse models lead to severe 
dilation of the gastrointestinal tract and urinary bladder (Angstenberger, Wegener et al. 
2007, Mericskay, Blanc et al. 2007). Reduction of SRF also showed a decrease in the 
number of actin filaments formed in colon SMC from mutant mouse (Angstenberger, 
Wegener et al. 2007). Altogether, these findings support our hypothesis about LMOD1 as 
the disease-causing-gene of MMIHS.
 LMOD1 appears to interact with tropomyosins (Kostyukova 2007), however, mice 
null for the major SMC tropomyosin isoform (Tpm2) are embryonic lethal thus precluding 
analyses in postnatal visceral SMC functions (EN: 6550). It will be interesting to assess 
whether SMC-specific KO of Tpm2 has an MMIHS-like phenotype. Additionally, several 
other null phenotypes, among proteins that presumably are all tied to contractile activity, 
have been described. Chronic intestinal pseudo-obstruction with defective intestinal SMC 
contraction is seen in mice lacking Smoothelin A (EN: 6546) (Niessen, Rensen et al. 2005). 
These results should be contrasted with the relatively normal GI/bladder phenotypes 
observed in mice lacking other SMC cyto-contractile genes such as Cnn1 (EN: 2683), 
Telokin (EN: 4318), Acta2 (EN: 3018), Cald1 (EN: 6548), Csrp1 (EN: 6549), and Tagln 
(EN: 3131). The reason for such different null phenotypes among proteins that presumably 
are all tied to contractile activity is unclear.
 Mutations in two other genes, ACTG2 and MYH11, have been identified previously 
(Thorson, Diaz-Horta et al. 2014, Wangler, Gonzaga-Jauregui et al. 2014, Gauthier, Ouled 
Amar Bencheikh et al. 2015, Halim, Hofstra et al. 2016). In vitro assays showed that 
disease-causing-variants in ACTG2 impair actin polymerization (Halim, Hofstra et al. 
2016). The Actg2 null mouse, which based on human data would have a MMIHS-like 
phenotype, has yet to be generated. Meanwhile, knockout of Myh11 in mouse causes 
the inability of SMC to maintain the initial high-force phase of muscle contraction which 
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precipitates hypocontractility of the bladder and the intestine (EN:2957) (Morano, Chai et 
al. 2000). 
 We conclude that this discovery adds LMOD1 to the list consisting ACTG2 and 
MYH11, as MMIHS disease-causing-genes. This shows that MMIHS is a heterogeneous 
disease of the smooth muscle of visceral organs, with multiple patterns of inheritance.
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Supplemental table 1
Primer Sequence
Sequencing forward mutation in exon 2 Human LMOD1 GGAGGTGGCCAAGAAAGAGG
Sequencing reverse mutation in exon 2 Human LMOD1 ATCATGAAGCCAGGGTCTCC
qRT-PCR forward human LMOD1 GAGGCCATGCTCAACTTCTG
qRT-PCR reverse human LMOD1 CTCTCCATTCTTGGCATCTG
qRT-PCR forward human COPS5 CCAGGAACCATTTGTAGCAG
qRT-PCR reverse human COPS5 GTAGCCCTTTGGGTATGTCC
qRT-PCR forward human CLK2 TCGTTAGCACCTTAGGAGAGG
qRT-PCR reverse human CLK2 TGATCTTCAGGGCAACTCG
PCR forward deletion in exon 1 mouse Lmod1 GCCCAAAGAGCTGCAGTGC
PCR reverse deletion in exon 1 mouse Lmod1 CTCACATCCACAGACATCTCTCTC
qRT-PCR forward Exon 1 mouse Lmod1 TGTGGATGAAAGCAAGCAAGTG
qRT-PCR reverse Exon 2 mouse Lmod1 AATACCTCTGATGACCTTCTCCTC
qRT-PCR forward Exon 2 mouse Lmod1 CTGCCATCCGTTCTAGCAAC
qRT-PCR reverse Exon 3 mouse Lmod1 CAAGAGTCTGGGCAGTCATG
qRT-PCR forward mouse Gusb CATCAGAAGCCGATTATCCAGAG
qRT-PCR reverse mouse Gusb TGTTTCCGATTACTCTCAGCG
Supplemental table 2
Guide RNA Sequence
gRNA1                                                      CCAAAGTAGCTAAGTACCGG
gRNA2                                                      GGTCTTCACTCACCTGCCGC
gRNA3                                                      TCCCGGTTGAATGAGCCCGA
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Supplemental table 4
Gene Coding 
Effect
Zygosity Read 
depth 
Type Location Exon HGVS cDNA-level 
FNDC1 missense heterozygous 24 snp exonic 14 NM_032532.2:
c.4436C>G
ITGA8 missense heterozygous 34 snp exonic 2 NM_003638.1:
c.245C>T
LMOD1 stopgain homozygous 65 snp exonic 2 NM_012134.2:
c.1108C>T
NEB missense heterozygous 20 snp exonic 125 NM_001271208.1:
c.19396C>T
PPP1R13L missense heterozygous 22 snp exonic 6 NM_001142502.1:
c.823T>G
RYR1 missense heterozygous 26 snp exonic 21 NM_000540.2:
c.2654G>A
SMTN missense heterozygous 65 snp exonic 9 NM_001207018.1:
c.1504G>A
SMTN missense heterozygous 54 snp exonic 9 NM_001207018.1:
c.1558G>A
SMTN missense heterozygous 76 snp exonic 10 NM_001207018.1:
c.1762C>G
TCF3 missense heterozygous 60 snp exonic 18 NM_003200.3:
c.1600G>A
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Chapter 4
ABSTRACT
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS) is a congenital dis-
ease characterized by the loss of smooth muscle contraction in the bladder and the in-
testine. Two genes: ACTG2 and MYH11, have been identified as the disease-causing 
genes of MMIHS. Nonetheless, the genetic cause of this disease in some patients remains 
unknown. By using homozygosity mapping and whole exome sequencing, we determined 
the deleterious variation shared between three MMIHS patients from two different con-
sanguineous families. Splicing assay and immunohistochemistry were used to confirm the 
pathogenicity of the identified variants. We identified homozygous variants in the Myosin 
light chain kinase (MYLK) gene in both families. A duplication of seven base pairs was 
found in one family, while s splice-site variant was identified in the other family. Expression 
studies indicated that these variants severely reduced MYLK expression. Histopathology 
analyses in one patient excluded other significant changes in the structure and cellular 
contents of the intestine and bladder. Our results show that MYLK is a new disease-
causing gene of recessive MMIHS, confirming MMIHS is a heterogeneous disease of the 
visceral organs, with multiple patterns of inheritance.
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INTRODUCTION
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS [OMIM 249210]) is 
a congenital disease of the visceral organs, characterized by severe hypocontractility of 
the urinary bladder and the intestine (Berdon, Baker et al. 1976, Wymer, Anderson et al. 
2016). Total parenteral nutrition and multivisceral transplantation are the only currently 
available treatments for MMIHS patients (Yokoyama, Fujimoto et al. 1989, Masetti, 
Rodriguez et al. 1999, Raofi, Beatty et al. 2008, Lopez-Munoz, Hernandez-Zarco et al. 
2013). Although long term survival has been documented, most patients with MMIHS do 
not survive through the early years of their life (Hirakawa, Ueno et al. 2009, Lopez-Munoz, 
Hernandez-Zarco et al. 2013, Halim, Hofstra et al. 2016). 
 Initial studies suspected that defects in either muscles, neurons or interstitial 
cells of Cajal are the underlying cause of MMIHS (al-Rayess and Ambler 1992, Rolle, 
O'Briain et al. 2002, Piotrowska, Rolle et al. 2003, Piaseczna Piotrowska, Rolle et al. 
2004, Szigeti, Chumpitazi et al. 2010). However, recent findings have reported mutations 
in three muscle-related, including enteric smooth muscle actin γ2 (ACTG2), myosin 
heavy chain-11 (MYH11) and Leiomodin-1 (LMOD1), as the genetic etiologies of this 
lethal syndrome (Wangler and Beaudet 1993, Thorson, Diaz-Horta et al. 2014, Wangler, 
Gonzaga-Jauregui et al. 2014, Gauthier, Ouled Amar Bencheikh et al. 2015, Tuzovic, Tang 
et al. 2015, Halim, Hofstra et al. 2016). De novo mutations in ACTG2 lead to the autosomal 
dominant form of MMIHS, while mutations in LMOD1 and MYH11 cause recessive forms 
of MMIHS. Altogether, these discoveries have led to the hypothesis that MMIHS is caused 
by disruption of actin-myosin interactions in smooth muscle cells (SMC) of the visceral 
organs.
 Despite these findings, the genetic etiology in some patients with MMIHS 
remained unknown, leading us to hypothesize that another locus might be responsible. 
Here, we describe genetic studies in three MMIHS patients from two consanguineous 
families, for which no variants in two known MMIHS genes was identified.  
 Considering that consanguinity is known to increase regions of shared haplotypes, 
identical by descent (IBD) regions, we used a combined strategy of homozygosity mapping 
and WES to identify deleterious variations in these consanguineous patients. Two different 
loss of function variants in the gene encoding myosin light chain kinase (MYLK) (OMIM 
600922) were found in these families (Bittles 2001); (Lander and Botstein 1987).
MATERIALS AND METHODS
Patient inclusion
We included three patients suspected of having a recessive form of MMIHS. From family 
I, two patients were analyzed, whereas from family II, one patient was examined. Family 
anamnesis suggested that the parents were consanguineous. DNA of all patients was 
isolated from peripheral blood lymphocytes. Paraffin-embedded intestinal and bladder 
specimens were obtained from patient 1. This study was approved by the Erasmus Medical 
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Center ethical committee (Medisch Ethische Toetsings commissie - METc 2011/148, ABR 
form: NL35920.042.11). Written informed consents were granted by the families. 
SNP-array analysis
250 ng of DNA from patient 1 was processed according to standard protocols and 
hybridized to the CytoSNP-850K v0 array (Illumina, Inc., San Diego, USA). The normalized 
output generated with Illumina’s Genome Studio program version 2011.1 (Illumina, San 
Diego, CA, USA) was visualised with Nexus CN8.0 (Biodiscovery Inc, El Segundo, CA, 
USA) using analysis settings and Copy Number Variation (CNV) prioritization methods 
as previously described (Brosens, Marsch et al. 2016). The genotype information of the 
SNP-array was used to confirm family relations (patient 1 and her parents) and determine 
Runs of Homozygosity, the consanguinity coefficient (f), and the inbreeding coefficient (F). 
Homozygosity mapping
The genotype information collected from the SNP-arrays was used to identify ROH possibly 
harbouring homozygous recessive variants (Kearney, Kearney et al. 2011). As ROH can 
vary in length between populations and in different individuals of the same population, 
strict criteria have to be used to increase the likelihood of detecting a recessive variant 
in these regions. A suggested criterium is at least 50 SNPs (minor allele frequency of at 
least 5%) in a 1 cM region (Auton, Bryc et al. 2009), roughly 500kb-2000kb (Yu, Zhao et 
al. 2001). Here we use a 50 SNP minimum and at least a 1Mb ROH length. 
Whole Exome Sequencing
Fragmentation of DNA (Covaris, Inc. Woburn, Massachusetts, USA), Target capture 
(SureSelect Human All Exon 50 Mb Targeted exome enrichment kit v4, Agilent Technologies, 
Inc., Santa Clara, California), library preparation (paired-end, 101 bp, TruSeq version 4 
protocol, Illumina, Inc., San Diego, USA) and processing of raw sequence data using the 
NARWHAL pipeline was done as described before (Brouwer, van den Hout et al. 2012). 
Reads were aligned to the hg19 reference genome using Burrows-Wheeler Aligner version 
0.6.2. Variants were determined using the Bayesian genotyper that is incorporated in the 
genome analysis toolkit version 1.2.9. The results were then uploaded to the Cartagenia 
Bench NGS version 4.1.7 (Cartagenia Inc, Boston, MA, USA) for filtering. Copy Number 
Variants (CNV) and ROH regions were transferred from Biodiscovery Nexus CN7.5. into 
Cartagenia Bench CNV and NGS in order to determine the overlap between the identified 
ROH regions and rare variants. 
 High frequency in our in-house control cohort (n=280, with similar capture, 
alignment and variant calling procedures and n=500 additional in-house controls) were 
ruled out. Furthermore, variants with an allele frequency above 0.1% in public databases 
(ExAC release 0.3, ESP6500SI-V2; 1000 Genomes Phase 3 release v5.20130502 and 
GoNL SNPs and Indels release 5) were excluded. Only variants predicted to affect splicing, 
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nonsense variants, and coding and non-coding variants with a CADD score above 20 
(CADD v1.3) were retained.
Sanger sequencing 
Sanger sequencing was used to validate the presence of the MYLK variants identified. 
For that, 15 ng of genomic DNA was used to replicate each amplicon using standard 
PCR methods, and the primers set listed in Supplemental table 4. PCR products were 
purified using ExoSap it (GE Healthcare, Little Chalfont, Buckinghamshire, UK), and 
Sanger sequencing was conducted using dye labelled primers (forward and reverse; Big 
Dye Terminator v3.1 Sequencing Kit, Applied Biosystems, Waltham, MA, USA) on the ABI 
3130XL genetic analyser. Sequencing reads were performed by using SeqScape® v2.5 
software (Thermo Fisher Scientific, Waltham, MA, USA).
Cell culture and transfection
Human embryonic kidney cells (HEK293) cells were cultured in DMEM (Lonza, Basel, 
Switzerland), complemented with 10% FCS (Sigma-Aldrich, St. Louis, Missouri, USA) and 
1% Penicillin-Streptomycin (Gibco, Waltham, MA, USA). Cells were incubated at 37˚C 
and 5% CO2. For transient transfection, 300,000 cells were plated in a 6-well-plate (Nunc, 
Rochester, NY, USA). Twenty-four hours after, cells were transfected using Lipofectamine 
2000 (Thermo Fisher Scientific, Waltham, MA, USA) as a transfection reagent according 
to the manufacturer’s instructions.
Generation of splicing constructs
Wild-type (WT) and mutant constructs were generated using 15 ng of genomic DNA from 
control and patient, as template, respectively. Primer sets were designed to include the 
genomic sequence that stretch from the last part of intron 21 of MYLK to the beginning 
of intron 22 (Supplemental table 4). After confirmation of successful amplification by gel 
electrophoresis, PCR products were subjected to enzyme restriction with NotI and PstI 
(New England Biolabs, MA, USA), ligated into pSPL3 using T4 DNA ligase (Invitrogen, 
Carlsbad, CA, USA), and transformed into E.coli One Shot TOP10 competent cells 
(Thermo Fisher Scientific, Waltham, MA, USA). Constructs were isolated with a MIDI prep 
kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s instructions. All 
constructs were Sanger sequenced to confirm successful ligation and transformation.
Splicing assays
48 hours after transfection of HEK293 cells with splicing constructs, cells were collected 
and used to isolate mRNA using the RNeasy mini kit (Qiagen, Venlo, The Netherlands) 
according to the manufacturer’s instructions. Reverse transcriptase (RT)-PCR was 
performed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). To evaluate 
the produced transcripts from WT, mutant, empty vector and nontransfected cells, forward 
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SD6 and reverse SA2 primers (Supplemental table 4) were used in a standard PCR 
protocol. PCR products were analysed by electrophoresis on a 3% agarose gel, and 
visualised using ChemiDoc XR+ System (Bio-Rad, Hercules, CA, USA).
Immunohistochemistry
Formalin-fixed paraffin-embedded human small intestinal and bladder tissues obtained 
from controls were retrieved from the Biobank of the Pathology Department, Erasmus 
University Medical Center. Intestinal and bladder specimens from patient 1 were obtained 
from the Department of Pathology of the Hôpital Universitaire Robert Debré. Specific 
antibodies directed against MYLK (1:100; Thermo Fisher Scientific, Waltham, MA, USA), 
Neurofilament (1:600; Monosan, Uden, The Netherlands), Smooth muscle actin α2 (ACTA2) 
(Ready to use; Dako, Glostrup, Denmark), Tyrosine protein kinase kit (c-Kit/CD117) 
(1:200; Cell Marque, Rocklin, CA, USA), and Tryptase (1:1600; Dako, Glostrup, Denmark) 
were applied. The biotinylated multilink secondary antibody and the avidin-biotin-complex 
with peroxidase were then used, followed by application of 3,3’-diaminobenzidine (DAB) 
chromogen (Ventana, Tucson, AZ, USA). All slides were counterstained with hematoxylin. 
Images were generated with a Nanozoomer 2.0-HT, and analyzed with the Nanozoomer 
Digital Pathology (NDP) viewer software (Hamamatsu Photonics, Hamamatsu City, 
Shizuoka, Japan).  
RESULTS
Clinical features of the patients
Three patients derived from two different consanguineous families. Patient 1 was 
the second child to consanguineous parents of North African origin. Prenatal 13-
week ultrasound acknowledged the presence of distended bladder, and a generalized 
subcutaneous edema (Fig. 1A). Hence, parents opted for termination of pregnancy at 
15-weeks of gestation. Autopsy of the fetus confirmed the diagnosis of MMIHS. Patient 2 
was the younger brother of patient 1. 
 Prenatal 24-week ultrasound detected the distended bladder, with hydronephrosis 
and severe oligohydramnios (Fig. 1B). The parents opted not to terminate the pregnancy, 
and labor was prematurely occured at 31-weeks of gestation. The neonate experienced 
respiratory distress, and succumbed. Further anamnesis on the family history revealed 
that the older sister of patient 1 was also acknowledged of having distended bladder prior 
to her intra uterine death at 30-weeks of gestation.
 Patient 3 was the first child of a couple of Indian origin. Antenatal period was 
complicated with polyhydramnios. Nevertheless, the baby was born at term by normal 
delivery, without any neonatal complications. At 2-days-old, she was admitted back to the 
hospital due to bilious vomiting. Barium enema testing confirmed intestinal obstruction, 
and suspected intestinal malrotation as the cause (Fig. 1C-E). Surgery at 3-day-old 
released the small intestinal congenital bands, and corrected the intestinal malrotation 
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with ileostomy. The surgery also revealed the unused distal microcolon. Additionally, 
the bladder was catheterized. Histopathology analysis of the mid-ileum identified the 
presence of ganglia. Since the ileostomy remained non-functional until 13 days after the 
initial surgery, second surgery was performed. Adhesions between the intestinal loops 
were revealed and released. The first ileostomy was removed, and a new double barrel 
ileostomy was made. 
Fig.1: Barium enema and ultrasonography examinations in the three MMIHS patients. (A) 
Prenatal ultrasonography on patient 2 at 13 weeks revealed distended bladder and generalized 
subcutaneous edema. (B) Prenatal ultrasonography on patient 3 at 24 weeks revealed distended 
bladder, hydronephrosis and severe oligohydramnios.(C-E) Barium enema testing suggested 
intestinal obstruction and malrotation. (F and G) Ultrasonography on patient 1 at neonatal revealed 
dilatation of the bladder and bilateral hydronephrosis. Legends: K: kidney, UB: urinary bladder.
 Despite all efforts, the new ileostomy was never functional, and the patient 
experienced sepsis. Abdominal ultrasound revealed distension of the bladder and bilateral 
hydroureteronephrosis (Fig. 1F-G), and the diagnosis of MMIHS was made. The parents 
were made aware of the poor prognosis, and they opted to have the patient discharged 
from the hospital. Further follow-up on the family acknowledged that the younger sister of 
patient 1 was also diagnosed with MMIHS.   
Homozygosity mapping confirms consanguinity in family I
Homozygosity mapping has been used to successfully determine causal genes in suspected 
autosomal recessive disorders both in inbred and outbred populations. Considering this, 
we performed homozygosity mapping in Family I as a starting point of our genetic analysis. 
Familial relations were confirmed and, as suggested by the anamnesis, the genotype 
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information indicated consanguinity (f of 0.25 and F of 0.125 with 372 Mb of ROH). Fifty-
five homozygous regions were identified in patient 1 of at least one Mb in length and 
harboring at least 50 probes. Of these 55 regions, 38 were present in the parents in a 
heterozygous state (Supplemental table 1). No deleterious CNVs were identified in patient 
2 (Supplemental table 2).
   
Whole Exome Sequencing identified deleterious variants in MYLK in patient 1 and 3
As consanguinity increases the risk for autosomal recessive disorders (Hamamy, 
Antonarakis et al. 2011, Hamamy 2012), we screened patient 1 for deleterious recessive 
mutations using WES. Segregation of identified variants was investigated in her affected 
brother, patient 2, and unaffected sister. Out of 1075 rare variants found (MAF below 
0.1%), 98 were located in one of the identified 38 ROH regions. 
Fig.2: Identification of the homozygous mutations in MYLK in MMIHS patients. (A) Out-of-frame 
mutation is identified in patient 2 and patient 3, while the presence of this variant in a heterozygous 
state in their parents confirmed the recessive pattern of inheritance. (B) Splice-site mutation is 
identified in patient 3. (C) An overview of MYLK with its 33 exons and its three major isoforms, with all 
the identified variants in MMIHS and TAA7 patients.
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 51 of these variants were inherited recessively. To screen for known recessive 
disease gene involvement, we uploaded the 38 ROH regions, present only in the patient 
and not in the parents, in the genomic oligoarray and SNP-array evaluation tool v3.0 
(Wierenga, Jiang et al. 2013) and screened for recessive candidate syndrome genes 
using Human Phenotype Ontology terms “abnormality of the gastrointestinal tract” and 
“abnormality of the genitourinary system”. One-hundred genes were prioritized, none of 
which had rare recessive deleterious variants in patient 1. Eleven out of 51 recessive 
variants were predicted to be deleterious: two variants were predicted to affect splicing, 
two frameshift mutations and 7 missense variants (see supplemental table 3). Of these, 
one affected gene was involved in the biological process known to be affected in MMIHS: 
SMC contraction. This variant, a frameshift insertion in exon 23 of the MYLK gene 
(NM_053025.3: c.3838_3844dupGAAAGCG) was present in a 2,898,353 bp ROH region 
(hg19, chr3:120,385,537-124,830,052). Sanger sequencing confirmed this homozygous 
variation in the affected patients 1 and 2 and absence in their unaffected sister, while 
heterozygous in their parents (Fig. 2A). Sanger sequencing of the healthy sibling showed 
no mutant allele was inherited. This genetic finding was submitted to ClinVAr (http://www.
ncbi.nlm.nih.gov/clinvar/) and was given the following accesion number: SCV000299345.
 Patient 3 was also submitted to WES and data analysis was performed as 
described before (Wangler, Gonzaga-Jauregui et al. 2014). We identified splice variant in 
intron 22-23 of MYLK as the only homozygous rare variant in this patient (NM_053025: 
c.3985+5C>A). 
 
MYLK is expressed in all SMC throughout the developmental stages of the human 
intestine and bladder 
As we hypothesized that rare variants in MYLK cause MMIHS we assume that MYLK is 
physiologically expressed during the development of the intestine. Hence, loss of MYLK 
expression during embryogenesis might hamper normal development of these organs. 
By using a specific antibody against MYLK, we performed immunostainings on human 
intestinal and bladder specimens collected at different developmental stages. We show 
that MYLK is strongly expressed in all SMC that form all muscular structures of the intestine 
and bladder, across all the developmental stages included in this study (Fig. 3A-F).  
Homozygous out-of-frame variant in patient 1 severely reduces MYLK expression in 
the intestine and bladder
To assess the effect of the out-of-frame variant in the expression of MYLK, we 
immunostained the intestinal and bladder specimens collected from patient 1. Intestinal 
tissue collected from age-matched controls were used for comparisons. 
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Fig.3: Expression of MYLK in human intestine and bladder. (A-F) MYLK is expressed in SMC that 
constitute muscular structures of the intestine and the bladder, including muscularis mucosa, blood 
vessels, circular and longitudinal muscles of the muscularis propria. Similar patterns and levels of 
expression were present throughout all developmental stages included in this study. 
As expected, we observed that MYLK is strongly expressed in SMC of the intestine of 
controls. However, no expression was detected in the small intestine, rectum and bladder 
of the patient (Fig. 4A-E), confirming pathogenicity of the duplication found.  
Homozygous splice variant in patient 3 severely impairs splicing of exon 22 of MYLK
Fig.4: The identified mutations caused the loss of MYLK expression in patients with MMIHS (A-
E) Immunohistochemistry results showed that the out-of-frame mutation in patient 2 eliminated MYLK 
expression in the intestine and the bladder. (F) Splicing assay revealed the diminished transcripts in 
mutant mini-gene consisting of the splice variant found in patient 1. 
To test the effect of the presumed splice site variant found in patient 3 (NM_053025: 
c.3985+5C>A), we performed splicing assays. For that, HEK293 cells were transfected 
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Fig.5: Immunohistochemistry of the intestine and bladder specimens from patient 1 showed 
no structural and cellular defects due to the out-of-frame mutation. (A-T) H&E staining and 
immunostainings using specific antibodies against ACTA2, Neurofilament, c-Kit/CD117, Tryptase and 
ACTA2 on control and patient specimens showed were not significantly different.
with one of the following splicing constructs generated: wild type, mutant, empty vector, 
and non-transfected. Non-transfected cells were also included as a control. The expected 
transcript of the wild type construct is 414 bp, while the empty vector should produce 
a transcript of 261 bp. Our results showed that the wild type construct produced the 
transcript with the expected size (414 bp). However, several other transcripts were also 
generated, suggesting that exon 22 is normally target of alternative splicing. Conversely, 
the mutant construct eliminated all the transcription products seen in the wild type situation, 
and produced only a band identical to the one showed by the empty vector. This result 
suggests that the identified variant leads to loss of a splice site in intron 22 of MYLK, and 
is likely to lead to the absence of exon 22 in the final expression product (Fig. 4F). 
No structural abnormalities were found in the intestine and bladder of patient 1 
To investigate the impact of the loss of MYLK expression on the histopathology of the 
intestine and bladder, we immunostained specimens collected from the small intestine, 
rectum and bladder of patient 1 using antibodies against Neurofilament, c-Kit/CD117, 
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Tryptase and ACTA2. Intestinal specimens obtained from the autopsy of age-matched 
controls was used for comparison. Our results did not detect any abnormal expressions of 
the investigated proteins when compared with controls (Fig. 5), suggesting that absence 
of MYLK does not significantly alter the structure of the intestine and bladder.    
DISCUSSION
Along with neurons and interstitial cells of Cajal, SMC are crucial for the contractility 
of the intestine and the bladder. SMC contraction results from an elaborate molecular 
process, involving the cross-bridge interaction between thin actin filaments and thick 
myosin filaments. Therefore, loss of any of the proteins involved in this process is likely 
to affect cell physiology, resulting in loss of contractility. In this manuscript we report the 
identification of pathogenic variants in one of the genes involved in this process, MYLK, 
in three patients diagnosed with MMIHS, a congenital disease that is characterized by 
inability of the bladder and intestine to contract. MYLK is an important protein kinase that 
phosphorylates the regulatory light chain (RLC) of myosin II in SMC (Kamm and Stull 
2001, Hong, Haldeman et al. 2011), leading to its activation. Therefore, it is not surprising 
that altered expression of this protein may cause loss of contractility in the bladder and 
intestine, as experienced by MMIHS patients. 
 In humans, three major MYLK isoforms exist, including the long MYLK isoform 
(~210 kD) referred to as non-muscle MYLK (nmMYLK), the short MYLK isoform (~130 kD) 
referred to as smooth muscle MYLK (smMYLK), and a very small isoform called telokin (~17 
kD) (Hong, Haldeman et al. 2011).The nmMYLK and the smMYLK isoforms are composed 
by several important functional domains, including actin binding domains, a kinase and 
a regulatory domain. However, the nmMYLK has 922 additional amino acid residues at 
the N-terminal region that results in the presence of six additional immunoglobulin (Ig) 
modules and two actin binding motifs (Garcia, Lazar et al. 1997, Kamm and Stull 2001). 
 Until now, the functional role of the additional domains present in nmMYLK 
remains unclear. However, as implied by their names, smMYLK predominantly functions to 
phosphorylate RLC of smooth muscle myosin (SMM) in SMC, while nmMYLK is involved 
in both non-muscle and SMC contraction (Hong, Brizendine et al. 2015).Two different 
deleterious variants were identified in the two families included in this study, that based on 
their genomic location may affect both nmMYLK and smMYLK. In patient I.1 from family 
I, we identified a splice site variant that disrupts splicing of exon 22. In patient II.1 and II.2 
from family II, we found an out-of-frame duplication in exon 22 that results in the absence 
of MYLK expression in the intestine and the bladder. Exon 22 encodes an immunoglobulin 
(Ig)-like domain that has been suggested to have an actin binding function. However, 
MYLK immunostainings on intestinal and bladder specimens from patient II.1 showed 
that the out-of-frame duplication in exon 22 abolishes expression of MYLK in SMC of 
the bladder and the intestine (Fig. 4A-E), indicating loss of the whole protein. Hence, we 
remain open to the possibility that the region encoded by exon 22 might have an important 
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role in the function of MYLK in visceral organs.
 As showed by our results, MYLK is continuously expressed during the 
development of the intestine (Fig. 3A-F), but to our surprise, no abnormalities in the 
structure and cellular constituents of the intestine and bladder were evident with the loss of 
MYLK (Fig. 5A-T). This finding suggests that although MYLK plays an important role in the 
regulation of SMC contractility in visceral organs, it is not involved in the embryogenesis of 
these organs. These results also suggest that the acquired phenotypes found in MMIHS 
patients with MYLK variants, are solely due to the loss of SMC contractile ability, and not 
because of abnormalities in the structure of the visceral organs. Based on our current 
understanding, we suspect that loss of MYLK causes failure of phosphorylation of the 
RLC, leading to a reduced interaction between actin and myosin, and consequently to 
reduced contractility of SMC (Fig. 6).  
 This hypothesis is supported by the presence of severe gut dysmotility, 
accompanied with abnormal urinary bladder function in a conditional knockout mouse 
for the smMYLK isoform (He, Peng et al. 2008). The similarities between the phenotype 
presented by the mouse with the one showed by MMIHS patients, strongly support our 
conclusion that MYLK is a new disease-causing-gene for MMIHS.  
Fig.6: Schematic illustration of the role of MYLK in the molecular mechanism of SMC contraction, 
and the effect of MYLK variant on this mechanism. In wild-type, MYLK phosphorylates regulatory 
MLC, causing the interaction between actin and myosin filaments that leads to the SMC contraction. 
In mutants, no phosphorylation of regulatory MLC occurs, thus myosin cannot interact with actin 
filaments, and SMC contraction fails.      
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 The answer to the question on how microcolon could develop in MMIHS patients 
remains unclear. Nonetheless, research on human fetal lung muscle contraction indicates 
that fetal lung smooth muscle contraction may provide an important physical force that plays 
a role in lung development (McCray 1993). Therefore, we speculate that gastrointestinal 
SMC contraction may provide an important physical stimulation for the development of 
colon, thus when its absent, microcolon develops.  
 Since SMC do not only constitute the muscular structures in the intestine and the 
bladder, but also blood vessel walls, we expected that the identified homozygous variants 
would cause extra-visceral phenotypes in patients. Interestingly, the phenotypes that were 
acquired in our patients are restricted to the intestine and the bladder. To our knowledge, 
two possibilities may cause such specific defects. The first possible explanation is the 
fact that since none of our patients survived, we were unable to assess extra-visceral 
phenotypes that may be visible at later stages in life. However, it could also be that 
other kinases salvage the contraction in non-muscle and SMC inhabiting extra-visceral 
organs (Goeckeler, Masaracchia et al. 2000, Totsukawa, Yamakita et al. 2000, Niiro and 
Ikebe 2001). Both hypothesis are supported by previous evidence. Heterozygous MYLK 
variants found in patients with familial thoracic aortic aneurysm 7 (TAA7 [OMIM 613780]) 
are in support of the first, since in these patients aneurysms often occur without being 
preceded by gradual dilatation of the aorta (Wang, Guo et al. 2010, Hannuksela, Stattin 
et al. 2016).This suggests that it takes time for the reduction of MYLK to cause its toll on 
major blood vessels. On the other hand, data collected from mouse models are in support 
of the latter possibility. Isolation of aortic cells from mice where the expression of all three 
MYLK isoforms was abolished resulted in induced RLC phosphorylation (Somlyo, Wang 
et al. 2004). In conclusion, our findings add MYLK to the list of existing MMIHS-causing 
genes, which already includes ACTG2, MYH11 and LMOD1. Interestingly, all these four 
genes encode for products involved in the cross-bridge interactions between actin and 
myosin filaments necessary for SMC contraction. Alterations in the expression of ACTG2 
or LMOD1 impair the formation of actin filaments, while loss of MYH11 and MYLK are 
likely to impair formation of thick myosin filaments. Hence, it is tempting to state that 
MMIHS is caused by a defect in the actin-myosin interaction which eventually leads to 
failure of visceral smooth muscle contraction. 
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Supplemental table 1: “new” ROH regions in patient 2
Chromosome ROH region Size (kb)
1 chr1:242944438-244084838 1140400
1 chr1:145416055-147826789 2410734
1 chr1:150856155-165465569 14609414
1 chr1:70267535-120553638 50286103
2 chr2:193957725-194971610 1013885
2 chr2:228026937-231049859 3022922
2 chr2:132604119-139882966 7278847
2 chr2:231059532-240330999 9271467
3 chr3:120385537-121923035 1537498
3 chr3:121931699-124830052 2898353
4 chr4:87160439-91509561 4349122
4 chr4:77709496-86985942 9276446
5 chr5:92602370-93717798 1115428
5 chr5:41416674-42624527 1207853
5 chr5:87090359-88357858 1267499
5 chr5:179620442-180915260 1294818
5 chr5:1483897-8953381 7469484
6 chr6:15067080-19041846 3974766
6 chr6:19050234-25173355 6123121
7 chr7:122810117-123980215 1170098
7 chr7:101954468-103191686 1237218
7 chr7:40483744-43163338 2679594
7 chr7:29178667-40443341 11264674
8 chr8:0-2683108 2683108
8 chr8:46886735-119798778 72912043
9 chr9:70984372-84389822 13405450
11 chr11:54794237-56482051 1687814
11 chr11:79726393-91682741 11956348
12 chr12:42347636-71689131 29341495
13 chr13:23646794-24668110 1021316
15 chr15:36662007-54162140 17500133
16 chr16:68580385-73593216 5012831
17 chr17:44287381-45879796 1592415
17 chr17:41687610-44278785 2591175
18 chr18:334419-3513265 3178846
19 chr19:55569398-59128983 3559585
20 chr20:0-1613328 1613328
22 chr22:18922645-21800198 2877553
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Supplemental table 2: Identified rare CNVs in patient 2
CNV Zygosity Segregation overlap in DDD 
controlsa
Genesb Authors 
classification
hg19 chr2:g.
(152,849,322_152,849,625)_
(152,880,509_152,881,908)del
Heterozygous Paternal Noc CACNB4 Uncertain- 
likely benign
hg19 chr7:g.
(40,442,062_40,444,621)_
(40,481,539_40,485,949)del
Homozygous Parental Yes C7orf10 Benign
hg19 chr1:g.
(46,216,575_46,221,440)_
(46,465,662_46,476,587)dup
Heterozygous Maternal Yes MAST2 Benign
hg19 chr16:g.
(80,441,420_80,442,198)_
(80,551,598_80,554,948)del
Heterozygous Maternal Yes - Benign
hg19 chr17:g.
(77,364,581_77,364,843)_
(77,384,557_77,387,550)dup
Heterozygous De novo Yes RBFOX3 Uncertain- 
likely benign
a CNVs present in the control groups of the developmental delay studies (Cooper, Coe et al. 2011, 
Kaminsky, Kaul et al. 2011, Coe, Witherspoon et al. 2014) and hundred percent CNV overlap, b Genes 
located in the maximum CNV interval, c No CNVs are described in the Developmental delay control 
group, there are losses present. However, these are much larger ranging from several hundred Kb to 
several Mb in length. 
Supplemental table 3: Rare recessive mutations predicted deleterious in ROH regions
Gene Type Exon Effect HGVS genomic-level cDNA Protein CADD 
PHRED
DENND4B Ins 18 F NC_000001.10:g.153907306_15
3907307insGCTGCTGC
c.2702_2703
insGCAGCAGC
p.Gln904Hisfs*48 32
LENEP SNV 1 MS NC_000001.10:g.154966258C>G c.175C>G p.Leu59Val 23.6
MYLK Ins 23 F NC_000003.11:g.123383093_12
3383099dup
c.3838_3844
dupGAAAGCG
p.Glu1282Glyfs*51 36
AD-
AMTS16
SNV 16 MS NC_000005.9:g.5239937C>T c.2422C>T p.Arg808Trp 25.7
ID4 SNV 1 MS NC_000006.11:g.19838067C>G c.82C>G p.Leu28Val 25.7
ZNF596 Del 4 CSP NC_000008.10:g.193799_19381
2delCTGCAAGGTGAGCT
c.217_223+7
delCTGCAAGGT-
GAGCT
. 23.2
C8orf34 SNV 13 S, SP NC_000008.10:g.69728122T>C c.1551T>C p.= 6.825
PKHD1L1 SNV 71 MS NC_000008.10:g.110523018A>G c.11408A>G p.His3803Arg 24.2
CCDC81 SNV 4 MS NC_000011.9:g.86103688C>T c.404C>T p.Ser135Leu 28.3
NSF SNV 20 MS NC_000017.10:g.44832731G>A c.2209G>A p.Gly737Arg 33
USP29 SNV 4 MS NC_000019.9:g.57642673G>A c.2630G>A p.Gly877Glu 24.4
Depicted are the rare recessive mutations predicted deleterious in the new ROH regions of patient 
P1. All minor allele frequencies of variants are below 0.1% in the public databases and in-house 
cohorts described in the method section. Ins; insertion, Del; deletion, SNV, Single nucleotide variant, 
MS; missense, F; frameshift , S; synonymous variant, SP predicted to affect splicing, CSP; Canonical 
splice site
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Supplemental table 4 : List of primers used in this research
Primer Sequence
Sequencing forward mutation in exon 22 Human MYLK TCAGGGAAGCTGGACTCTGG
Sequencing reverse mutation in exon 22 Human MYLK CAGGGAGTCTGTGGGTTGC
PCR forward minigene construct GCCCCCTTCCTTTCCTAGCC
PCR reverse minigene construct GCAGGGAGTCTGTGGGTTGC
Forward SD6 TCTGAGTCACCTGGACAACC
Reverse SA2 GCTCACAAATACCACTGAGAT
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ABSTRACT
Congenital short bowel syndrome (CSBS) is a rare gastrointestinal disorder in which the 
mean length of the small intestine is substantially reduced when compared to its normal 
counterpart. Families with several affected members have been described and CSBS has 
been suggested to have a genetic basis. Recently, our group found mutations in CLMP 
as the cause of the recessive form of CSBS, and mutations in FLNA as the cause of the 
X-linked form of the disease. These findings have improved the quality of genetic counsel-
ing for CSBS patients and made prenatal diagnostics possible. Moreover, they provided 
a reliable starting point to further investigate the pathogenesis of CSBS, and to better 
understand the development of the small intestine. In this review, we present our current 
knowledge on CSBS and discuss hypotheses on how the recent genetic findings can help 
understand the cause of CSBS.
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INTRODUCTION
Short bowel syndrome (SBS) refers to the sum of functional alterations that are the result 
of a critical reduction in the length of the intestine. In the absence of adequate treatment, 
SBS presents as chronic diarrhea, chronic dehydration, malnutrition, weight loss, and 
nutriment and electrolyte deficiency. In most cases, SBS occurs as a result of surgical 
intervention for other diseases, such as necrotizing enterocolitis and intestinal atresia. 
However, in a small number of cases the small intestine is already shortened at birth, 
leading to a diagnosis of Congenital Short Bowel Syndrome (CSBS). CSBS is a heritable 
gastrointestinal disorder, first described by Hamilton et al in 1969 (Hamilton, Reilly et 
al. 1969). For many years the underlying genetic cause of the disease was unknown. 
Recently, mutations in CLMP were identified to cause the autosomal recessive form of 
CSBS (Van Der Werf, Wabbersen et al. 2012), and mutations in FLNA as the cause of the 
X-linked form of the disease (van der Werf, Sribudiani et al. 2013). These findings brought 
new insights into disease pathogenesis, but the mechanisms in which CLMP and FLNA 
contribute to intestinal elongation are still unknown. 
 In this review we describe the clinical aspects of CSBS, the recent genetic findings, 
and the aetiological aspects of this gastrointestinal disorder. Moreover, we hypothesize 
about the mechanisms underlying the development of CSBS and the signaling pathways 
that might be essential for development and elongation of the small intestine, based in 
previously described mouse models. 
Clinical presentation
CSBS patients are characterized by the presence of a substantially shortened small 
intestine at birth, approximately 50 cm, when compared to 250 cm in neonates delivered 
at term (> 35 weeks of gestation). As a consequence, they have a reduced absorptive 
surface of the small intestine and suffer from malabsorption (Sabharwal, Strouse et 
al. 2004). CSBS can be detected by radiography, but the diagnosis is usually done by 
laparotomy. Patients with CSBS often present within a few days after birth with bile-stained 
vomiting and diarrhoea or failure to thrive, but in some cases the diagnosis has been made 
later in life when an exploratory laparotomy was performed for significant gastrointestinal 
complaint (Siva, Brasington et al. 2002). Malrotation of the bowel is always present, and 
although this can point to an independent developmental defect, it can also be just a 
consequence of the shortened small intestine. The cecum is often positioned in the left 
upper quadrant of the abdomen close to the splenic flexure (Hamilton, Reilly et al. 1969, 
Konvolinka 1970, Schnoy, Bein et al. 1978, Iwai, Yanagihara et al. 1985, Dorney, Byrne 
et al. 1986, Ordonez, Sondheimer et al. 2006), but it can also be located in the lower left 
quadrant of the abdomen when nonrotation of the bowel is observed (Tiu, Chou et al. 
1984). In three reported patients the appendix was absent (Iwai, Yanagihara et al. 1985, 
Sarimurat, Celayir et al. 1998, Sabharwal, Strouse et al. 2004), and volvulus was found in 
four patients (Yutani, Sakurai et al. 1973, Tanner, Smith et al. 1976). In a few cases, not 
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only the small intestine was shortened, but also the colon was affected (Yutani, Sakurai et 
al. 1973, Iwai, Yanagihara et al. 1985, Sarimurat, Celayir et al. 1998, Sabharwal, Strouse et 
al. 2004). Another gastrointestinal anomaly that has been described in ten CSBS patients 
is hypertrophic pyloric stenosis (Kern and Harris 1973, Royer, Ricour et al. 1974, Nezelof, 
Jaubert et al. 1976, Tanner, Smith et al. 1976, Schnoy, Bein et al. 1978, Sansaricq, Chen 
et al. 1984). However, it has been suggested that hypertrophic pyloric stenosis is not 
part of the general developmental defect of the gastrointestinal tract, but a physiological 
consequence from the attempts of the remnant small intestine to slow down the gastric 
emptying and improve absorptive capacity. CSBS patients usually have normal intellectual 
ability (Huysman, Tibboel et al. 1991, Schalamon, Schober et al. 1999) and do not present 
any extra-intestinal symptoms. However, in three patients a patent ductus arteriosus was 
found (Royer, Ricour et al. 1974, Sansaricq, Chen et al. 1984), and in two patients minor 
dysmorphic features were reported (De Backer, Parizel et al. 1997, Ordonez, Sondheimer 
et al. 2006).
Histological findings in CSBS patients
Based on the literature available, it is difficult to assess if abnormal peristalsis is associated 
with CSBS pathogenesis, or if it is an independent event to the presence of a short bowel 
(Matter and Balda 2003, Shehata, Chang et al. 2011, van der Werf, Sribudiani et al. 2013). 
In most CSBS patients the bowel wall seems macroscopically normal, but an abnormal 
histology has been described in some patients. Tanner et al performed silver staining 
in patients material and found an abnormally high number of neurons in the ganglia 
(Tanner, Smith et al. 1976). This result led the authors to suggest that the normal fall-out 
of ganglion cells does not occur in CSBS patients. They also found that the neuronal 
nuclei showed clumped chromatin, which is characteristic for neuroblasts, and the intrinsic 
argyrophilic ganglion cells were absent or reduced in number. However, these results 
lacked a quantitative analysis of the data and comparison to suitable controls in order to 
support hyperganglionosis as the cause of reduced intestinal motility. In an independent 
study, Schalamon et al also observed an abnormal bowel wall with signs of neuronal 
intestinal dysplasia in two siblings with CSBS (Van Der Werf, Wabbersen et al. 2012). 
In another CSBS patient heterotopic gastric mucosa was found (Shehata, Chang et al. 
2011). Conversely, in other cases, no abnormalities of the nerves plexus were seen on 
routine acetylcholinesterase staining (Hamilton, Reilly et al. 1969, Dumke and Schnoy 
1974, Sansaricq, Chen et al. 1984, Dorney, Byrne et al. 1986, Peng, Chen et al. 1993, 
Sarimurat, Celayir et al. 1998, Erez, Reish et al. 2001). Nezelof et al described three cases 
with several congenital malformations, which included a shortened small intestine and 
heterotopia. In these patients a normal myenteric plexus was observed by cytoenzymatic 
and silver stainings (Nezelof, Jaubert et al. 1976). In another study, Kapur et al reported 
an extensive pathologic analysis performed on intestinal tissue collected from five male 
patients diagnosed with CSBS and X-linked intestinal pseudo-obstruction. They observed 
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that these patients had diffused abnormal layering of the small intestinal smooth muscle, 
in which the muscularis propria layer was formed by three perpendicular muscle laminae, 
instead of two. Such abnormal structure was restricted to the small intestine without any 
extension to the colon (Kapur, Robertson et al. 2010). Based on this report, a myopathic 
cause for the abnormal intestinal peristalsis found in CSBS patients was suggested. 
Despite the contradictory results, these histological fi ndings can account for the motility 
abnormalities described in CSBS patients, but to date it still remains unclear whether the 
reduced peristalsis observed in these patients results from a neuronal or a myopathic 
defect.
 To our knowledge, there has never been a precise histological confi rmation to 
defi ne which part of the small intestine is affected in CSBS patients. It is possible that every 
part of the small intestine is shortened in general, but one cannot rule out the possibility 
that only one specifi c part of the small intestine is affected. If this is the case, a correlation 
between the type of the remaining small intestine and prognosis of CSBS patients can 
be established. Since different parts of the small intestine have different histology and 
function (Figure 1), it would not be surprising that depending on the region affected, 
different degrees of severity for CSBS could exist. Findings in acquired SBS cases support 
this idea, as it has been shown that the residual length of the jejunum and ileum with the 
presence of ileocecal valve (ICV), are important factors to determine the outcome of the 
disease (Koffeman, van Gemert et al. 2003). Therefore, we believe that identifying the part 
of the small intestine that is affected in CSBS patients should be a priority. 
Fig.1: Histological characteristics and function of each part of the small intestine.
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Treatment management and outcome
To date, there is no cure for CSBS and patients need total parenteral nutrition for long-
term survival until sufficient bowel length and functions are gained. In some cases, total 
parenteral nutrition has to be continued for the first two years of life (Dorney, Byrne et al. 
1986, Ordonez, Sondheimer et al. 2006), and oral feeding is introduced gradually. With 
time, the function of the remnant small intestine in CSBS patients improves, both in length 
and absorption capacity, leading to better absorption of fat and vitamin B12 (Hamilton, 
Reilly et al. 1969, Yutani, Sakurai et al. 1973, Dorney, Byrne et al. 1986). The weight and 
height of CSBS patients are frequently below the 50th percentile (Hamilton, Reilly et al. 
1969, Sansaricq, Chen et al. 1984, Dorney, Byrne et al. 1986, Schalamon, Schober et al. 
1999, Chu, Luo et al. 2004), but no nutritional deficiencies are observed (Dorney, Byrne et 
al. 1986, Ordonez, Sondheimer et al. 2006, Hasosah, Lemberg et al. 2008).
 Parenteral nutrition has brought a new lease of life to an otherwise fatal condition. 
However, its use is often associated with very high rates of complications, such as sepsis 
and liver failure (Sansaricq, Chen et al. 1984). Small bowel transplantation can also be 
considered, but due to its relatively poor overall survival it is viewed only as a last resort 
treatment option. It has been recommended that CSBS patients should be managed in a 
multidisciplinary manner in a centre specialized in the care of children with intestinal failure 
(Ordonez, Sondheimer et al. 2006), but despite considerable efforts to improve treatment, 
most patients die of starvation or sepsis within the first few days of life, and only a quarter 
of the reported patients survived for more than one year (Table 1). Thus, an improved 
understanding of the mechanisms underlying the development of CSBS is necessary to 
develop better methods to treat this condition. 
Disease aetiology
To understand the causes underlying the pathogenesis of CSBS, a better understanding 
of the mechanisms involved in the development of the small intestine is required. In this 
section, we describe the embryonic events necessary for intestinal growth and elongation.
During embryogenesis, the primitive gut tube is divided in three regions: the foregut, the 
midgut and the hindgut, each of them with their own arterial supply (the celiac artery, 
the superior mesenteric artery and the inferior mesenteric artery, respectively). The small 
intestine (jejunum and ileum) originates from the midgut, as well as the distal duodenum, 
cecum, ascending colon, and the proximal two-thirds of the transverse colon. In the fifth 
week of embryonic development the future ileum is elongating rapidly (Figure 2), but as 
the abdominal cavity grows slower, the midgut forms an anteroposterior loop called the 
primary intestinal loop. The cranial limb of this loop includes the ileum and the caudal 
limb includes the ascending and transverse colons. In the sixth week of development, 
the primary intestinal loop herniate into the umbilicus forced by elongation of the loop 
and growth of other abdominal organs. At this time the loop rotates 90 degrees counter 
clockwise around the axis of the superior mesenteric artery. The future ileum is now 
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lying on the right, and the cecum on the left. The cecum and the appendix continue to 
differentiate and the small intestine elongates further forming the jejunal-ileal loops. The 
attached mesentery accompanies this intestinal growth but it does so at a lower rate. 
Recent studies have shown that it is the differential growth rate between the intestine and 
the mesentery that creates specific patterns of looping and rotation of the gut in different 
species (Savin, Kurpios et al. 2011). Therefore, any disturbance of this differential growth 
rate may lead to abnormal growth patterns and result in intestinal malrotation. During the 
tenth week of gestation, the intestinal loop returns rapidly to the abdominal cavity. The 
small intestine returns first and the ascending and transverse colons follow later. It is not 
known what causes this retraction, but an increase in the size of the abdominal cavity and 
a relatively decrease in the size of the liver and kidneys seem to play an important role. 
To reach the definitive configuration of the small and large intestines, the intestinal loop 
rotates another 180 degrees counter-clockwise (Moore and Persaud 2003, Schoenwolf 
and Larsen 2009, Carlson 2014).
Fig.2: Embryogenesis of the human small intestine.
 Following this intricate growth, looping and rotation of the gut, intestinal patterning 
and regionalization takes place. All intestinal organs derived from the foregut, midgut and 
hindgut consist of similar layers, which include mucosa, muscularis mucosa, submucosa, 
submucosal plexus, muscularis propria, myenteric plexus and serosal layer. Formation 
of these layers requires extensive proliferation and differentiation of cells that compose 
the epithelial and muscle of the intestine. The neuronal network responsible for intestinal 
innervation is mainly formed by enteric neural crest cells (ENCCs) that migrate from 
the neural tube in a rostral to caudal direction to promote neuronal colonization of the 
intestinal tract (Goldstein, Hofstra et al. 2013). Interestingly, cell differentiation and radial 
patterning of the gut is largely dictated by signals exchanged between the different cell 
types that constitute the various layers. For example, the Hedgehog signaling initiated in 
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the intestinal epithelium affects cell proliferation and differentiation of cells derived from all 
embryonic layers (endoderm, mesoderm and ectoderm), playing an important role in the 
establishment of the villus-crypt patterning, smooth muscle cells proliferation, and ENCCs 
proliferation, differentiation and migration (Ramalho-Santos, Melton et al. 2000, De Santa 
Barbara, Williams et al. 2005). Several other morphogenetic pathways that regulate 
cellular interactions and that are necessary for intestinal elongation are discussed further 
in section 8 of this review. Nonetheless, it is important to acknowledge here the existence 
of such interactions in the context of CSBS, since the gut abnormalities found in these 
patients may well arise due to dysregulation of these cellular interactions.    
                                                                                                                                                                 
Genetics
Familial occurrence of CSBS was described in the very first case report in 1969. Hamilton 
et al reported a French-Canadian couple who were not related and who had five daughters, 
two of them diagnosed with CSBS. One of the affected girls died at the age of 1 month 
and 1 week, and prior to death a laparotomy showed a small intestine of 30 cm in length 
(Hamilton, Reilly et al. 1969). More case reports followed and a familial occurrence was 
described in approximately 60% of the cases published in the literature. In most of these 
cases siblings were affected, and in approximately 25% of the cases the parents were 
consanguineous (Table 1). It has therefore been suggested by several authors that genetic 
factors were involved in CSBS and an autosomal recessive pattern of inheritance was 
proposed by many of them (Royer, Ricour et al. 1974, Schnoy, Bein et al. 1978, Shawis, 
Rangecroft et al. 1984, Wei and Lai 1985, Dorney, Byrne et al. 1986, Huysman, Tibboel 
et al. 1991, Aviram, Erez et al. 1998, Erez, Reish et al. 2001). However, since only boys 
were found affected in some families, an X-linked pattern of inheritance has also been 
suggested (Nezelof, Jaubert et al. 1976, Sansaricq, Chen et al. 1984, Kern, Leece et al. 
1990, Duveau, Bardot-Labbe et al. 2000). In this section, we focus on the genetic findings 
described in CSBS patients.
Table 1. Overview of the reported cases with CSBS as the main symptom.
Sex Small bowel length (cm) Reference
Year of 
publication
Age at 
time of 
presentation
Age at death Familial Consan-guinity
F 40 [1] 1969 4 months Alive at time of publication Yes No
F 30 [1] 1969 Unknown 1 month Yes No
M 30 [8] 1970 3 months 5 months Unknown Unknown
F 42 [14] 1973 3 days 35 days No No
M 70 [15] 1973 7 weeks 5 months Unknown Unknown
F 25 [17] 1974 1 month 21 days Yes Unknown
M 70 [17] 1974 Unknown 4 days Yes Unknown
M 45 [17] 1974 15 days 7 months Yes Yes
F 40 [17] 1974 5 days 2 months No No
M 106 [24] 1974 22 days 25 days Yes Yes
M 75 [7] 1976 6 days 6 months No No
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M 70 [16] 1976 18 days 22 days Yes No
M Unknown [16] 1976 7 days 16 days Yes No
M 50 [16] 1976 15 days 7 months Yes No
M 24 [11] 1984 32 days 55 days Yes No
M 27 [11] 1984 2 days 5 months Yes No
F 45 [39] 1984 Unknown 3 months Yes Yes
F 45 [39] 1984 1 day 6 weeks Yes Yes
M 72 [18] 1984 6 weeks Alive at time of publication Yes No
M 65 [18] 1984 18 days 2 months Yes No
M 24 [40] 1985 3 days 55 days Yes No
M 27 [40] 1985 2 days 5 months Yes No
M 45 [7] 1985 5 weeks 2 months No No
M 69 [6] 1986 5 weeks Alive at time of publication No Yes
M 112 [42] 1990 1 month 6 weeks Yes No
M 70 [42] 1990 6 hours 6 months Yes No
M 237* [42] 1990 3 months Alive at time of publication Yes No
F 54 [19] 1991 2 months Alive at time of publication No No
F 30 [26] 1993 2 days 4 months Yes No
M 39 [26] 1993 Unknown 6 months Yes No
F 30 [26] 1993 Unknown 2 months No No
F 30 [43] 1996 1 day Alive at time of publication No No
F 50 [21] 1997 1 day Alive at time of publication No No
F 25 [12] 1998 4 days 6 months No No
M 47 [20] 1999 9 days Alive at time of publication Yes Yes
M 42 [25] 2001 2 days 5 months Yes No
F 51 [25] 2001 3 days 2 weeks Yes No
M 95 [25] 2001 2 months Alive at time of publication No Yes
M 35 [25] 2001 2 days 2 months Yes No
M 228,6** [5] 2002 15 years Alive at time of publication No No
M 56 [4] 2004 4 months Alive at time of publication No No
F 20 [29] 2004 4 days Alive at time of publication No No
F 30 [9] 2006 days Alive at time of publication Yes No
M 50 [30] 2008 6 weeks Alive at time of publication Yes Unknown
M 20-25 [44] 2010 26 days 1 month No No
M unknown [3] 2013 Unknown Alive at time of publication Yes No
*At 14 years of age; **At 15 years of age.
Chromosomal abnormalities
Two patients have been described with chromosomal abnormalities. Hou et al reported 
a female patient with multiple congenital anomalies, such as congenital short bowel, 
malrotation, and patent ductus arteriosus, in addition to major malformations, such as 
left upper amelia, dextrocardia and asplenia. Chromosomal investigation of this patient 
showed a mosaic pattern with complex rearrangements of chromosome 4: 85% of the 
peripheral lymphocytes showed a normal female cell line (46,XX), while 12% of the cells 
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showed a pattern with one normal chromosome 4 and a ring chromosome 4 (46,XX-4,+r(4)
(p16q22.3). The ring caused a deletion of the long arm of chromosome 4. Approximately 
4% of the cells from this patient had a pattern with a partial trisomy of chromosome 4: 
one normal chromosome 4, one ring chromosome 4 and one chromosome 4 with the 
same deletion of the long arm of chromosome 4 (47,XX,4,+r(4)(p16q22.3),+del(4)
(pterq22.3:)) (Hou and Wang 1996). De Backer et al also described a female CSBS 
patient with a de novo balanced translocation between chromosome 2 and 11 (46,XX,t(2,11)
(q32.2,p12)) (De Backer, Parizel et al. 1997). However, no functional implications of these 
chromosomal abnormalities have been reported in these cases that could explain the 
development of CSBS.
Loss-of-function mutations in CLMP cause recessive CSBS
In seven CSBS patients from five unrelated families, different homozygous and compound 
heterozygous loss-of-function mutations have been identified in the gene encoding for 
the Coxsackie- and adenovirus receptor-like membrane protein (CLMP) (Van Der Werf, 
Wabbersen et al. 2012). The reported length of the small intestine of these patients was 
30 to 54 cm and they all presented malrotation of the bowel. Neuronal intestinal dysplasia 
was reported in two patients (from one family) with a more complex mutation, presumably 
an inversion (Schalamon, Schober et al. 1999, Van Der Werf, Wabbersen et al. 2012).
  CLMP, located on chromosome 11 (11q24.1), encodes a transmembrane 
protein that co-localizes with tight junction proteins and acts as an adhesion molecule 
(Raschperger, Engstrom et al. 2004, Van Der Werf, Wabbersen et al. 2012). It is 
expressed in the intestine during different stages of human development, and knockout of 
its orthologue in zebrafish resulted in developmental defects of several organs, including 
the intestine. As tight junction proteins play an important role in proliferation (Balda and 
Matter 2000, Matter and Balda 2003), we hypothesized that loss-of-function of CLMP 
results in less proliferation of the small intestinal cells during human development, leading 
to a shortened small intestine at birth (Van Der Werf, Wabbersen et al. 2012). Recently, 
this hypothesis was tested using an in vitro approach where a mutant CLMP (V124D), 
was over-expressed in a human intestinal epithelial cell line (T84). This mutant has been 
previously reported to mislocalized to the cytoplasm (Van Der Werf, Wabbersen et al. 
2012), but in vitro assays failed to confirm the role of CLMP in cell viability, proliferation 
and migration in this cell line (van der Werf, Hsiao et al. 2013). Thus, the role of CLMP in 
small intestinal development and its function still remain unclear.
Mutations in FLNA cause X-linked CSBS
Mutations in Filamin A (FLNA) have been associated with a wide spectrum of disorders 
characterized by a variable phenotype. Loss-of-function mutations are found in 
patients with bilateral periventricular nodular heterotopia, a neuronal migration disorder 
characterized by seizures affecting mainly females, as it is often lethal in males (Fox, 
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Lamperti et al. 1998). Mutations that alter the function of FLNA are associated with three 
different disorders: otopalatodigital syndromes type 1 and 2, frontometaphyseal dysplasia, 
and Melnick Needles syndrome. These syndromes constitute a phenotypic spectrum that 
includes skeletal dysplasia, craniofacial-, cardiac-, genito-urinary and intestinal anomalies, 
and central nervous system defects (Robertson, Twigg et al. 2003). In addition, missense 
mutations in FLNA are associated with X-linked cardiac valvular dystrophy (Kyndt, Gueffet 
et al. 2007, Bernstein, Bernstein et al. 2011). CSBS has also been described in some of 
the patients reported with loss-of-function mutations in FLNA. However, these patients 
presented multiple congenital anomalies and the short bowel was described as part of 
the disease phenotype. A male patient, stillborn at 33 weeks of gestation, was reported 
with a duplication of the first 28 exons of FLNA. Prenatal ultrasounds showed normal 
growth with a single umbilical artery, umbilical vein varix, and persistent dilatation of the 
bowel first seen at 20 weeks gestation. These findings were confirmed by an autopsy 
of the foetus, which also detected a bifid uvula, an atrial septal defect, and a malrotated 
short small intestine of 45 cm (164 cm would be the expected length at this gestational 
stage). This duplication was also detected in his mother, who was diagnosed with a 
bifid uvula and patent ductus arteriosus, and in his maternal uncle, who had multiple 
congenital anomalies including a bifid uvula, intestinal malrotation, undescended testes, 
partial agenesis of the corpus callosum, patent ductus arteriosus, patent foramen ovale, 
ventricular septal defect and periventricular heterotopia, and a small intestine measuring 
only 115 cm at the age of 10 years (Kapur, Robertson et al. 2010). Another patient with a 
hemizygous nonsense mutation in FLNA (c.7021C>T, Q2341X) was diagnosed prenatally 
with a left diaphragmatic defect, which caused a displacement of the spleen, left hepatic 
lobe, and portions of the stomach and small intestine into the left hemithorax. He also had 
dysmorphic facial features, spina bifida occulta, natal tooth, periventricular heterotopia, a 
posterior fossa arachnoid cyst, and proximally placed thumbs. He died at 6 weeks of age 
and his small intestine measured only 68 cm (Kapur, Robertson et al. 2010). Recently, a 
family has been described with two affected male siblings where a novel no-stop mutation 
in FLNA (c.7941_7942delCT, p.(*2648Serext*100)) was identified upon genetic screening. 
The same mutation was detected in their male cousin. These patients were diagnosed 
with congenital short bowel syndrome, “wandering spleen”, periventricular nodular 
heterotopia, persistent ductus arteriosus, and urinary tract abnormalities (Oegema, Hulst 
et al. 2013). All these reports confirm that CSBS patients with mutations in FLNA have, 
in general, multiple congenital anomalies and not only a congenital shortened small 
intestine. Recently, however, a mutation in the second exon of FLNA has been identified in 
two unrelated male patients where CSBS appeared as an isolated symptom without other 
major congenital anomalies (van der Werf, Sribudiani et al. 2013). In these patients, a 
two-base-pair (bp) deletion in FLNA (c.16-17delCT) was identified. In another male patient 
previously described with Chronic Idiopathic Intestinal Pseudo-obstruction, a 2-bp deletion 
was also found in the second exon of FLNA (c.65-66delAC). This patient was diagnosed 
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with malrotation, pyloric hypertrophy, intestinal pseudo-obstruction, and CSBS (Auricchio, 
Brancolini et al. 1996, Gargiulo, Auricchio et al. 2007). In these three patients the length 
of the small intestine ranged from 55 to 235 cm, and the age of diagnosis varied from 1 
day to 15 years (Kern and Harris 1973, Kern, Leece et al. 1990, Siva, Brasington et al. 
2002), suggesting that in some cases, the small intestine is less reduced in length and the 
diagnosis is made later in life when compared to CSBS patients with CLMP mutations. 
These 2-bp deletions are located between two nearby methionines at the N-terminus of 
FLNA. Previous studies showed that translation of FLNA occurs from both methionines, 
resulting in two protein isoforms (Gargiulo, Auricchio et al. 2007). In the presence of this 
2-bp deletion the longer isoform is not translated anymore, but there is still expression of 
the shorter FLNA isoform. We hypothesized that this is the reason why these deletions are 
not lethal for males in utero, and they only develop CSBS. Screening of exon 2 of FLNA 
is therefore recommended in such cases. In X-linked families where CSBS is associated 
with multiple congenital anomalies it is advisable to screen the entire FLNA for mutations. 
  FLNA encodes a cytoskeletal protein that binds to actin and has a well-
characterized role in the cytoplasm. It regulates cell shape by cross-linking actin filaments, 
and plays an important role in cell signaling and migration in response to environmental 
changes (Robertson 2005). A role for FLNA has also been recently discovered in the 
nucleoli, where it inhibits ribosomal RNA transcription (Deng, Lopez-Camacho et al. 
2012). FLNA has been reported to play an important role in vascular development and 
cardiac morphogenesis (Feng, Chen et al. 2006), but its role is still unclear in intestinal 
development. Nishita et al reported that FLNA is able to interact with the tyrosine kinase-
like orphan receptor 2 (Ror2), and showed that this interaction is required for filopodia 
formation and migration (Nishita, Yoo et al. 2006). Since disruption of Ror2 expression has 
been shown to lead to a shortened small intestine in mice (Yamada, Udagawa et al. 2010), 
it is tempting to hypothesize that FLNA mutations leading to CSBS disrupt the FLNA-Ror2 
interaction and impair cell migration. However, further studies are required to clarify the 
role of FLNA in intestinal elongation.
Link between CLMP, FLNA and CSBS
We now know that mutations in CLMP and FLNA underlie CSBS pathology (Van Der Werf, 
Wabbersen et al. 2012, van der Werf, Sribudiani et al. 2013). However, it is still unclear 
whether CLMP and FLNA interact  with each other (directly or indirectly) and, therefore, 
whether mutations in one of these two genes result in a similar course of events during 
development of the small intestine. In this section, we discuss different hypotheses to 
explain CSBS pathogenesis, and speculate about a possible link between CLMP, FLNA 
and each of these hypotheses.
Embryologic and intrauterine events 
As we mentioned in section 4, during the 7th and 10th week of embryonic development, 
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the primitive digestive tube needs to return to the intraumbilical coelom. Hamilton et al 
suggested that in CSBS this process is prevented. As a consequence, the primitive bowel 
is forced to stay in the abdominal cavity and the cranial portion of the bowel is not able to 
elongate, leading to a shortened small intestine (Hamilton, Reilly et al. 1969). In another 
report, Aviram et al observed the presence of bowel loops inside the umbilical cord on a 
prenatal sonography of a patient with CSBS, showing that the gut was able to elongate, 
but the return of the intestine to the abdominal cavity was in fact delayed. They speculated 
that the incomplete dextral rotation and elongation of the bowel caused this delay  (Aviram, 
Erez et al. 1998). Delayed return of the intestine into the abdominal cavity is also associated 
with volvulus and intestinal obstruction (Finley, Burlbaw et al. 1992). However, volvulus 
has only been described in four CSBS cases, and adhesions, atresia, stenosis and scars 
are rarely found in CSBS patients. In a case report of a premature neonate in whom the 
small bowel was absent, there was also no evidence of an abdominal wall defect or other 
intra-abdominal anomalies on prenatal sonography (Besner, Bates et al. 2005). Antenatal 
intussusception followed by auto-anastomosis and auto-amputation is also suggested as 
a cause of CSBS (Sarimurat, Celayir et al. 1998). However, failure of intestinal elongation 
can also be the cause, rather than the outcome of the observed malrotation in CSBS 
patients (Kern and Harris 1973). In cases were auto-anastomoses were found, intrauterine 
events like volvulus and infarction can be a reasonable explanation for the shortened small 
intestine (Sabharwal, Strouse et al. 2004). Another hypothesis is that vascular events 
underlie CSBS (Kern and Harris 1973). Intrauterine infarction of the bowel may lead to 
reabsorption of the ischemic bowel and result in a decreased length of the remaining gut.
Considering the proposed embryologic and intrauterine events one could hypothesize that 
CLMP might play a role in these events. As mentioned earlier, tight junction proteins play 
an important role in proliferation (Balda and Matter 2000, Matter and Balda 2003). Hence, 
we hypothesized that loss-of-function of CLMP results in less proliferation of the small 
intestinal cells during human development, leading to a shortened small intestine at birth. 
The processes and pathways that may be disturbed by the loss of CLMP still remain 
unknown. 
  FLNA can also be linked to embryologic and intrauterine events, since it is known 
to play an important role in vascular development. Patients with FLNA mutations have 
been reported with developmental anomalies of the blood vessels (Kakita, Hayashi et 
al. 2002, Guerrini, Mei et al. 2004), and omphalocoele (Robertson 2005). An intrauterine 
vascular event causing small intestinal infarction (Kern and Harris 1973) might, therefore, 
be a reasonable explanation for the development of CSBS, supporting the hypothesis 
that the developmental defect seen in CSBS patients originates in the embryonic stage 
at which the bowel is accommodated in the intraumbilical coelom (Hamilton, Reilly et al. 
1969). 
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Lack of neurotransmitters and hormones
As abnormal peristalsis has been observed in some CSBS patients, Sansaricq et al 
hypothesised that CSBS patients may lack synthesis of neurotransmitters (Sansaricq, 
Chen et al. 1984). However, abnormal peristalsis is not reported in all patients. Schalamon 
et al also suggested that CSBS patients lack growth-stimulating hormones like epidermal 
growth factor, insulin-like growth factor, and human growth hormone, but they were unable 
to detect abnormal hormone levels in their patients (Schalamon, Schober et al. 1999). 
  How mutations in CLMP and FLNA can lead to disturbed or lack of neurotransmitters 
is unclear. However, as these genes do not encode or even have an (direct) effect on the 
production of neurotransmitters, it is unlikely that a lack of neurotransmitters is the cause 
for the shortened small intestine observed in CSBS patients. 
CLMP and FLNA
CSBS patients with mutations in CLMP seem to have a phenotype more restricted to 
the intestine, whereas patients with mutations in FLNA are more likely to have multiple 
congenital anomalies. However, CSBS patients with a deletion in the second exon of 
FLNA are very similar to patients with mutations in CLMP. This observation together with 
the fact that both gene products are involved in similar cellular processes, such as cell-
cell contact and actin organization, suggest that FLNA and CLMP might be involved in the 
same protein network that is essential for intestinal development. 
  FLNA is an actin-binding protein and its actin-binding domain is located in its 
N-terminal region (Robertson 2005, Nakamura, Osborn et al. 2007, Qiu, Nomiyama et 
al. 2011). Gargiulo et al showed abnormal actin organisation in a lymphoblastoid cell 
line of a patient with a c.65-66delAC deletion in FLNA (Gargiulo, Auricchio et al. 2007). 
There is therefore evidence that the cytoskeletal actin organisation is disturbed in CSBS 
patients with mutations in FLNA. However, it is still not known whether patients with 
mutations in CLMP have a similar problem. Raschperger et al showed that CLMP co-
localizes with actin filaments (Raschperger, Engstrom et al. 2004). They speculated that 
CLMP interacts with a protein that directly binds to actin filaments, which would bring 
CLMP to the tight junctions by anchoring CLMP to the actin cytoskeleton. They suggested 
that ZO-1 could be such an interacting protein. As FLNA also binds to actin filaments 
and is known to play a role in anchoring transmembrane proteins to the cytoskeleton 
for correct targeting to the cell membrane, such as integrin beta and the cystic fibrosis 
trans-membrane conductance regulator (CFTR) (Playford, Nurminen et al. 2010, Qiu, 
Nomiyama et al. 2011), it is tempting to suggest that FLNA is the link between CLMP and 
the actin cytoskeleton and is responsible for the proper localization of CLMP to the tight 
junctions (Figure 3). Another possibility is that FLNA plays a role in the internalization of 
CLMP into the plasma membrane. As FLNA is known to control the internalization of the 
chemokine receptor 2B in different dynamic membrane structures (Minsaas, Planaguma 
et al. 2010), one can speculate that mutations in FLNA influence the expression levels of 
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CLMP on the plasma membrane. Further research is needed to determine whether CLMP 
and FLNA interact with each other as part of the same protein network and, if so, which 
other proteins are involved in this network. However, we cannot exclude the possibility that 
different pathways underlie X-linked CSBS and autosomal recessive CSBS, with different 
disease mechanisms leading to a similar disease phenotype. 
  It is also not known whether more genes are involved in the pathogenesis of 
CSBS. We did not identify a mutation in all patients screened for CLMP and the second 
exon of FLNA. However, we did not screen all exons of FLNA in all patients analysed, 
which means that FLNA might still play a role in disease development in some of these 
patients. Based on the finding of an abnormal karyotype with a ring chromosome 4 in 
one CSBS patient with multiple congenital anomalies (Hou and Wang 1996), a gene on 
the long arm of chromosome 4 might also be involved. Further research on the protein 
networks of CLMP and FLNA might help find more candidate genes for CSBS.
Fig.3: Tight junction complexes and the possible link between CLMP and FLNA
Mouse models for CSBS and intestinal elongations
In order to get new insights about the pathogenesis of CSBS, observations on CLMP and 
FLNA knockout animal models might be important. They can help us identify which cell 
types are affected, and also determine if there is a general shortening or if specific parts 
of the intestine are affected. To date, there is no mouse model available for CLMP, only 
a zebrafish model that was recently reported by our group (Van Der Werf, Wabbersen et 
al. 2012). In this model, there was an overall reduction of the body length accompanied 
by a drastic reduction in the size of the small intestine. Histological findings showed that 
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there was a significant difference in gut morphology in knockout zebrafish, marked by the 
absence of goblet cells in the mid intestine. This result confirmed the importance of CLMP 
for small intestine development and elongation, but further investigation is required to 
determine the role of CLMP in intestinal embryogenesis. 
  For FLNA, two mouse models have been reported: a conditional knockout model, 
and a N-ethyl-N-nitrosourea induced model called Dilp2 (Feng, Chen et al. 2006, Hart, 
Morgan et al. 2006). Both of them showed complete loss of Flna and resulted in embryonic 
lethality. Vascular defects were also reported in both of these models, and in one of them 
there was a delayed resorption of the umbilical hernia (Hart, Morgan et al. 2006). Feng 
et al further investigated the reasons associated to the vascular phenotype, and showed 
that migration and motility of different cell types were not affected in Flna-null embryos 
(Feng, Chen et al. 2006). However, abnormal epithelial and endothelial organization, and 
aberrant adherent junctions were observed in several tissues, including developing blood 
vessels, heart, and brain. A defect in intestinal elongation was not reported in any of these 
models, but it is possible that a more detailed examination of these embryos could shed 
some light into the role of FLNA in normal intestinal development.
  With respect to intestinal elongation, several mouse models have been reported 
with a shortened small intestine: Fgf9-/-; Shh-/- Ihh-/-; Notch-/-; Wnt5a-/-; Ror2-/-; Sfrp1-/-Sfrp2-/-
Sfrp5-/- and Hlx-/- (Hentsch, Lyons et al. 1996, Geske, Zhang et al. 2008, Yamada, Udagawa 
et al. 2010, Bakker, Raghoebir et al. 2012). All these genes encode for proteins involved 
in highly conserved signaling pathways known to play a crucial role in normal embryonic 
development (Geske, Zhang et al. 2008). In this section, we describe these proteins and 
associated pathways, and discuss their contribution towards the elongation of the small 
intestine.
Fibroblast Growth Factor 9 (FGF9)
FGF9, also known as glia activating factor, is part of a large family of polypeptide 
growth factors that are involved in a variety of biological processes, such as embryonic 
development, cell growth, morphogenesis, tissue repair, tumor growth and invasion (Itoh 
and Ornitz 2008). A knockout mouse model for Fgf9 showed a disproportional small 
intestine, suggesting that Fgf9 is particularly important for small intestinal morphogenesis. 
However, this effect was only seen after embryonic day 14.5 (E14.5), suggesting that Fgf9 
regulates small intestinal elongation during late stage embryogenesis (Geske, Zhang et 
al. 2008). The mechanism by which FGF9 regulates this process is not totally known, but 
Geske et al showed that this effect might be due to a significant increase of the transforming 
growth factor beta (TGFβ) signaling pathway in the absence of FGF9 (Geske, Zhang et al. 
2008). TGFβ signals are well known to drive the transition of mesenchymal fibroblasts to 
myoblasts by activation of intermediate molecules, such as Smad2 and Smad3 (Waite and 
Eng 2003). However, this process is mostly seen as the small intestine transitions to the 
postnatal period, when the proliferative properties of the mesenchymal fibroblasts are less 
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required. In the Fgf9-/- mouse model, an increase in TGFβ signaling was detected at earlier 
stages of embryogenesis, leading to a premature differentiation of the mesenchymal 
fibroblasts into myofibroblasts and hence, to decreased proliferation (Geske, Zhang et 
al. 2008). As a consequence, the normal elongation of the small intestine was impaired. 
Sonic (Shh) and Indian Hedgehog (Ihh)
The mammalian family of lipid-modified hedgehog (Hh) signals are composed of three 
members: Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), and Desert Hedgehog (Dhh). 
Each of them is thought to signal through a common mechanism that involves binding 
and inactivation of Ptch1, a multi-pass transmembrane receptor. As a consequence, the 
seven-pass membrane protein smoothened (Smo) is activated, leading to a transcriptional 
response controlled by the Gli family of transcription factors (Zhang, Ramalho-Santos et 
al. 2001). Hh signaling is involved in proliferation, patterning and differentiation of many 
tissues (McMahon, Ingham et al. 2003). In the mammalian gut, Shh and Ihh are known 
to be co-expressed in the endodermal epithelium from early developmental stages (E8.5) 
(Bitgood and McMahon 1995), and dysregulation of this pathway has already been impli-
cated in both congenital defects and cancers arising from the gastrointestinal tract (Bit-
good and McMahon 1995, de Santa Barbara, van den Brink et al. 2002). However, mouse 
models where the expression of Shh or Ihh was abolished only showed limited anomalies, 
likely due to functional redundancy between these two proteins (Ramalho-Santos, Melton 
et al. 2000). Mao et al. generated a double mutant mouse model where expression of 
both Shh and Ihh was abolished (Mao, Kim et al. 2010). They showed that at E11.5 the 
digestive tract of double mutant embryos was normal in shape, orientation and location 
in the embryo, but was dramatically reduced in size relative to wild-type controls. At the 
end of gestation this difference was even more striking as the intestine of Shh and Ihh null 
embryos completely failed to expand (Mao, Kim et al. 2010). However, the primary pat-
terning of the gut into distinct organ segments was not affected. They further investigated 
the reasons behind the phenotype and showed that double null embryos present a dra-
matically reduced number of mesenchymal progenitors necessary for normal endodermal-
mesenchymal interplay in the mammalian gut. Vasculature integrity was intact and no 
significant change in the levels of necrotic and apoptotic markers were detected in these 
embryos, suggesting that the decreased number of mesenchymal progenitors was a pri-
mary effect of absent Hh signaling. Considering that intestinal smooth muscle cells are 
derived from local mesenchymal progenitors, the authors also investigated the effect of 
absent expression of Shh and Ihh for smooth muscle development (Mao, Kim et al. 2010). 
They showed that double mutant embryos do not express smooth muscle α actin (SMA), 
and have impaired smooth muscle differentiation due to reduced expansion of the early 
mesenchymal progenitor pool. Taken together, these results showed that Hh signaling is a 
mitogenic factor necessary for expansion of gut mesenchymal progenitors including those 
of the smooth muscle compartment, and is thus, essential for embryonic gut development.
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Notch
The Notch gene encodes for a transmembrane receptor protein known to activate a 
signaling cascade critical for normal embryonic development and tissue homeostasis 
(D'Souza, Meloty-Kapella et al. 2010). In mammals there are four Notch receptors (Notch 
1-4), which upon ligand binding, trigger a series of proteolytic cleavages to release the 
intracellular domain of Notch  (NICD), a biologically active signal transducer (Kopan 
and Ilagan 2009). NICD translocates to the nucleus and binds to a transcription factor, 
recombining binding protein suppressor of hairless (RBP-J), and to a co-activator, 
Mastermind, activating transcription of several target genes involved in cell proliferation or 
apoptosis (Collu, Hidalgo-Sastre et al. 2014). The Notch signaling pathway is widely used 
in different cell types and cellular processes. Therefore, it is not surprising that defects in 
this pathway are associated with developmental disorders and cancers (Koch and Radtke 
2007, Turnpenny, Alman et al. 2007).
  In the intestine, genetic analyses of zebrafish and mouse mutants have 
revealed a requirement of the Notch signaling pathway for cell expansion and proper 
lineage allocation of epithelial progenitors (Crosnier, Vargesson et al. 2005, Fre, Huyghe 
et al. 2005). In addition, this pathway is particularly active in the developing intestinal 
mesenchyme, specifically in sub-epithelial fibroblasts, and its dysregulation was shown 
to play a role in intestinal elongation. Selective disruption of the Notch pathway in the 
mesenchyme by the use of a conditional knockout mouse for the effector gene RBP-J, or 
constitutive activity of Notch by forced expression of NICD, led to a reduction of intestinal 
length (Kim, Kim et al. 2011). In both cases, a progressive loss of sub-epithelial fibroblasts 
was detected, but the phenotype observed was more severe in the presence of constitutive 
Notch activation. A close inspection of the mutant embryos showed that despite similarities 
in the phenotype, the mechanisms leading to a reduction of sub-epithelial fibroblasts were 
different in each case. While the absence of Notch signaling led to reduced proliferation 
of sub-epithelial fibroblasts but no significant increase in apoptosis, over-activation of this 
pathway resulted in apoptosis, and consequently cell death (Kim, Kim et al. 2011). These 
observations showed a critical role of Notch signaling for the development of the intestinal 
mesenchyme, and revealed that tight regulation of this pathway is needed to fine-tune its 
effects during intestinal elongation. 
Wnt5a
The Wnt proteins are secreted glycoproteins known to activate various intracellular sig-
naling cascades upon binding to their receptors, Frizzled (Fzd) and/or transmembrane 
co-receptors, such as the lipoprotein receptor-related protein 5/6 (Lrp5/6), Ror2, and the 
related to receptor tyrosine kinase (Ryk) [89]. Wnt signaling pathway is divided in two 
general categories - canonical and non-canonical - based on transcriptional involvement 
of β-catenin. Independent of the pathway activated, Wnt signaling is essential for diverse 
processes, including cell fate, proliferation, differentiation, migration, polarity and asym-
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metric cell division (Clevers and Nusse 2012).
  Wnt5a is one of the ligands involved in the activation of the non-canonical Wnt 
signaling pathway. It is known to bind Ror2 and is required for normal embryogenesis, 
playing a pivotal role in the elongation process of several organs, including the small 
intestine (Reya and Clevers 2005, Green, Kuntz et al. 2008, Cervantes, Yamaguchi et al. 
2009). Loss of either Wnt5a or Ror2 expression in mice was reported to lead to a dramatic 
shortening of the small intestine (Cervantes, Yamaguchi et al. 2009, Yamada, Udagawa et 
al. 2010, Bakker, Raghoebir et al. 2012). Accordingly, expression levels of Wnt5a and Ror2 
have been shown to peak during the critical period of midgut elongation in mice, which 
is between E10.5 and E13.5 [93]. Moreover, Bakker et al showed that Wnt5a expression 
during mouse intestinal embryogenesis is tightly orchestrated in certain time frames, and 
overexpression or loss of expression during the critical period of midgut elongation (before 
E13.5) leads to intestinal elongation defects (Bakker, Raghoebir et al. 2012). It is still not 
clear how Wnt5a and Ror2 regulate intestinal elongation, but at the cellular level, they are 
known to be involved in cell migration and proliferation (He, Xiong et al. 2008). Therefore, 
a decrease in cell proliferation and migration induced by the absence of Wnt5a or Ror2, 
might lead to a shortened small intestine. 
  Wnt5a is also known to activate the Wnt/Jun N Kinase (JNK) signaling pathway, 
defined as the planar cell polarity pathway, as it mediates orientation of the cell movements 
during development (Qian, Jones et al. 2007). Previous studies showed that JNK plays an 
irreplaceable role in preserving endoderm cell-cell adhesion and maintaining the stability 
of microtubules, which are required for normal intestinal elongation. However, activation 
of this pathway has to be tightly regulated for proper GI tract development. The secreted 
Frizzled-related protein 1 (Sfrp1) has been shown to directly interact with Wnt5a, playing a 
key role regulating its activity (Matsuyama, Aizawa et al. 2009). Sfrp1 together with Sfrp2 
and Sfrp5, belong to the type 1 subfamily of Sfrp antagonists of the Wnt signaling [96]. 
Since there is functional redundancy between the members of each subfamily (Satoh, 
Matsuyama et al. 2008), loss of Sfrp1, 2 and 5 in a compound mutant mouse model (Sfrp1-
/- Sfrp2-/- Sfrp5+/-) led to dysregulation of the Wnt5a signaling pathway detected by elevated 
levels of phosphorylated c-Jun in the epithelium of the small intestine. As a consequence, 
mutant embryos exhibited a shorten body axis and unsurprisingly, a dramatic reduction in 
gut length (Matsuyama, Aizawa et al. 2009). On the other hand, absence of active JNK 
signaling led to dissociation of endoderm cells and perturbation of the cytoskeleton due to 
microtubule destabilisation, resulting as well, in an impairment of gut elongation (Dush and 
Nascone-Yoder 2013). 
Hlx
The divergent murine homeo box gene Hlx encodes for a transcription factor that during 
embryogenesis is mainly expressed in tissues of mesodermal origin, such as visceral 
mesenchyme, skeletal myoblasts, sclerotome and limb mesenchyme (Allen, Lints et 
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al. 1991, Lints, Hartley et al. 1996). Hlx expression is detected around E9.5 of mouse 
development in the midgut and hindgut, and from E10.5 to E12.5 in the liver, gall bladder, 
and gut. Homozygous disruption of Hlx led to a dramatic impair of visceral organogenesis 
specifically of the liver (only reached 3% of its normal size) and the gut (only reached 
a quarter of its normal length), suggesting that neither of these organs were able to go 
through the dramatic expansion characteristic of normal organogenesis in the absence of 
Hlx [74]. A detailed examination of the Hlx-/- embryos showed a normal appearance with 
characteristic midgut and hindgut structures at E10.5. However, from E11.5 to E14.5 the 
extensive looping and midgut umbilical hernia observed in wild-type embryos was absent 
in the Hlx-/- mice. These mutants exhibited only a single intestinal loop at E13.5 and E14.5, 
but the mesenchyme became normally stratified into histologically distinct layers [74]. 
The mechanism by which Hlx controls visceral organogenesis is still not well understood. 
Henscht et al suggested that Hlx controls a mesenchymal-epithelial interaction critical for 
liver and gut extension. This interaction is likely mediated by mitogenic factors or matrix 
components secreted by the mesenchyme, and is required for proliferation of both liver 
and gut epithelia (Hentsch, Lyons et al. 1996).
Concluding remarks
Genetic studies have identified two genes, CLMP and FLNA, that when mutated lead to 
the development of CSBS. These findings have improved the quality of genetic counseling 
for CSBS patients and made prenatal diagnostics possible. However, the mechanisms 
by which CLMP and FLNA lead to CSBS are still unknown. Mouse models have also 
identified several other genes that are instrumental for intestinal elongation. All these genes 
encode for proteins that play an instrumental role in major signaling pathways required for 
embryonic development. However, the involvement of these genes in the development of 
CSBS has not yet been reported. Based on our current knowledge, it is difficult to place 
CLMP and FLNA in one of the complex networks involved in intestinal elongation, but it is 
tempting to speculate that CLMP and FLNA can either control or be controlled by one (or 
more) of these signal transduction pathways. All these findings provide new insights into 
CSBS pathogenesis, and represent a first step to identify major processes required for 
intestinal development and elongation. 
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ABSTRACT
Congenital Short Bowel Syndrome (CSBS) is an intestinal pediatric disorder, where pa-
tients are born with a dramatic shortened small intestine. Pathogenic variants in CLMP 
were recently identified to cause an autosomal recessive form of the disease. However, 
due to the rare nature of CSBS, only a small number of patients have been reported to 
date with variants in this gene. In this report, we describe novel inherited variants in CLMP 
in three CSBS patients derived from two unrelated families, confirming CLMP as the major 
gene involved in the development of the recessive form of CSBS. 
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INTRODUCTION
During embryogenesis, the small intestine experiences major growth expanding several 
times the total length of the whole body (Moore and Persaud 2003). This is a complex 
process that starts around the fifth week of human development, when the midgut 
forms a simple linear tube that runs down the midline of the embryo, and is completed 
by the twentieth week of development. Several pathways have been reported to play a 
role in intestinal elongation (van der Werf, Halim et al. 2015), but to date the molecular 
mechanism(s) responsible for this process remains unclear. 
 In Congenital Short Bowel Syndrome (CSBS) intestinal elongation is impaired, 
and patients are born with a substantially shortened small intestine (approximately 50 cm 
in length instead of 250 cm in a normal counterpart) (Hamilton, Reilly et al. 1969). It is a 
rare disorder for which no cure is available. Total parenteral nutrition is required for long-
term survival, but despite considerable efforts to improve treatment, most patients die of 
starvation or sepsis within the first few days of life (Howard, Ament et al. 1995). CSBS was 
first described by Hamilton et al. in 1969, and it has always been considered to have a 
genetic cause (Hamilton, Reilly et al. 1969). However, it was only recently that two genes 
were identified as the cause of CSBS: CLMP and FLNA (Van Der Werf, Wabbersen et 
al. 2012, van der Werf, Sribudiani et al. 2013). CLMP encodes for the Coxsackie-and 
adenovirus receptor-like membrane protein, an adhesion molecule that co-localizes with 
tight junction proteins, but whose function is still unknown (Raschperger, Engstrom et 
al. 2004). FLNA encodes for Filamin-A, an actin binding protein known to regulate cell 
shape and to control cell signalling and migration (Robertson 2005). Pathogenic variants 
present in CLMP and FLNA have been linked to the recessive and X-linked forms of 
CSBS, respectively. 
 Here, we report the genetic screening of three CSBS patients derived from two 
unrelated families, and describe the identification of three novel variants in CLMP.
MATERIALS AND METHODS
Patient information
In this study, three female patients diagnosed with CSBS were investigated (Table 1). 
Two of these patients were siblings of consanguineous descent (P1 and P2). The third 
patient (P3) was previously described, when a de novo translocation was found between 
chromosome 2 and 11 (46,XX,t(2,11)(q32.2,p12)) (De Backer, Parizel et al. 1997). However, 
no gene was identified as the causative factor at that time. A complete description of the 
patients can be found in supplementary data. Written informed consent was given by 
the two families reported, and ethical approval was obtained from the Erasmus Medical 
Center ethical committee (Medisch Ethische Toetsings commissie - METc 2009/364, ABR 
nr: NL31708.042.10).
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Table 1: Clinical and molecular features of the CSBS patients included in this study.
P1 P2 P3
Gender female female female
Age of diagnostic 3 months 38 days 1 week
Ethnicity Iranian Iranian Caucasian
Consanguinity + + No
Malrotation + + +
Length of the small 
intestine (cm)
76 26 50
Additional features Intestinal dysmotility
UPJO*
Intestinal dysmotility
UPJO*
Very mild mental retardation
CLMP variants c.508C>T; p.(R170*) c.508C>T; (p.R170*) c.410G>A; p.(C137Y)
c.29-2A>G
Zygosity Homozygous Homozygous Compound heterozygous
*UPJO: Ureteropelvic junction obstruction
Genetic analysis
Genomic DNA was isolated from peripheral blood lymphocytes using standard methods. 
Exons 1-7 of CLMP (ENST00000448775) were amplified using 30 ng of genomic DNA, as 
described before5. PCR products were purified (ExoSap it – GE Healthcare, Eindhoven, 
The Netherlands), and Sanger sequencing was performed with dye labelled primers 
(forward and reverse; Big Dye Terminator v3.1 Sequencing Kit, Applied Biosystems, 
Bleiswijk, The Netherlands) on an ABI 3130XL genetic analyzer. Sanger reads were 
analysed using SeqScape software and compared to the reference CLMP genomic 
sequence, ENSG00000166250. Genetic data was submitted to ClinVAr (http://www.ncbi.
nlm.nih.gov/clinvar/) and the following accession numbers were obtained: SCV000264793 
[p.(R170*)] and SCV000264792 [p.(C137Y) and (c.29-2A>G)].
Exon trapping assay
The exon trap assay was performed as previously described5. Primers used to amplify 
exon 2 of CLMP and its flanking regions (±150 bp) containing the wild type (WT) and the 
mutant allele, are described in supplementary table 1 (CLMPtrapF and CLMPtrapR).
Expression vectors 
Generation of the expression vectors used is described in supplementary data.
Immunofluorescence 
Chinese Hamster cells (CHO-K1) were cultured as described before5. Five hundred 
thousand cells were seeded in a 6-well plate, and transiently transfected with pcDNA-HA-
CLMP WT or pcDNA-HA-CLMP C137Y expressing vectors, using GeneJuice (Millipore, 
Amsterdam, The Netherlands) as transfection reagent. Twenty four hours after transfection, 
immunofluorescence was performed as previously described5. Images were taken in a 
Leica (AOBS) microscope, and analysed with the Leica LAS AF Lite software.
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RESULTS AND DISCUSSION 
As the three patients included in this study are females, an X-linked pattern of inheritance 
involving FLNA was considered unlikely, and only CLMP was screened. In all patients we 
identified previously unreported variants in CLMP. None of these variants is listed in any 
of the available human genome variant databases. 
Fig.1: Genetic analysis of three CSBS patients. A) Pedigree of the two families included in this study 
with Sanger sequencing results showing the presence of homozygous or compound heterozygous 
variants in CLMP. B) Conservation alignments showed that the missense variant p.(C137Y) leads to 
a change of a cysteine residue highly conserved among vertebrates. C) CHO-K1 cells transfected 
with constructs expressing wild-type (WT) CLMP or the p.(C137Y) variant, show different cellular 
distribution of CLMP. While the WT protein normally localizes to the tight junctions (see arrows), the 
mutated protein has a punctuated distribution through the cytoplasm. Scale bars: 30µm. D) Splicing 
predictions suggested that the intronic variant identified in patient 3 likely affects normal splicing, as 
it is predicted to disrupt an acceptor-splicing site (c.29-2A>G). E) Exon trapping assay confirmed 
disruption of exon 2 splicing by the c.29-2A>G variant. F) Schematic overview of all the variants 
identified to date in CLMP. In black are the variants reported in this report, while in red are the variants 
previously described. Figures 1B and 1D were generated using Alamut prediction software.
 Patients P1 and P2 possess a homozygous nonsense variant in exon 4 
[c.508C>T; p.(R170*)], leading to the appearance of an early stop codon (Fig.1A). This 
nonsense variant was inherited from the parents, who were found to be heterozygous. 
Patient P3 is compound heterozygote, and has two heterozygous variants in CLMP. 
Although we suspect that both variants were inherited from the parents, we were unable to 
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investigate segregation of the variants in the family due to unavailability of parental DNA. 
In this patient a missense variant located in exon 4 was identified leading to an amino acid 
substitution [c.410G>A; p.(C137Y)], together with a possible splice site variant located two 
base pairs upstream of exon two (c.29-2A>G) (Fig.1A). 
 Prediction programs used to infer pathogenicity (PolyPhen-2, MutationTaster, 
SIFT, Human Splicing Finder and Alamut Visual) showed that both variants are likely to 
disturb protein function. The C137Y variant is located in a highly conserved region present 
in all mammals (Fig.1B), and affects the cellular localization of CLMP to the tight junctions 
(Fig.1C). The c.29-2A>G variant is predicted to disrupt normal splicing of exon 2 of CLMP 
(Fig.1D), and we were able to confirm this effect using an exon trapping in vitro assay 
(Fig. 1E). Considering that both variants functionally affect CLMP, we believe that the de 
novo translocation previously identified in this patient9 is an independent event unrelated 
to CSBS. 
 Currently, only seven patients have been described carrying pathogenic variants 
in CLMP5. All the variants reported were loss of function, leading to the absence of CLMP, 
or to the expression of a mutant protein with a disrupted function (Fig.1F). In this report, 
we expand the mutational spectrum of CLMP variants involved in CSBS, consolidating the 
involvement of this gene in the development of the recessive form of this disease. We also 
show that it might be worthwhile to screen previously described patients for whom an X-
linked pattern of inheritance has been disregarded, for the presence of variants in CLMP, 
as this might shed some light on the genetic basis of the disease in these cases. To date, 
the role of CLMP in intestinal elongation is still largely unknown, making it difficult to de-
termine the molecular mechanisms underlying the development of CSBS. We believe that 
the results here described reinforce the need to further study the role of CLMP in intestinal 
elongation, as this might contribute for the development of new therapeutic strategies for 
CSBS patients.  
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Supplementary Material and Methods
Patient information
Patients P1 and P2 were both admitted to the hospital shortly after birth due to bilious 
vomiting and diarrhea. Patient P2 had a distended abdomen, but an otherwise normal 
physical exam. Abdominal x-ray showed air fluid level, and transit of small bowel showed 
a distended loop. A final diagnosis of malrotation and the presence of a congenital short 
bowel measuring 76 and 26 cm in P1 and P2 respectively, was made by laparotomy.  
Patient P3 was admitted to the hospital in the first days after birth due to diarrhea, vomit-
ing and poor weight increase, as previously described9. Radiological examination showed 
malrotation and the presence of a congenital short bowel. The final diagnosis was made 
by exploratory laparotomy that confirmed the presence of a small intestine measuring only 
50 cm in length.
All patients included in this study are still alive at the time of publication, and for all of them 
additional symptoms have been reported. Patients P2 and P3 presented with intestinal 
dysmotility and ureteropelvic junction obstruction, while patient P3 was diagnosed with 
mild mental retardation. Mild dysmorphic features were also initially reported for patient 
P39. However, they were later disregarded, as they resulted from malnutrition during the 
neonatal period. 
Expression vectors 
pcDNA-HA-CLMP WT was generated by PCR amplification of CLMP using the primers 
CLMP-HAF and CLMP-HAR (supplementary table 1). BamHI-NotI restriction sites includ-
ed respectively in the forward and reverse primers (see underlined nucleotides in the 
primer sequence), were used to clone CLMP into pcDNA-HA vector. pcDNA-HA-CLMP 
(C137Y) was originated by site directed mutagenesis according to the manufacturer’s 
instructions (QuickChange II site-directed mutagenesis kit, Agilent technologies). Primers 
used to insert the C137Y variant were the CLMPmutF and CLMPmutR (Supplementary 
table1; the mutated nucleotide is underlined in the primer sequence). The following muta-
genesis, the entire CLMP insert was checked by Sanger sequencing.
Supplementary Table 1: Primers used in this study. 
Primer name Sequence (5’-3’)
CLMPHAF CATATAGGATCCATGTCCCTCCTCCTTCTCCTC
CLMPHAR CATATAGCGGCCGCTCAGACCGTTTGGAAGGCTCTG
CLMPmutF CCATCCAAGCCCAAGTATGAGTTGGAAGGAGAGC
CLMPmutR GCTCTCCTTCCAACTCATACTTGGGCTTGGATGG
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ABSTRACT 
Pathogenic variants in Filamin A (FLNA) have been associated with a wide spectrum of 
disorders, and more recently with an X-linked form of Congenital Short Bowel Syndrome 
(CSBS). Since the role of FLNA in intestinal development is largely unknown, we 
performed expression studies at different human fetal stages, and a combination of in 
vitro and in vivo assays, to understand the molecular mechanisms associated with FLNA 
variants underlying CSBS. Our results show that FLNA is expressed in the muscular layer 
of the small intestine from early human fetal stages. Moreover, FLNA variants associated 
with CSBS block expression of one of its two isoforms, possibly explaining why these 
patients only have intestinal complaints. Finally, by generating a transgenic zebrafish line 
using TALEN, we show that the long flna isoform is required for intestinal elongation and 
function. flna mutant fish have stastistically significant reduction of gut length, but are 
otherwise phenotypically indistinguishable from wild-types. Moreover, intestinal transit 
assays showed an increased transit time for the transgenic zebrafish. Taken together our 
results bring new insights to the role of FLNA during intestinal development and elongation, 
and contribute to a better understanding of CSBS pathogenesis.
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INTRODUCTION
Filamin A (FLNA) is a cytoplasmic protein with a well characterized role. It was the first actin 
filament cross linking protein to be identified in non-muscle cells, and is involved in a series 
of events required for cell motility, migration and maintenance of cytoskeletal integrity 
(Onoprishvili, Ali et al. 2008, Nakamura, Stossel et al. 2011). FLNA has several known 
binding partners, including ion channels, receptors, intracellular signaling molecules and 
transcription factors (Nakamura, Stossel et al. 2011). Therefore, it is not surprising that 
loss of function variants affecting the normal expression levels of FLNA result in a wide 
range of abnormalities associated with different human disorders (Robertson 2005, Kyndt, 
Gueffet et al. 2007, Bernstein, Bernstein et al. 2011, Oegema, Hulst et al. 2013, van der 
Werf, Sribudiani et al. 2013). 
 Recently, FLNA was associated with the development of an X-linked form of 
Congenital Short Bowel Syndrome (CSBS), when a two base pair deletion (c.16-17delTC) 
was identified in three male patients born with a dramatically shortened small intestine 
(van der Werf, Sribudiani et al. 2013). This deletion is located in exon two of FLNA and 
results in a frameshift with the subsequent appearance of an early stop codon a few base 
pairs later. In a previous study, a similar deletion (c.65-66delAC) was identified in two 
related male patients diagnosed with Chronic idiopathic intestinal pseudo-obstruction 
(CIIP) associated with CSBS (Gargiulo, Auricchio et al. 2007). Considering that in both 
these studies intestinal abnormalities were reported without other major congenital 
abnormalities, it was suggested that two FLNA isoforms exist, and in the presence of the 
two base pair deletion, only the expression of the long isoform was affected (Gargiulo, 
Auricchio et al. 2007). This would explain why these deletions are not lethal for males in 
utero and that they only have intestinal complaints. However, the role of FLNA in intestinal 
development is largely unknown, making it difficult to pinpoint the pathogenic mechanism 
involved in the development of CSBS.
 Here we bring new insights into the role of FLNA, as we further investigate the ex-
istence of two FLNA isoforms and provide evidence that the long FLNA isoform is required 
for intestinal elongation. 
MATERIALS AND METHODS
Immunohistochemistry
Paraffin-embedded human small intestinal specimens from controls were collected from the 
department of Pathology, Erasmus University Medical Center. Slides were immunostained 
using a specific antibody against human FLNA dilution 1:1000; Eurogentec). After 
incubation with the primary antibody, samples were treated with anti-rabbit secondary 
antibody and the avidin-biotin-complex with peroxidase. 3,3’-diaminobenzidine (DAB) 
chromogen (Ventana) was applied, and hematoxylin was used as counterstain. Images 
were acquired using the Nanozoomer 2.0-HT (Hamamatsu Photonics), and analyzed with 
the Nanozoomer Digital Pathology (viewer software (Hamamatsu Photonics).  
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Expression vectors and site-directed mutagenesis
pAAV2.1-CMV-EGFP-FLNA wild-type (WT) and pAAV2.1-CMV-EGFP-FLNA mutant 
1 (c.65-66delAC) constructs were kindly provided by Dr. Alberto Auricchio from the 
University of Napoli. pAAV2.1-CMV-EGFP-FLNA mutant 2 construct containing the other 
2 base pair deletion (c.16-17delTC), was made by site–directed mutagenesis according to 
the instructions provided by the manufacturers (Stratagene), using the WT construct. The 
following primers were used: FLNAmutF: GAGTAGCTCCCACTCGGGCGGGCCAGAG 
and FLNAmutR: CTCTGGCCCGCCCGAGTGGGAGCTACTC. 
Cell culture and transfection
Human embryonic kidney cells (HEK293) were cultured in DMEM with high glucose content 
supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were incubated at 370C 
in the presence of 5% CO2. For transient transfection, 300,000 cells were cultured in a 6 
well plate. Twenty-four hours after, cells were transfected with 1µg of plasmid DNA using 
GeneJuice (Millipore) as transfection reagent, according to the manufacturer’s instructions.
Cell lysis and Western Blot
Cells were lysed 48 hours after transfection using m-PER (Thermo Scientific) and 1X 
protease inhibitors (Roche). Cell lysate preparation, protein quantification and Western blot 
analysis were performed as described before (Halim, Hofstra et al. 2016). The following 
antibodies were used: HA (Cell Signaling) and actin (Santa Cruz Biotechnologies). 
Secondary antibodies used were IRDye 800CW Goat anti-mouse and IRDye 680RD Goat 
anti-Rabbit (Li-Cor).
RNA isolation, cDNA preparation and RT-PCR
Zebrafish embryos collected at different embryonic stages were lysed in Trizol, and RNA 
isolation was performed with the RNeasy mini kit (Qiagen), according to the manufacturer’s 
instructions. 1 µg of RNA was used for cDNA preparation with the iScript cDNA Synthesis 
Kit (Bio-Rad). A Reverse transcriptase PCR was performed using 100 ng/µl of cDNA as 
template and a standard protocol. The primers used for amplification were: flnazebF: 
ATGCCCGCTACAGAGAAAGA; flnazebR: ATGGGCATGGAGATGGAATA; actinzebF: 
TGAAGTACCCCATCGAGCAGG; actinzeb R: GCAAGATTCCATACCCAAGAAGG.
Whole mount in situ hybridization
RNA isolated from 48 hours post fertilization (hpf) embryos was used as a template for cDNA 
using a One-Step RT-PCR kit (Qiagen). Primers used for amplification were: flnazebprobeF: 
TCCAAAATCACAGGTGACGA; flnazebprobeR: TACACCAGCTTCTGCCCTCT.  Amplified 
bands were subcloned into the TOPO TA PCRII cloning vector (ThermoFisher). Digoxigenin 
labelled anti-sense probes (Roche) were generated by linearizing the plasmids with NotI 
(NEB), then transcribed with SP6 polymerase (Roche). In situ hybridization was performed 
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on staged zebrafish embryos as previously described (Thisse, Thisse et al. 1993).
Generation of the flna long isoform knockout zebrafish 
TALENs were designed in order to target exon one of flna and recognize the following 
sequences: 5’- CCCCTATCCAACGCTTC and 3’- GACGCCGACATGCCCGC. To establish 
the flna long knockout mutant fish, 100 pg mRNA of each TALEN was injected into the cell 
of a one-cell stage embryos collected from wild-type zebrafish crossings. The Tupfel long 
fin (TL) zebrafish line was used for all in vivo experiments described in this manuscript. 
All injected embryos were raised to adulthood and crossed to generate F1. F1 transgenic 
embryos were raised to adulthood and genotyped. One homozygous fish containing a 6 
base-pair deletion followed by a 1 base-pair insertion was crossed with a heterozygous 
fish containing the same genetic alteration. F2 transgenic fish were generated, raised 
to adulthood and genotyped. All in vivo experiments described in this manuscript were 
performed in F3 fish.
Genotyping of transgenic zebrafish
Tail clip of transgenic zebrafish was performed followed by DNA isolation using a 
mixture containing Tris-HCl (pH9.0), KCl, Triton X-100, and protease K (Sigma Aldrich). 
After incubation at 550C for one hour, protease K was inactivated at 980C for 10 min. 
Isolated DNA was used as a template for a PCR reaction with a standard program 
and the following primers: flnazebF: CACCCGAATTGCAGTTTCTC and flnazebR: 
CATCAAGCTGGTCTCCATTG. The PCR product was subjected to restriction digestion 
with NciI (New England Biolabs) for 1h at 370C, and submitted to Sanger sequencing, which 
was performed with dye labelled primers (flnazebF and flnazebR; Big Dye Terminator v3.1 
Sequencing Kit, Applied Biosystems) on a ABI 3130XL genetic analyzer. Sanger reads 
were analysed using SeqScape software.
Intestinal length measurements in zebrafish
Zebrafish embryos were collected after fertilization and individually placed in a 24-well 
plate. Each larvae was imaged every twenty-four hours under the microscope (Leica 
DFC550) for four days. Gut measurements were made using Fiji software, and were 
based on the distance between mouth and anus. All embryos were genotyped at the end 
of the experiment. Statistical significance was calculated using a two-paired ttest.
Intestinal transit assays in zebrafish
Seven day old zebrafish larvae were fed for two hours with a mixture containing 100 
mg of powdered larval feed, 150 µL of fluorescent 2.0 µm polystyrene microspheres 
(Invitrogen) and 50 ul of water. After two hours, the larvae were anesthetized with Tricaine 
and were individually checked under the microscope (Leica DFC550) for the presence 
of fluorescence. Individual larvae were placed in separate wells of a 24-well plate, and 
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examined once again under the microscope twenty-four hours after feeding. All larvae 
were genotyped at the end of the experiment.
RESULTS
FLNA is expressed in the muscle layer of the small intestine
FLNA is a cytoplasmic protein that is ubiquitously expressed in all tissues of the body. 
However, not much is known about FLNA expression during human development. Since 
CSBS affects elongation of the small intestine, we investigated the expression of FLNA 
in the human intestine (jejunum/ileum) at weeks 17 and 22 of fetal development, at the 
neonatal stage and postnatally (three-months old). At all developmental stages FLNA was 
abundantly expressed in the cytoplasm of smooth muscle cells, including smooth muscle 
cells of the muscularis mucosa, and the inner circular layer and outer longitudinal layer of 
the muscularis propria (Fig. 1). 
Fig.1: FLNA expression is localized in the muscular layer of the human small intestine since early 
fetal stages. Immunohistochemistry performed in human intestinal specimens collected at different 
developmental stages shows that FLNA is expressed in the muscular layer of the small intestine. 
mm: muscularis mucosa; cm: circular layer of the muscularis propria; lm: longitudinal layer of the 
muscularis propria.
The two base pair deletions found in patients with CSBS disrupt expression of the 
long FLNA isoform
Considering that the two base pair deletions identified in CSBS are located between two 
methionine residues (Fig. 2A), it was hypothesized that two FLNA isoforms exist, and that 
in the presence of these deletions only the expression of the long isoform was affected. A 
previous study already confirmed that the c.65-66delAC deletion identified in two related 
male patients diagnosed with CIIP associated with CSBS, leads to expression of only 
one FLNA isoform (Gargiulo, Auricchio et al. 2007). The authors observed this effect by 
introducing the 2bp deletion in a mini-gene construct where only exon 2 of FLNA (WT) 
was present fused to a HA-tag. Here, we made use of the same WT construct to evaluate 
the effect of the c.16-17delTC deletion. We used the c.65-66delAC construct as control. 
By expressing the three constructs (WT, c.65-66delAC, and c.16-17delTC) in HEK293 
cells we observed that the WT construct produced 2 bands, suggesting that two different 
FLNA isoforms are normally expressed (Fig. 2B). In the presence of both deletions, c.65-
66delAC, and c.16-17delTC, expression of only the lower band was detected (Fig. 2B). 
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Fig.2: Two FLNA isoforms are normally expressed from a single transcript. A) Schematic represen-
tation of FLNA where two isoforms are depicted: long FLNA isoform (red + blue), and short FLNA 
isoform (blue). Amplification of the region between the two methionine residues show DNA sequence 
of FLNA. In the presence of the 2-base pair (bp) deletions identified in CSBS patients (del1: c.16-
17delTC; del2: c.65.66delAC), an early stop codon appears leading to the expression of only the 
short isoform (blue). B) Western blot analysis using a mini gene construct expressing wild-type (WT) 
and mutant [Mut1(c.65-66delAC); Mut2 (c.16-17delTC)] versions of FLNA fused to an HA-tag, show 
that while in the WT situation two bands are normally expressed, in the presence of either one of the 
deletions identified in CSBS patients, only one band is present. 
 
 In light of these results, we concluded that in the presence of the c.16-17delTC 
deletion, as well as the c.65-66delAC, only the short FLNA isoform is expressed.
Generation of the flna long isoform knockout zebrafish
Fig.3: flna expression is detected in the zebrafish from early embryonic stages. A) RT-PCR performed 
in RNA isolated from zebrafish embryos at different embryonic stages shows that flna transcripts are 
present from as early as the 4 cell stage, and its expression seems to increase during development. 
B) In situ hybridization shows that flna is highly expressed in the brain and the gut of the zebrafish at 
different stages of development. smt - somites; hpf - hours post fertilization.
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To evaluate the effect of the long FLNA isoform on the development and elongation of the 
intestine, we used the zebrafish as an in vivo model. We started by determining where 
and when flna was expressed, and for that the expression levels of flna were analysed by 
RT-PCR at different embryonic stages. Our results showed that flna is expressed in early 
embryonic stages starting at the four cell stage, and that its expression seems to increase 
during development (Fig. 3A). In situ hybridization also showed that flna is abundantly 
expressed in the brain and intestine of the zebrafish at all stages analyzed (Fig. 3B).
 To generate the transgenic zebrafish line where only the short isoform is expressed, 
we used two TALENs designed to target the region between the two methionine residues 
located in the first exon of flna. Considering that disruption of NciI restriction site would 
occur if the TALENs have successfully annealed, we used this enzyme to differentiate 
between wild-type (WT) and transgenic fish (Fig.4A). A deletion of six base pairs followed 
by insertion of one base pair in a homozygous (flna long isoform-/-) and in a heterozygous 
(flna long isoform+/-) state was identified in one male and one female fish, respectively (Fig. 
4B). This out-of-frame deletion followed by an insertion resulted in the appearance of an 
early stop codon in the end of exon 1, leading to a similar effect to the deletions described 
for CSBS patients. 
Fig.4: Generation of the long flna knockout zebrafish line. A) Genotype of the transgenic flna zebraf-
ish generated with TALENs. Wild-type (WT) and transgenic fish can be distinguished after treatment 
with NciI restriction enzyme. In the WT situation a restriction site for NciI is present between the two 
methionine residues. Therefore, treatment with this enzyme generates two bands. If the TALENs had 
successfully annealed, the restriction site for NciI is disrupted, leading to a single uncut band [ho-
mozygous (hom)], or to a combination of both cut and uncut bands [heterozygous (het)]. B) Sanger 
sequencing of the transgenic flna long-/- zebrafish detected a homozygous deletion of 6-base pairs 
(bp) (underlined), disrupting the NciI restriction site (GGGCC), followed by an insertion of one bp, 
thymine (arrow). 
The long FLNA isoform is required for intestinal elongation 
Since the main feature of CSBS patients is a dramatically shortened small intestine, we 
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investigated the effect of the disruption of the long FLNA isoform on the total length of 
the intestine in zebrafish. We crossed the flna long isoform-/- fish to generate offspring 
where the out-frame deletion plus insertion was present in a homozygous state. Unlike 
humans, the zebrafish does not have X and Y chromosomes, and two copies of flna are 
normally present. Therefore, flna long+/- fish were also crossed with WT TL in order to 
evaluate the effect of the out-of frame variant in a heterozygous state. The intestinal length 
of approximately 150 offspring (F3) was measured every day for four days, and revealed 
that the flna long isoform-/- zebrafish had a statistically significant shorter intestine than the 
WT (0.318 mm ± 0.014 vs. 0.334 mm ± 0.015, respectively) (Fig. 5A). 
Fig.5: flna long-/- zebrafish embryos have a shorter small intestine. A) Measurement of the intestinal 
length of a total of 150 WT and transgenic fish show that flna long-/- (hom) embryos have significantly 
shorter intestine when compared to WT and flna long+/- (het). No difference was observed between 
WT and flna long+/- (het) embryos. B) Measurement of the total body length of WT and transgenic ze-
brafish reveals no difference between WT, flna long-/- (hom) and flna long+/- (het) embryos. hpf - hours 
post fertilization. *p<0,05; ** p<0,006; ***p<0,000003.
 However, disruption of only one of the flna alleles had no effect on the total length 
of the gut (0.331 mm ± 0.016 for flna long isoform+/- vs. 0.334 mm ± 0.015 for WT) (Fig. 
5A). In order to exclude that the shortened intestine found in flna long isoform-/- fish was 
the result of an overall reduction in body length, the total length of each zebrafish was also 
measured every day for four days. Our results showed that homozygous, heterozygous 
and WT zebrafish were undistinguishable in total body length (0.573 mm ± 0.026; 0.587 
mm ± 0.020 and 0.583 mm ± 0.025, respectively) (Fig. 5B). 
Intestinal motility is reduced in the flna long isoform-/- transgenic zebrafish 
CSBS patients carrying the c.65-66delAC deletion were also diagnosed with CIIP 
(Gargiulo et al., 2007). To investigate whether the intestinal obstruction experienced by 
these patients might be related to the expression of the long FLNA isoform, we performed 
intestinal transit assays using the flna long isoform-/-, flna long isoform+/-, and WT zebrafish 
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larvae. For these studies, 7 day old larvae were fed for two hours with fluorescently labelled 
larval feed, and imaged to select the ones that showed fluorescence in their intestinal bulb 
(Fig. 6A). Twenty-four hours after, these larvae were imaged again and we observed that, 
while almost all WT and heterozygous fish no longer had fluorescence within the GI tract 
(6 out of 25 ; 24% for WT and 4 out of 24 ; 16,6% for flna long isoform+/-), for a substantial 
amount of homozygous fish (15 out of 35 ; 42,8%) fluorescence was still present in the 
gut (Fig.6A, 6B). 
Fig.6: Intestinal transit assays show that flna long-/- larvae have reduced intestinal motility. A) WT, flna 
long+/- and flna long-/- larvae fed for two hours with a mixture of powdered larval feed and fluorescence 
microspheres, were screened for the presence of fluorescence in the intestinal bulb (see arrows). 
Positive larvae were separated and imaged again 24 hours after feeding. While most of the WT and 
heterozygous larvae no longer had fluorescence signal in the gut, a substantial number of flna long-/- 
larvae still had fluorescence (see arrow). B) Quantification of the number of zebrafish larvae for which 
fluorescence was detected in the intestinal tube 24 hours after feeding. 43% of the flna long-/- (hom) 
larvae have delayed intestinal motility when compared to WT (24%) and flna long+/- (17%; het) fish. 
* intestinal bulb.
 This result shows that intestinal transit is delayed in the homozygous mutant fish 
(it is only delayed in some of the homozytoes – you need to say something about that), 
and suggests? that the long isoform of flna is required for normal intestinal peristalsis.
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DISCUSSION
FLNA has been extensively studied since loss-of-function variants in its coding gene 
are generally lethal in males, and have been associated with several disorders, such 
as periventricular nodular heterotopia (OMIM 300049) (Poussaint, Fox et al. 2000, 
Sheen, Dixon et al. 2001), otopalatodigital syndrome type I (OMIM 311300) (Robertson, 
Twigg et al. 2003, Hidalgo-Bravo, Pompa-Mera et al. 2005) and type II (OMIM 304120) 
(Marino-Enriquez, Lapunzina et al. 2007), frontometaphyseal dysplasia (OMIM 305620) 
(Robertson, Twigg et al. 2003, Zenker, Rauch et al. 2004), and Melnick-Needles syndrome 
(OMIM 309350) (Parrini, Mei et al. 2015). Recently two out-of-frame deletions located 
between two methionines of FLNA were identified in five patients diagnosed with CSBS 
and CIIP (Gargiulo, Auricchio et al. 2007, van der Werf, Sribudiani et al. 2013). Considering 
that these patients mainly had gastrointestinal complaints, it was hypothesized that the 
deletions identified change the transcription starting site of FLNA to the second methionine, 
and result in the expression of only the short FLNA isoform (Gargiulo, Auricchio et al. 2007, 
van der Werf, Sribudiani et al. 2013). This hypothesis is corroborated by the results of our 
mini-gene assays, which showed that similar to the findings presented for the c.65-66delAC 
variant (Gargiulo et al. 2007), the c.16-17delTC deletion leads to loss of expression of the 
FLNA long isoform (Fig. 2). Based on this result it is tempting to speculate that the FLNA 
long isoform is required for intestinal elongation. To test this hypothesis, we generated a 
transgenic zebrafish line whereby the presence of an out-of-frame deletion plus insertion 
had a similar effect to the deletions described in CSBS patients, and led to the expression 
of the short flna isoform only. The length of the intestine, as well as total body length, 
was measured for homozygous, heterozygous, and WT zebrafish from 1-4 dpf, and we 
observed that while the majority of flna long isoform-/- embryos had significantly shortened 
intestines, there was no difference in the total body length of wt, heterozygous and 
homozygous fish (Fig. 5). These findings confirm the importance of the long FLNA isoform 
for intestinal elongation, and indicate that its function is conserved between species. To 
our surprise, the reduction observed in intestinal length for the flna long isoform-/- embryos 
is limited to 5%, which is far below the reduction observed in CSBS patients (>75%). 
This discrepancy can be attributed to differences between species, as the fish gut is just 
a straight simple tube with no defined regions, while in humans it is very elongated and 
requires complex patterns of rotation and looping to reach its final configuration. However, 
we also cannot exclude the involvement of another protein in the zebrafish with a redundant 
function. Previous studies have shown that three other genes are known to encode for 
flna homologs in the zebrafish, which include flnb, flnca, and flncb. Although the function 
of all flna proteins in the zebrafish is not yet clear, shared characteristics between all of 
the homologs suggest possible functional redundancy. Such redundancy has also been 
suggested to exist between human FLNA and FLNB during neuronal migration (Sheen, 
Feng et al. 2002). However, the reasons why such redundancy is not able to compensate 
for the loss of the long FLNA isoform, still needs to be elucidated. Speculation over species 
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specific issues may provide a reasonable explanation, but this is yet to be confirmed by 
further investigation on the function of FLNA and its interacting proteins in these species.
CIIP has been reported as a co-morbidity in CSBS patients with FLNA variants (Gargiulo, 
Auricchio et al. 2007, Kapur, Robertson et al. 2010). Thus, we made use of the flna long 
isoform-/- zebrafish to assess the effect of the deletion on intestinal motility. Data from 
gastrointestinal transit assays performed in WT, flna long isoform+/- and flna long isoform-/- 
zebrafish showed that intestinal transit time is significantly longer in the flna long isoform-/- 
fish (Fig. 6). This suggests that the CIIP phenotype observed in CSBS patients might well 
be directly related to the FLNA deletions. An involvement of the Enteric Nervous System 
(ENS) has been suggested to contribute to the reduced intestinal motility observed 
(Camilleri, Carbone et al. 1991, Pingault, Guiochon-Mantel et al. 2000). However, 
histological analysis performed on bowel tissues of these patients show contradictory 
results. While some CSBS patients have signs of ENS defects, others show abnormal 
gut smooth muscle. Based on our immunohistochemistry data, we clearly show that 
FLNA is expressed only in the smooth muscle cells of the human intestine during various 
developmental stages (Fig. 1), suggesting that expression of this protein is essential for 
the function of human intestinal smooth muscle cells. Since the muscular structures make 
up a major part of the intestine, and play an indispensable role in intestinal contractility, 
it is logical to hypothesise that the loss of FLNA long isoform may also cause failures in 
intestinal contractility. A recent study where Flna expression was specifically abolished in 
smooth muscle cells of an adult mouse showed that Flna is involved in signalling cascades 
that underlie smooth muscle contractility (Retailleau, Arhatte et al. 2016). Thus, it is very 
likely that a muscular defect is the cause of the intestinal obstruction diagnosed in CSBS 
patients with FLNA variants, but further investigations in the flna long isoform-/- zebrafish 
are currently on-going to test this hypothesis.
 Besides FLNA, one other gene has been identified as the cause of the recessive 
form of CSBS, CXADR like membrane protein (CLMP) (Van Der Werf, Wabbersen et al. 
2012). To date, no relationship between FLNA and CLMP has been found. However, FLNA 
is known to directly interact with actin filaments and is involved in the transport of various 
proteins, including receptors and tight junctions, to the cell membrane (Feng and Walsh 
2004). Considering that CLMP encodes for a tight junction protein (Raschperger, Thyberg 
et al. 2006, Sze, Lee et al. 2008), it is tempting to speculate that FLNA interacts with 
CLMP in smooth muscle cells of the gut, and is required for the proper cellular localization 
of CLMP. Further studies are currently on-going to investigate a possible relationship 
between these two proteins in order to bring new insights into the molecular mechanisms 
required for intestinal elongation and functioning. 
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Abstract 
Hereditary Multiple Intestinal Atresia (HMIA) is a familial form of multiple intestinal atresia 
that often comorbid with severe immunodeficiency. Recently, mutations in TTC7A have 
been identified in patients with this disease. Further investigation has been hampered by 
the unavailability of animal models that recapitulate the human intestinal phenotype. We 
studied two sibs who were diagnosed with HMIA. Intestinal specimens from both patients 
were immunostained to analyze the histopathology of the intestine. Moreover, by utilizing 
Transcription Activator Like Effector Nucleases (TALEN) genome editing, a transgenic 
zebrafish model was generated. Histological and functional characterization of the 
transgenic zebrafish larvae was performed to further evaluate the effect of the mutations 
to the intestine. We identified a homozygous deletion of 13,123 bp that includes exon 2 
of TTC7A in 2 sibs from a consanguineous family. Histopathology of patients’ intestinal 
specimens showed a distinctive phenotype of multiple lumens that configure a sieve-like 
appearance, without any clear abnormalities in the muscular and neuronal structures of the 
intestine. Histology of zebrafish larvae, carrying an out-of-frame mutations in ttc7a, showed 
dramatic segmental narrowing of the intestinal lumen. Motility assays showed decreased 
gastrointestinal transit time (GIT) in the group of ttc7a mutant fish. We corroborate the role 
of TTC7A as the gene for HMIA and we show that the ttc7a mutant zebrafish is a suitable 
animal model to study the pathogenesis of intestinal atresia in human, and to elucidate 
normal embryogenesis of intestinal lumen formation.
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Introduction
Multiple intestinal atresia (MIA) (OMIM 243150) is a rare cause of neonatal intestinal 
obstruction that is characterized by discontinuity of the intestinal lumen at multiple sites 
of the small and large intestine (Guttman, Braun et al. 1973). Some cases of MIA are 
familial, and often referred as hereditary MIA (HMIA). Interestingly, in most HMIA cases, 
immunodeficiency has been reported as a comorbidity. 
 Like the treatment for any other type of intestinal atresia, surgical removal of the 
atretic intestine, followed by anastomosis of the residual intestine is the standard treatment 
(Dalla Vecchia, Grosfeld et al. 1998). Despite successful surgery, post-surgical recurrence 
of intestinal obstruction and prolonged dysmotility are often observed in patients (Avitzur, 
Guo et al. 2014). This condition is worsened by the inability of patients’ immune system to 
resist infections (Ali, Rahman et al. 2011). 
 Although HMIA has long been suggested as a genetic disease with an autosomal 
recessive pattern of inheritance (Bilodeau, Prasil et al. 2004), recently, variants in 
Tetratricopeptide-7A (TTC7A) were identified in patients with HMIA (Samuels, Majewski 
et al. 2013). TTC7A is a gene that encodes a protein known to hold an important role 
in normal iron haemostasis (White, McNulty et al. 2005). This important finding is then 
followed by in vitro studies that suggest the importance of TTC7A protein in the regulation 
of intestinal polarity and cell adhesion (Avitzur, Guo et al. 2014, Bigorgne, Farin et al. 
2014). Nevertheless, the mechanism on how the change in intestinal polarity and cell 
adhesion could lead to the narrowing of intestinal lumen and immunodeficiency remains 
unclear.     
 Unfortunately, the effort to study the disease mechanism further has been 
hampered mainly by the unavailability of animal models, since Ttc7 knockout mouse 
models do not recapitulate the phenotype in HMIA patients (White, McNulty et al. 2005, 
Kasahara, Shimizu et al. 2008). For example, in one of the Ttc7 mutant mice known 
as the flaky skin (fsn) mice, the deficit of TTC7 protein leads to hypochromic anemia, 
and skin abnormalities that resemble human psoriasis (Sundberg, Dunstan et al. 1994, 
Helms, Pelsue et al. 2005). Beamer et al. suggested that a general impairment of iron 
uptake by the intestinal epithelial cells leads to the anemia (Beamer, Pelsue et al. 1995). 
However, none of these mouse models acquire any intestinal phenotype that resemble 
intestinal atresia in human, suggesting that a species-specific difference likely exists. As 
an alternative, zebrafish has long been used in intestinal research due to similarities in its 
gastrointestinal (GI) system to the GI system in mammals. 
 In this study we corroborate the role of TTC7A as the gene for HMIA and based on 
our finding in patients with HMIA, we generate and characterize a ttc7a knockout zebrafish 
model.
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Materials and Methods
Human sample collection and DNA isolation
We studied two sibs from a consanguineous family who were diagnosed with HMIA 
and immunodeficiency at the Erasmus University Medical Center in Rotterdam, The 
Netherlands. Genomic DNA was isolated from peripheral blood lymphocytes using 
standard protocol (Chemagic DNA Blood Kit Special, Chemagen) (Perkin Elmer, Waltham, 
Massachusetts, USA). Based on earlier reports about the mutations in TTC7A in patients 
with HMIA and immunodeficiency, genetic screening in a diagnostic setting was performed 
on the two siblings.
Sanger sequencing 
Sanger sequence of exons 1-20 in TTC7A was performed using the set of primers 
described in Supplementary table 1. 15ng of genomic DNA was used to amplify each 
exon, using a standard PCR protocol. PCR products were purified (ExoSap it – GE 
Healthcare, Fairfield, Connecticut, USA), and Sanger sequencing was performed with dye 
labelled primers (forward and reverse; Big Dye Terminator v3.1 Sequencing Kit, Applied 
Biosystems) on an ABI 3130XL genetic analyzer. Sequencing results were analysed using 
SeqScape software version 2.6 (Applied Biosystems, Foster City, California, USA).
Immunohistochemistry
Human intestinal tissues from controls and patients II.1 and II.2 were embedded in paraffin, 
and obtained from the Department of Pathology at the Erasmus University Medical Center. 
Hematoxylin and eosin staining was performed using a standard protocol. Immunostainings 
were performed using specific antibodies against Neurofilament (dilution 1:600; Monosan), 
Smooth muscle actin-α2 (ACTA2; ready to use; Dako), Tyrosin protein kinase Kit (c-Kit/
CD117) (dilution 1:200; Cell Marque). All images were taken with a Nanozoomer 2.0-HT 
(Hamamatsu Photonics, Shizuoka, Japan), and analyzed using the Nanozoomer Digital 
Pathology (NDP) viewer software (Hamamatsu Photonics, Shizuoka, Japan). 
 
Generation of ttc7a mutant zebrafish line
The Transcription Activator Like Effector Nuclease (TALEN) genome editing technique 
was used to create a double strand break in exon 3 of ttc7a in zebrafish. Once injected 
zebrafish embryos reached adulthood, genomic DNAs was isolated from the tails using 
standard method, and used directly to amplify exon 3 of ttc7a. The PCR products 
underwent purification (Exosapt it – GE Healthcare, Little Chalfont, UK) and Sanger 
sequencing with dye labelled primers using ABI 3130 XL Genetic analyzer. Sequencing 
results were analyzed with SeqScape software version 2.6 (Applied Biosystems, Foster 
City, California, USA). Heterozygous fishes with an out-of-frame deletion or insertion were 
then bred and crossed to create homozygous ttc7a out-of-frame mutants’ larvae that were 
used in this research.  
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Histology of zebrafish larvae and image analysis
Adult heterozygous out-of-frame ttc7a mutants were crossed, and larvae were kept until 
5 dpf. The 5 dpf larvae were then euthanized using Tricaine methanesulfonate (Sigma 
Aldrich, St. Louis, Missouri, USA), and tail clipped for genotyping. The larvae were fixed in 
4% paraformaldehyde. After fixation, zebrafish larvae underwent serial dehydration, and 
embedded in paraffin. 5 µm serial transverse sections were stained with hematoxylin and 
eosin using standard protocol. All histological images were taken using a Nanozoomer 2.0-
HT, and analyzed with Nanozoomer Digital Pathology (NDP) viewer software (Hamamatsu 
Photonics, Hamamatsu City, Shizuoka, Japan).      
In vivo analysis of gut function
Study protocols involving the use of zebrafish larvae for in vivo analysis of gut function 
using a fluorescent pellet were approved by the Erasmus Animal Experiments Committee 
(Erasmus Dierexperimenteel Centrum – EDC). To make the fluorescence pellet, we 
use FluoSpheres® Carboxylate-Modified Microspheres, 2.0 µm, Nile Red fluorescent 
(535/575), 2% solids according to the manufacturer’s instruction (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA). In brief, 200 µl of FluoSpheres is mixed with 100 µg 
of fish pellet and 100 µl of water. Then the stirred mixtures formed a paste, were air 
dried, and scrapped into a fine powder. As previously suggested (Field, Kelley et al. 
2009), we fed this fluorescence pellet into a mixed population of zebrafish larvae, results 
from crossings of heterozygous out-of-frame ttc7a mutants. The larvae were kept in the 
incubator at 28˚C. After 2-3 hours, we assessed the larvae using fluorescence stereo 
microscope Leica M165FC (Leica, Wetzlar, Germany) to select larvae with their intestinal 
bulb filled completely with fluorescent pellet. Thereafter, larvae with a full intestinal bulb 
were individually placed in a well of a 24-well-plate, and kept in the incubator at 28˚C for 
24 hours. Final assessment were taken using the fluorescence microscope. Then, the 
zebrafish larvae were euthanized and genotyped. 
 Furthermore, to record the phenotype of the ttc7a mutant zebrafish, we also 
performed live imaging using intravital microscopy on 7 dpf zebrafish larvae that underwent 
the in vivo assay of gut function using fluorescent pellets. 5-6 hours after feeding, larvae 
were assessed under the fluorescent stereo microscope, and larvae that were filled with 
fluorescent pellet were selected to be used. To embed these larvae, low melting agarose 
was (Bio-Rad) diluted in embryo E3 buffer to make 1% low melting agarose embedding 
solution. The larvae were embedded, and viewed using the Leica SP5 upright confocal 
microscope with 20x water lens (Leica, Wetzlar, Germany). Standard parameters were 
then set to perform a time lapse recording at 15-20 minutes interval, for the total duration 
of 9 hours. Results were analysed with Fiji software (Schindelin, Arganda-Carreras et al. 
2012).  
 We applied these assays in three groups, including wildtype, heterozygous 
mutant and homozygous mutant ttc7a zebrafish larvae. 
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Results
Patients Information
Patient 1 was a male infant who, born at an estimate 35-weeks of gestation. Both parents 
are Dutch, and believed to be non-consanguineous. During pregnancy, polyhydramnios 
was identified, and ultrasonography suggested multiple dilated bowel loops. Thus, the 
child was immediately admitted to the paediatric surgery intensive care unit after birth. 
Physical examination acknowledged no signs of major abnormalities. However, evaluation 
by plain abdominal X-ray showed multiple fluid levels. Consequently, either jejunal or ileal 
atresia was suspected.  
 Explorative laparotomy was performed. The entire small intestine looked 
macroscopically normal, without any evidence of a disconnected intestinal tube or a 
mesenteric defect. However, Further exploration revealed a duodenal web. This was 
resected and the duodenum was subsequently closed. Intestinal lumen was atretic from 
the duodenal region that was attached to the Treitz ligament, until 5 cm prior the end 
of distal ileum, where a considerably normal lumen was observed. Other atretic sites at 
the caecum and the flexura lienalis were revealed. Microcolon appearance was identitied 
at the descending colon. After surgery, he received total parenteral nutrition (TPN) and 
ventilation. He was considered for bone marrow and intestinal transplantation, but the 
disease progressed thus his condition quickly deteriorated. The patient died at an age of 
40 days.
 The second patient was the younger female sibling of the first patient. She was 
born at an estimate 35 weeks and 5 days of gestation. Clinical signs and operative findings 
were identical to her late brother. After being informed of the operative findings, the parents 
opted not to continue her treatment. 
Table 1: Hematologic evaluation of lymphocyte counts  
Cell type Value (x109/l)
Patient 1 Patient 2 Normal range
Lymphocyte 1.09 4.45 0.7-7.3
B-lymphocyte 0.16 0.98 0.4-1.1
T-lymphocyte 0.50 2.54 0.6-5.0
CD4+ T-lymphocyte 0.35 2.23 0.4-3.5
CD8+ T-lymphocyte 0.03 0.18 0.2-1.9
HLA-DR+ T-lymphocyte 0..02 <0.01 0.03-0.4
Natural killer (NK) cell 0.17 0.71 0.1-1.9
 
In both patients, measurement of lymphocyte subpopulations revealed that CD8+ 
T-lymphocytes (cytotoxic T-cells) and HLA-DR+ T-lymphocytes were lower than normal 
(Table 1).   
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Homozygous deletion of exon 2 of TTC7A in 2 sibs with HMIA
Sanger sequencing identified a homozygous deletion of 13.123 bp from intron 1 until intron 
2 (g.47.169.356_47.182.479del), including the entire length of exon 2 (Fig. 1).  
Fig. 1: (A-B) Pedigree of the studied family, with their Sanger Sequencing results showing homozygous 
deletion in the siblings with HMIA. (C) Schematic illustration of all the reported variants in TTC7A, 
with red arrows indicate variants found in HMIA, while black arrows indicate variants identified in 
inflammatory bowel disease.
Patients’ atretic intestine featured multiple lumen without abnormalities in other 
major cellular constituents of the gut
H&E stainings of the atretic intestine revealed multiple lumen with focal villous atrophy, 
crypts loss and increased number of apoptotic cells. By ACTA2 stainings, we acknowledged 
that half of the lumens have their own individual muscularis mucosa, while the other 
half does not. Surrounding them all, there was a common muscularis propria, including 
circular and longitudinal mucosa. Similarly, CD117 staining also showed the presences of 
interstitial cells of Cajal between circular and longitudinal muscles. The myenteric plexus 
in the patients’ intestine looked normal. Hence, other than abnormal intestinal lumens and 
mucosa, we could not detect any other cellular abnormalities in the patients’ intestine (Fig. 
2A-L).      
The intestinal lumen in homozygous ttc7a mutant zebrafish is significantly narrowed 
Macroscopically, homozygous ttc7a mutant zebrafish looked identical to wildtype zebrafish. 
H&E staining in wt ttc7a larvae (n=5) and mutant ttc7a larvae (n=5) at 5 dpf identified a 
narrowing of the intestinal lumen in homozygous ttc7a mutant zebrafish throughout the 
intestine (Fig. 3A-M). Apart from the mucosa in the intestinal bulb, the intestinal mucosa at 
the other parts of the intestine are flattened. In 4 out of 5 mutant larvae, intestinal stenosis 
was found at 1 segment of the intestine (Fig. 3K). None of the observed wt larvae acquired 
this phenotype.   
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Fig. 2: Immunohistochemistry in age-matched control and patients’ intestine. (A-L) 
Immunohistochemistry performed in intestinal material obtained from two HMIA patients, P1 and P2, 
and an age matched control. Apart from the phenotype of multiple lumen in patients’ atretic intestine 
No significant changes were detected in any cellular constituents of the intestine of MMIHS patients, 
shown by immunohistochemistry for ACTA2, c-Kit/CD117 and Neurofilament.
Gastrointestinal transit time in ttc7a mutant zebrafish was significantly longer 
compared towildtype and heterozygous fish
Results from the motility assays assays (Fig. 4A). showed that as many as 45,6% (n=57) 
of the homozygous mutant ttc7a larvae did not completely passed the fluorescence 
Fig. 3: Macroscopy and histology of wildtype and ttc7a homozygous mutant. (A and G) 
Macroscopically, there is no noticeable different between the wt and ttc7a mutant fishes at 5 dpf. 
Histologically, the intestinal lumen in ttc7a mutant fishes is narrowed, and the mucosa is flattened 
when compared with the intestine in wt fishes.  
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pellets within 24 hours, compared to 37,5% (n=27) in wt ttc7a larvae and 37,8% (n=140) 
in heterozygous mutant ttc7a larvae. These differences are statistically significant 
(P<0,00006; Chi2 test), showing a slower gastrointestinal transit time in homozygous 
mutant ttc7a zebrafish (Fig. 4B-C).
Intravital fluorescence microscopy time lapse imaging revealed segmental defects 
in the intestine that delays food passage in homozygous mutant ttc7a zebrafish  
Time-lapse movies show that the affected intestinal segment prevents the food to pass. 
Discussion
In this study, we identified a homozygous deletion of the entire exon 2 in TTC7A in 2 
siblings that were diagnosed with HMIA and immunodeficiency. This result is in line with 
the findings from other groups where different variants in the same gene were found 
in patients with identical conditions(Chen, Giliani et al. 2013, Samuels, Majewski et al. 
2013). Thus, this confirms TTC7A as the disease-causing gene in patients with HMIA and 
immunodeficiency. 
Fig. 4: Gastrointestinal transit assays in wildtype, heterozygous and homozygous ttc7a 
knockout fishes at 7 dpf. (A) Fishes that have its intestinal bulb filled with fluorescence pellet were 
included in the assays. (B-C) Compared with wildtype and heterozygous fishes, the tt7a homozygous 
mutant fishes show slower gastrointestinal transit time.  
 Subsequently, we analysed intestinal specimens from both siblings with HMIA. 
H&E and antibodies stainings were performed against neurofilaments, interstitial cells of 
Cajal and smooth muscle cells. Apart from the multiple lumen phenotype, no other cellular 
abnormalities are seen, suggesting that the intestinal phenotype in HMIA is solely because 
of the failure of intestinal lumen formation, and not causing any abnormalities in other 
major cellular constituents of the gut. The mechanism on how the variants in TTC7A lead 
to this phenotype is only partly understood. 
 Bigorgne et al. and Yavitzur et al. respectively showed that loss of TTC7A leads 
to abnormal polarity and loss of cellular adhesion (Avitzur, Guo et al. 2014, Bigorgne, 
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Farin et al. 2014). Furthermore, by using Rho kinase (ROCK) inhibitor, the abnormal 
polarity in patient-derived intestinal organoids was reversed to normal, suggesting that the 
function of TTC7A in humans serves as an endogenous ROCK inhibitor (Bigorgne, Farin 
et al. 2014). Interestingly, the experiment that was used to show the abnormal polarity 
in HMIA patient-derived intestinal organoids was also used to test the polarity in IBD 
patient-derived intestinal organoids (Louw and Barnard 1955). The authors show that the 
abnormal polarity in IBD patient-derived intestinal organoids are also reversible by the 
addition of ROCK inhibitor. The question of how the same molecular mechanism may lead 
to these two different diseases is yet unanswered.  
 Meanwhile, Yavitzur et al. showed that human TTC7A also plays an important 
role in the translocation of Phosphatidylinositol-4 Kinase (Pi4K) to the plasma membrane, 
in order to phosphorylate Phosphatidylinositol (Pi) (Avitzur, Guo et al. 2014). The level 
of phophorylated Pi has been suggested as an important molecule in the maintenance 
of cellular polarity and survival. How to link both these processes to the function of the 
gene remains largely unknown. As the name implied, TTC7A is a protein consisting of 
9 tetratricopeptide repeat regions (TPR), each is formed by a sequence of 33-37 amino 
acids. In mouse, an ortholog of human TTC7A, referred to as Ttc7, is known to play an 
important role in normal iron homeostasis (White, McNulty et al. 2005). Whether iron 
homeostatis plays a role in gthese processes is yet unknown. 
 Animals models may help further in our understanding on how this protein is 
involved in the disease and in these cellular processes. Two mouse models already exist 
for Ttc7a. The first model is called hea, it has a deletion of the exons 1-14. It is called 
hea as it is a model for hereditary erythroblastic anemia (White, McNulty et al. 2005, 
Kasahara, Shimizu et al. 2008). The second mouse model is called fsn, it has a insertion 
of 183 bp between exon 14 and exon 15. It is called fsn as it is a model for flaky skin 
(Sundberg, Dunstan et al. 1994, Beamer, Pelsue et al. 1995, Helms, Pelsue et al. 2005, 
White, McNulty et al. 2005, Takabayashi, Iwashita et al. 2007). Both models suffer from 
anemia. Additonally, the fsn mice model, also acquire psoriasiform dermatitis, hence it 
has been known as the mouse model for human psoriasis. The mechanism that leads to 
the differences between each Ttc7 mutant mouse model is yet unknown. Nevertheless, 
except a decrease in the absorption of iron from intestinal lumen, none of the Ttc7 mutant 
mice show any signs of abnormal intestine.
 Unfortunately, the use of Ttc7 knockout mice to study the disease in more detail 
proved difficult as a species-specific function of TTC7A in human and mice seems to exist. 
Hence, another animal model that might have a more similarities with human is needed to 
further investigate the disease mechanism of HMIA.   
 Zebrafish (Danio rerio) has long been used in intestinal-related research due to 
the similarities in its gastrointestinal system with mammals, including humans. Similar with 
human intestine, zebrafish intestine is also formed by intestinal epithelium, smooth muscle 
cells and neurons (Wallace and Pack 2003, Wallace, Akhter et al. 2005). Moreover, the 
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failure of a single intestinal lumen formation in zebrafish that resulted in multiple lumen has 
also been reported (Bagnat, Cheung et al. 2007). For this reason, we opted to generate 
a ttc7a mutant zebrafish model. We could not identify multiple lumens in the intestine of 
ttc7a homozygous mutant zebrafish, however, the diameter of the intestinal lumen in the 
mutant fish is significantly narrowed. This indicates that ttc7a plays an important role in 
the intestinal lumen formation of zebrafish. When these mutant fishes underwent transit 
assays, live imaging shows that the narrowed intestinal lumen causes a slower intestinal 
transit time. Altogether, we conclude that zebrafish is an interesting animal model to study 
the intestinal lumen formation, and might shed light on the disease mechanism of HMIA.
 Our zebrafish model might give answers the question whether there are more 
intestinal abnormalities than the narrowing of the lumen, such as abnormal digestion and/
or absorption of the intestine. Moreover, the question on how the TTC7A variants could 
lead to immunodeficiency, and whether the abnormal immune system is somehow related 
to the intestinal phenotype might be answered.  
Acknowledgements: The authors would like to thank all the patients and families involved 
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Supplementary table 1: List of primers used in this study  
Primer Sequence
Sequencing forward in exon 1 Human TTC7A CCGGGTCTCCACTTCTTGG
Sequencing reverse in exon 1 Human TTC7A GCAAAAGCCGTTTCTCTTCC
Sequencing forward in exon 2 Human TTC7A GGGAACTCTGTCTTCCCAACC
Sequencing reverse in exon 2 Human TTC7A AGGGAGGACTGGACAGATGC
Sequencing forward in exon 3 Human TTC7A GGAGGAGGGGAGTTCTGAGC
Sequencing reverse in exon 3 Human TTC7A CGGCATCCACCTTAGACACC
Sequencing forward in exon 4 Human TTC7A GGGTGATGCACTGTGATTCC
Sequencing reverse in exon 4 Human TTC7A TCTTTGGGGGACAGAGAAGG
Sequencing forward in exon 5 Human TTC7A GTTGGATGGGGAGAGAATGC
Sequencing reverse in exon 5 Human TTC7A GTTCCCACCAATCCTCTTGG
Sequencing forward in exon 6 Human TTC7A AGTCTGACACCAGCCCAAGG
Sequencing reverse in exon 6 Human TTC7A CTCCCACCAAAGCTGACTCC
Sequencing forward in exon 7 Human TTC7A GGCAGATTTAGCTGGGATGG
Sequencing reverse in exon 7 Human TTC7A GGCTCCTGCTGAGACTGAGG
Sequencing forward in exon 8 Human TTC7A CTGTAGCCAACCAGCAGAGC
Sequencing reverse in exon 8 Human TTC7A CCCTGGGAGACAGAGTTTGG
Sequencing forward in exon 9 Human TTC7A GCTTGACCCCTCAGAACTGC
Sequencing reverse in exon 9 Human TTC7A GGTGGAGAAGGGACAAATGG
Sequencing forward in exon 10 Human TTC7A TGAACTGAGGGCCTGAGAGG
Sequencing reverse in exon 10 Human TTC7A ACCAGCGGCAGGATAATACC
Sequencing forward in exon 11 Human TTC7A TTGAATTCCTTGGGGAGACC
Sequencing reverse in exon 11 Human TTC7A CATGCACCCACACATACACG
Sequencing forward in exon 12 Human TTC7A CTTGGGTTCATGCTCTCAGC
Sequencing reverse in exon 12 Human TTC7A TGGTGTCTATGGAGGCATGG
Sequencing forward in exon 13 Human TTC7A GTATGTGGCCAGGCAGAGG
Sequencing reverse in exon 13 Human TTC7A TGTGAATCTGCCACCAAAGG
Sequencing forward in exon 14 Human TTC7A GCCCCTACCTCAGTGAGTGC
Sequencing reverse in exon 14 Human TTC7A CTTGCAGAGGGTCACACAGC
Sequencing forward in exon 15 Human TTC7A TGAGTGCCCTTGTTGACTGG
Sequencing reverse in exon 15 Human TTC7A GTCCTCACCCCTGTCTCTCC
Sequencing forward in exon 16 Human TTC7A TGGAGTGCTTCATGCTTTGG
Sequencing reverse in exon 16 Human TTC7A ACCCAGCTGTGGATTGTTGC
Sequencing forward in exon 17 Human TTC7A GTGAGGCTGTCCCATTCTCC
Sequencing reverse in exon 17 Human TTC7A CTCTTTCTTCACCCCCATGC
Sequencing forward in exon 18 Human TTC7A TGTGGACCTCTGACCACTGC
Sequencing reverse in exon 18 Human TTC7A GGACCTCCAATCCTCTCACG
Sequencing forward in exon 19 Human TTC7A GACTCCCCACCACTCACACC
Sequencing reverse in exon 19 Human TTC7A CAACAGAGCAGGAGGGAAGC
Sequencing forward in exon 20 Human TTC7A CTACTCACCCTGCCCTGTGC
Sequencing reverse in exon 20 Human TTC7A TCACCACAAAACTCTCCAAAGG
Long range PCR sequencing forward in exon 1 
Human TTC7A
CAGAGGCGGAGGTTGCTCCTGTACG
Long range PCR sequencing reverse in exon 3 
Human TTC7A
TCACCACAAAACTCTCCAAAGG
Sequencing reverse in intron 1 Human TTC7A CCGCGAGAGAAAAATCACAT
Sequencing reverse in intron 2 Human TTC7A AGAGGCATTGGAGGAGTTCA
Sequencing forward in intron 2 Zebrafish ttc7a GTTCCAGTCCTCCTTCTTCAG
Sequencing reverse in intron 3 Zebrafish ttc7a CTTTGCTCCCCAAACGAGCTTCTC
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Intestinal obstruction is one of the problems in neonates that requires surgery and 
intensive treatment (Hajivassiliou 2003). In many cases, surgical and post-operative 
care is sufficient. However, in some cases, current treatments are unable to correct 
the anatomical and functional defects of the intestine (Georgeson and Breaux 1992, 
Sondheimer, Cadnapaphornchai et al. 1998, Spencer, Neaga et al. 2005, Wales, de Silva 
et al. 2005). 
 For example, in patients who are diagnosed with megacystis microcolon 
intestinal hypoperistalsis syndrome (MMIHS), surgical resection of the defected intestine 
and bladder catheterization is not sufficient to repair the functional contractility of the 
visceral organs (Soh, Fukuzawa et al. 2015). Similarly, patients with hereditary multiple IA 
(HMIA) have a very poor prognosis, despite having the atretic intestine resected (Boyd, 
Chamberlain et al. 1994, Bilodeau, Prasil et al. 2004). Meanwhile, although the intestinal 
length of many elderly CSBS patients is more than 50 cm, most of these patients never 
regain normal intestinal length and function. 
 The mechanisms of how these diseases can be lethal were far from clear. 
Consequently, the efforts to improve the treatment and prognosis of the patients have also 
been hampered by our lack of knowledge towards the disease pathogenesis. Driven by the 
facts of our limited understanding on the molecular pathogenesis of MMIHS, CSBS and 
HMIA, and the lethality of these diseases, we focused our study on these three diseases. 
In our studies, we used genetics as a way to understand disease pathogenesis. Equipped 
with state-of-art genetic methodologies and the use of genome editing tools to create 
animal models, we extended our knowledge of the molecular mechanisms behind the 
disease phenotypes.   
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS)
ACTG2 variants cause a dominant form of MMIHS
Twelve patients who were diagnosed with MMIHS, including eight sporadic cases 
and four familial cases, were genetically screened. In all sporadic cases, we identified 
heterozygous missense variants in enteric smooth muscle γ-2 (ACTG2), a gene that 
encodes one of the six actin isoforms that is preferentially expressed in enteric smooth 
muscle cells (SMC). In three patients, we confirmed that the mutations were de novo. Our 
findings are in line with reports from five other groups that described the heterozygous 
ACTG2 variants in MMIHS patients (Thorson, Diaz-Horta et al. 2014, Wangler, Gonzaga-
Jauregui et al. 2014, Tuzovic, Tang et al. 2015, Lu, Xiao et al. 2016, Matera, Rusmini et 
al. 2016). These discoveries confirmed the abnormal muscle contractile apparatus as the 
cause in most sporadic MMIHS cases. Interestingly, two heterozygous variants in ACTG2, 
including R148S and G269E, have also been identified in patients diagnosed with visceral 
myopathy (VM), a disease that resembles MMIHS, but is less severe (Lehtonen, Sipponen 
et al. 2012, Klar, Raykova et al. 2015). To date, none of the variants found in MMIHS 
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patients were ever found in VM patients, and vice versa. Hence, the correlation between 
the variants and the severity is very likely. 
 We addressed this possible genotype-phenotype correlation partly in our 
functional studies, in which we included the R148S variant as a positive control. To our 
surprise, the results from molecular dynamics simulation, collagen contractility and actin 
polymerization assays did not show any significant differences between the variants in 
MMIHS patients with R148S variant. In brief, all variants seemed to equally impair the 
function of the mutant ACTG2 protein in binding to actin filaments, thus reducing cellular 
contractility (Halim, Hofstra et al. 2016). On the other hand, patients with the R148S 
variant survive longer than MMIHS patients with other ACTG2 variants. Based on the 
survival differences, we still believe that the correlation between variants with disease 
severity does exist. We hypothesize that the similarity between the the effects of one 
ACTG2 variant with the others are due to the insensitivity of the artificial systems used 
in functional studies. In this case, an in vivo model would certainly offer a more sensitive 
approach to any differences in the variants. Moreover, generation of an animal model with 
variants in ACTG2 would also give more clues on whether the MMIHS phenotypes are due 
to the decreased of normal ACTG2 protein, or because of the dominant negative effect of 
the mutant ACTG2 protein. For example, if we can show that an animal model carrying a 
heterozygous stop variant in ACTG2 could survive, while another animal model carrying a 
heterozygous MMIHS-causing missense variants could not survive, then we can suggest 
that the MMIHS phenotype is likely because of the dominant negative effect of the mutant 
ACTG2 protein. This information is highly important as each condition requires different 
therapeutic approach that can be applicable for future therapy in patients. 
MYH11, MYLK and LMOD1 variants as the cause of the recessive form of MMIHS
At the beginning of our study in 2012, any expectations to find more than one gene in 
a rare disease such as MMIHS would have been purely speculative. Nonetheless, this 
hypothesis became highly plausible when we did not identify any rare variants in both 
ACTG2 and myosin heavy chain-11 (MYH11) in our familial cases. In one familial patient, 
we identified a homozygous nonsense variant in Leiomodin-1 (LMOD1), a gene that 
encodes an actin filament nucleator that preferentially is expressed in SMC (Nanda and 
Miano 2012, Boczkowska, Rebowski et al. 2015). Knockout of LMOD1 in mice results in a 
phenotype similar to MMIHS in human, including distension of the bladder and the stomach. 
The molecular mechanism that led to this phenotype was provided by functional studies in 
human intestinal smooth muscle cells that shows a defect in actin filament formation due 
to the knockdown of LMOD1. As LMOD1 is not only expressed by the SMC of the visceral 
organs, but is also expressed by SMC of the blood vessels, we also expected to see 
abnormalities in the blood vessels of the Lmod1 knockout mice. To our surprise, we could 
not identify any abnormalities of the blood vessels in mice lacking Lmod1. One possibility 
that may explain this phenomenon is the existence of another actin filament nucleator that 
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might have a redundant function with Lmod1 in murine vascular SMC. Previous studies 
on the mechanisms of vascular SMC migration has reported a complex comprising an 
actin filament nucleator and actin-related protein 2/3 (ARP2/3) as an important complex in 
vascular SMC migration (Kaverina, Stradal et al. 2003, Williams, San Martin et al. 2012). 
Moreover, experiments in tracheal smooth muscle also showed that ARP2/3 complex 
formation is necessary for the development of tension in tracheal smooth muscle (Zhang, 
Wu et al. 2005). It could be that this or another protein takes over the function of LMOD1. 
Nevertheless, we could not identify any abnormal bladder nor intestinal functions in the 
parents of the MMIHS patient (both carriers) nor in the heterozygous mice, suggesting that 
reduced LMOD1 expression is not sufficient to cause any abnormal phenotypes in both 
human and mice.
 In two other families, a homozygous splice site and a homozygous out-of-frame 
variant in myosin light chain kinase (MYLK) were identified, respectively. Expression 
studies showed that these variants eliminate the normal expression of MYLK in these 
patients. Together with the phenotypes in the already published smooth-muscle specific 
Mylk knockout mouse model, MYLK is convincingly proven to be a gene responsible for 
recessive MMIHS. The parents who all are carriers of the variant identified show no signs of 
bladder nor gastrointestinal problems. Interestingly, heterozygous variants in MYLK have 
been reported as the cause of familial thoracic aortic aneurysm and dissection (FTAAD) 
(Wang, Guo et al. 2010, Hannuksela, Stattin et al. 2016). Different from FTAAD patients 
without MYLK variants, aortic aneurysm and dissection of the aorta in patients with MYLK 
variants occur rapidly, without a preceding chronic dilatation of the aorta (Wang, Guo et 
al. 2010). The mechanism underlying how this disease accelerates rapidly is still unclear. 
However, this characteristic acceleration of aorta dilatation in patients with a heterozygous 
MYLK variant has given an evidence-based reason for clinicians to consider prophylactic 
surgical repair of the aorta for these patients (Milewicz and Regalado 1993).
 Whether the MYLK carriers in the two families are at risk for FTAAD is still 
unclear. Within the families, no reports were made of aneurysms or any vessel problems. 
Nonetheless, based on the identification of MYLK variants in MMIHS patients, and the 
earlier reports about the heterozygous MYLK variants as the cause of an unforeseen 
thoracic aortic aneurysm, we advised the carriers to undergo a routine medical examination. 
 In accordance with our findings, no gastrointestinal dysmotility was ever reported 
in FTAAD patients with heterozygous MYLK variants. We hypothesize that a certain 
threshold must be passed to acquire any gastrointestinal disturbances. 
          
Actin-myosin cross-bridge interaction is fundamental in the functional contractility 
of the bladder and the intestine
It has been suggested that MMIHS might well be a neuropathy. However, all four MMIHS 
disease-causing genes (ACTG2, MYH11, LMOD1, MYLK) identified so far, encode 
proteins that are involved in smooth muscle contractility. More specifically, these proteins 
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are all involved in the actomyosin cross-bridge interaction that underlies smooth muscle 
contraction. Along with other published studies on the identified MMIHS genes, our studies 
suggest that ACTG2, LMOD1, MYLK and MYH11 form key molecules in actin-myosin 
interaction in visceral SMC specifically (Figure 1).    
Fig.1: Hypothesis on the molecular mechanism of smooth muscle contraction in visceral organs
 This makes a case for clinicians and scientists to prioritize the screening of 
acto-myosin related genes whenever studying patients with MMIHS. Hence, in cases 
where genetic screening fails to identify variants in known MMIHS genes, we recommend 
searching for variants in other genes that are related to the proteins that are closely related 
to the acto-myosin interaction pathway, such as calcium channels and Calmodulin. On the 
other hand, findings of any candidate variants in unknown genes should be followed by 
functional studies linking the encoded protein with acto-myosin interaction pathway.  
 All this, of course, does not exclude the possibility that some MMIHS cases 
present with a neuropathy. However, one should exclude variants in smooth muscle-related 
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genes first before looking at any possible variants in neuronal-related genes in MMIHS 
patients. Thus, in clinical setting, we suggest a genetic screening on known MMIHS genes 
and muscle-related genes, before applying a more universal genetic screening, such as 
exome sequencing, to find new candidate variants.
Information from MMIHS research may be used for genetic counseling and the 
development of future therapy for MMIHS patients
From all the histopathological analyses that we performed in this research, we concluded 
that the identified disease-causing variants did not cause any significant changes in the 
pathology of the intestine and the bladder (Halim, Hofstra et al. 2016). Thus, it seemed that 
the phenotypes found in these patients are solely due to the impaired functional contractility 
of these visceral organs. Clinically, this implies that surgery to resect the affected intestine 
and the hopes that the residual intestine would regain normal function may not considered 
to be realistic after all. Unfortunately, conventional therapy that includes long term total 
parenteral nutrition (TPN) and catheterization also come with formidable risks, such as 
recurrent sepsis and multiorgan failure(Bishay, Pichler et al. 2012, Naini and Lassman 
2012, Niel-Weise, van den Broek et al. 2012). The only available treatment to date that 
seemed to offer any possibility of survival is multivisceral transplantation (Abu-Elmagd, 
Kosmach-Park et al. 2012). Reports from Loinaz et al. and Masetti et al. described an 
acceptable rate of success in MMIHS patients that received such transplantations (Masetti, 
Rodriguez et al. 1999, Loinaz, Rodriguez et al. 2005). However, like in any other types of 
organ transplantation, the two major problems with multivisceral organ transplantation are 
the availability of donor organs and the recipient’s immune rejection (Kubal, Mangus et 
al. 2015, Mathew, Tryphonopoulos et al. 2015, Smith, Skeans et al. 2015). Thus, we can 
conclude that current therapeutic options for MMIHS patients are far from ideal. 
 Our data does, however, provide important information for genetic counseling. 
For example, so far all tested ACTG2 variants in MMIHS proved to be de novo. This lowers 
the recurrence risk on MMIHS in the next pregnancy to almost zero (~1%). For the variants 
in the three other genes, which have a recessive pattern of inheritance the recurrence risk 
on an affected child in the next pregnancy is 25%.
 As most MMIHS cases have a lethal outcome, we propose to include these 
three genes in a targeted sequencing panel that might be used for genetic screening in 
consanguineous couples (Rehm 2013). When mutations are identified in both parents 
they can opt for pre-implantation genetic diagnosis, genetic profiling of embryos prior to 
implantation or they might opt for prenatal screening during early pregnancy (Mastenbroek, 
Twisk et al. 2007). 
 Another option for genetic testing might be a search for a de novo mutation in 
ACTG2 in the prenatal setting, upon an MMIHS-suggestive ultrasonography. Identification 
of a de novo ACTG2 variant would provide a reliable foundation to distinguish MMIHS from 
other diseases that have similar prenatal findings, but are less severe than MMIHS, such 
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as prune belly syndrome and visceral myopathy (Fisk, Dhillon et al. 1990, Ghavamian, 
Wilcox et al. 1997, Cromie, Lee et al. 2001). This will enable the parents to consider 
pregnancy termination more carefully.
 Significant development in genome targeting techniques have been made, making 
gene therapy the technology to eventually correct any genetic diseases (Naldini 2015), 
including MMIHS. Even though this approach might seem plausible, several limitations 
must first be solved, such as the efficiency of genetic corrections in living tissues and the 
length of time needed to obtain any beneficial effects (Ginn, Alexander et al. 2013). 
 As mentioned earlier, it is also possible that the ACTG2 variants lead to MMIHS 
in a dominant negative manner. Even though this hypothesis is yet to be proven through 
the creation of an animal model, if this can be confirmed, then another possible method 
that may have a therapeutic potentials is antisense oligonucleotides (Bennett and Swayze 
2010, Kole, Krainer et al. 2012). By designing a specific oligonucleotide against the mutant 
mRNA, we may prevent the translation of mutant protein and rescue the phenotypes. 
Nevertheless, any treatments for these patients must have an immediate effect before 
disease progression becomes irreversible. 
Congenital Short Bowel Syndrome (CSBS)
CLMP and FLNA are the disease-causing genes of CSBS, and losing any of the two 
might cause more than just a shortened intestine
In agreement with the earlier report from our group (Van Der Werf, Wabbersen et al. 2012), 
we identified CLMP variants in three additional CSBS patients from two independent 
families. In two of the three patients, intestinal dysmotility was reported (Alves, Halim et 
al. 2016). Unfortunately, intestinal specimens were not available, hence no pathological 
analysis was performed. Extensive analyses of the pathology of the intestine of CSBS 
patients with CLMP variants may give an answer to the question whether the intestinal 
dysmotility is related to the loss of CLMP itself. Thus, a (conditional) knock-out animal 
model of CLMP might be informative.  
 Van der Werf et al. described FLNA mutation as the cause of X-linked CSBS 
(van der Werf, Sribudiani et al. 2013). To investigate this further, we generated a flna 
knockout zebrafish model and characterized it. Even though we could not see a reduction 
in intestinal length as dramatic as that described in CSBS patients (≥75%), we did see 
that the intestinal length in the homozygous knockout fish had shortened by approximately 
5% (P<0,05). Moreover, functional studies using a fluorescent pellet in a gastrointestinal 
transit assay, showed significant reduction of the motility rate in homozygous knockout 
fish compared to wt. This indicates that in addition to the shortening of the intestine, bowel 
motility may also be disturbed by the loss of flna. This finding seemed to agree with the 
report on FLNA mutations in five male patients with intestinal pseudo-obstruction, in which 
short bowel was also reported as a comorbidity (Kapur, Robertson et al. 2010). 
 As FLNA is expressed in SMC of the intestine, one could hypothesize that 
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muscle-related proteins play an important role in intestinal elongation. Based on mouse 
studies, Kaufman and Bard suggested that muscle contraction in the duodenum and 
the proximal jejunum plays an important role in the process of intestinal withdrawal 
into the peritoneal cavity from physiological umbilical hernia (Kaufman and Bard 1999). 
Interestingly, malrotation is always reported as a comorbidity in CSBS. Based on the finding 
of FLNA variants in CSBS patients, it is intriguing to speculate that the shortened bowel 
and malrotation in CSBS patients may be due to a common genetic entity. In addition to 
FLNA and CLMP, mutations in FOXF1 have also been reported to cause malrotation and 
congenital short bowel phenotypes in patients, supporting the hypothesis that the two 
phenotypes are linked (Stankiewicz, Sen et al. 2009). 
 So far, it is difficult to prove whether malrotation is primary or secondary to short 
bowel phenotype. It seems reasonable to hypothesize that malrotation is secondary to 
short bowel, since the reduced contraction in CSBS patients with FLNA mutations may 
disturb the movement that positions the intestine in its normal configuration at the end 
of embryogenesis. However, it can also be that malrotation causes a physical force 
that inhibits the elongation of the intestine during embryogenesis. Thus, the question of 
whether malrotation is primary or secondary to CSBS remains unanswered.
 Since the cellular mechanisms in intestinal rotation during normal embryogenesis 
in mammals are not the same with in zebrafish (Horne-Badovinac, Lin et al. 2001, Horne-
Badovinac, Rebagliati et al. 2003, Davis, Kurpios et al. 2008), as expected, we did not 
identify the occurrence of malrotation in the flna knockout zebrafish model. Therefore, 
studies in larger animal models are needed to investigate this further.    
Implications of our studies on future research to improve CSBS therapy
The fact that (acquired) short bowel syndrome patients survive much better than congenital 
short bowel syndrome patients with comparable intestinal length suggests that the length of 
the intestine may not be the only problem in CSBS patients. An intestinal transplantation to 
replace or elongate the short intestine by specific surgical procedures as bowel lengthening 
by plication of the bowel may be a therapeutic approach that might offer a more permanent 
solution. Current development in the creation of patients’ own induced pluripotent stem 
cells (iPS) gives hope on organ engineering in the near future. Results from research on 
the use of intestinal submucosa and chitosan as scaffolds are encouraging (Chen and 
Badylak 2001, Zakhem, Raghavan et al. 2012, Zakhem, Elbahrawy et al. 2015). Hence, 
the next challenge that scientists need to overcome is to combine the scaffold with all the 
cellular constituents of the intestine and the bladder, to engineer a full thickness organ that 
can be transplanted back into patients to achieve normal function. Clearly, this is yet far 
from reality. 
164
Chapter 9
Hereditary Multiple Intestinal Atresia (HMIA)
In two sibs from a consanguineous family with HMIA and severe immunodeficiency, we 
identified a homozygous deletion of 13.123 bp from intron 1 to intron 2, including the entire 
exon 2 of the tetratricopeptide repeat-7a (TTC7A) gene. It encodes a family member of the 
proteins that are characterized by the presence of tetratricopeptide repeat (TPR) domains. 
Immunohistochemistry was performed and results showed a typical sieve-like appearance 
of multiple lumens in the atretic intestine. This finding is in line with previous reports that 
described variants in TTC7A in patients with MIA and immunodeficiency (Chen, Giliani et 
al. 2013, Samuels, Majewski et al. 2013, Agarwal, Northrop et al. 2014, Bigorgne, Farin 
et al. 2014). To understand the molecular pathogenesis underlying how TTC7A mutations 
result in a MIA phenotype, Lemoine et al. and Bigorgne et al. utilized intestinal organoids 
from patients’ intestinal stem cells (Bigorgne, Farin et al. 2014, Lemoine, Pachlopnik-
Schmid et al. 2014). They observed that patients’ organoids have abnormal apicobasal 
polarity, that can be reversed by the addition of RhoA kinase (ROCK) inhibitor. Although the 
reversal of apicobasal polarity by the addition of a ROCK inhibitor seemed encouraging, 
an animal model is required to study the pathogenesis of this disease further and to test 
potential therapies. This might prove difficult as three different mouse models, all deficient 
for Ttc7, do not recapitulate the human MIA and immunodeficiency phenotypes (Helms, 
Pelsue et al. 2005, White, McNulty et al. 2005, Kasahara, Shimizu et al. 2008). Species-
specific issue may be the reason for these differences, hence an alternative animal model 
is required to study this disease further.
 An alternative animal model might be the zebrafish as it has long been used 
in intestinal research. The architecture of zebrafish intestine is similar to the intestinal 
architecture in larger mammals (Wallace, Akhter et al. 2005). Moreover, MIA-like 
phenotypes, including multiple lumens, have been observed in studies of other genes in 
zebrafish (Bagnat, Cheung et al. 2007). Hence, we opted to create a ttc7a mutant zebrafish 
model to study the pathogenesis of MIA and the physiology of intestinal recanalization.
       
Zebrafish is a reliable model to study the process of intestinal recanalization 
Although the homozygous ttc7a mutant zebrafish does not have the MIA phenotype with 
multiple intestinal lumens, histology shows that the intestinal lumen in these fish, at dpf 5, 
is dramatically narrowed when compared to wt fish. Similar to the phenotype in human, the 
intestinal villi in the ttc7a mutant fish, appeared flattened. We observed that certain parts 
of the intestine showed a severe decrease in luminal size, leaving almost no patent lumen. 
When the homozygous ttc7a mutant fish underwent a gastrointestinal transit assay using 
a fluorescent pellet, all these fish could transport and excrete the digested pellet, although 
longer time was required to complete this process. This indicates that although the size of 
the lumen is significantly decreased, the intestinal lumen is not completely blocked as one 
would expect to see in intestinal atresia. It is unclear if the size of the lumen, or whether 
abnormal contractility, cause the longer transit time in these fish. Ongoing research is 
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currently being performed to investigate the cause of the slower transit time.      
 Whether HMIA is directly related to the observed immunodeficiency, or if these 
two entities have a different molecular pathogenesis, even though they are caused by the 
same genetic defect, remain unanswered. Findings of TTC7A mutations in patients with 
immunodeficiency, without MIA may indicate that these two conditions have independent 
disease mechanisms. To study the effect of ttc7a mutations on the immune system, 
ongoing studies using crossings of ttc7a mutant fish with a T-cell specific tyrosine kinase 
(lck) reporter line that expresses GFP in their lymphocytes, are currently ongoing.  
     
Overall conclusion
In this thesis, we describe genetics and functional studies that were performed to identify 
mutations that cause three different congenital intestinal diseases: MMIHS, CSBS and 
HMIA. Our studies clearly show strategies and challenges in elucidating the pathogenesis 
of these diseases.
 Although rare diseases are often monogenic, our work on MMIHS and CSBS 
strongly suggest that we have to keep an open mind for the possibility of finding more 
than one disease-causing genes and that multiple patterns of inheritance in rare diseases 
are possible. We successfully identified mutations in three different causal genes of 
MMIHS (Chapter 2, 3 and 4). In our studies on MYLK and LMOD1, we used the genetics 
data to unravel the molecular pathogenesis of this disease. Importantly, we showed that 
by studying MMIHS pathogenesis, we obtained clues about the important molecular 
mechanism that regulates normal visceral SMC contraction.
 We managed to validate the findings of CLMP variants as the cause of recessive 
CSBS (Chapter 6). Correspondingly, we gained insights into the effect of flna depletion 
on the intestinal digestive function through a flna knockout zebrafish model (Chapter 
7).  Finally, we gained insights into the process of intestinal recanalization by creating a 
ttc7a mutant zebrafish, based on findings in HMIA patients (Chapter 8). Altogether, we 
showed that genetic research is an efficient way to advance our understanding of disease 
mechanisms and normal physiology of the gastrointestinal tract.      
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SUMMARY
Intestinal obstruction is the most common surgical emergency in neonates. Despite a 
steady increase in the prognosis of these patients, in cases where the underlying diseases 
are megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS), congenital 
short bowel syndrome (CSBS), or hereditary multiple intestinal atresia (HMIA), death 
remains as the most frequent outcome. Based on the prevalence of familial cases, these 
three congenital diseases have long been suggested to have a genetic origin. The work 
presented in this thesis consists of genetic studies, followed by functional studies to 
elucidate the aetiology of these three diseases (MMIHS, CSBS, and HMIA).  
In chapter one, we summarize what was already known of the three diseases when 
we started our studies in 2012. This includes the clinical presentation, histopathology, 
treatment, prognosis and genetics.
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS),
Chapter two describes the functional study of missense variants identified in the Enteric 
Smooth Muscle Actin γ-2 (ACTG2) gene that cause sporadic MMIHS. As implied within the 
name of the disease, patients with MMIHS have a distension of the bladder in combination 
with a decreased or absence of intestinal peristalsis in combination with microcolon, all of 
which can be identified during the neonatal period. In line with the findings of several other 
groups, we identified heterozygous variants in ACTG2 in eight sporadic MMIHS patients. 
Immunohistochemistry shows that ACTG2 is expressed in all developmental stages of 
the human intestine we examined. Interestingly, no visible abnormalities are seen in the 
intestinal histopathology of the patients we analysed. Results from molecular dynamics 
and in vitro assays indicate that mutations in ACTG2 impair its protein binding potentials 
to actin filaments, decreasing contractility. This make us speculate that these changes 
underlie the MMIHS phenotype.   
Since we could not find ACTG2 variants in the familial MMIHS patients, we hypothesised 
that another locus or loci are responsible for the incidence of familial MMIHS. Therefore, 
we performed exome sequencing and homozygosity mapping in several MMIHS patients 
from consanguineous families.
In chapter 3, we describe the identification of a homozygous nonsense mutation in the 
Leiomodin-1 (LMOD1) gene. LMOD1 encodes a protein that has been suggested to 
function as an actin filament nucleator in smooth muscle cells. To prove that LMOD1 as 
the disease-causing gene in familial MMIHS, we generated a Lmod1-KO mouse model 
and show that the phenotype in these mice is strikingly similar to MMIHS as seen in the 
patients. Mechanistic investigation using human intestinal smooth muscle cells and the 
jejunum from the Lmod1-KO mice show that the loss of LMOD1 reduces the formation of 
actin filaments. This leads to a decreased contractility, and might cause the inability of the 
bladder and the intestine to excrete metabolic products.
Despite this finding, the genetic aetiology in three patients from two separate consanguineous 
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families remained unidentified. Thus we analysed exome and homozygosity mapping 
data from these three patients, and we identified homozygous deleterious variants in the 
myosin light chain kinase (MYLK) gene in both family, including a duplication of seven base 
pairs in exon 22 in one family, and a splice variant in intron 22 in the other family; these 
are described in chapter 4. MYLK encodes a protein that phosphorylates the regulatory 
myosin light chain. This phosphorylation reaction causes thick myosin filaments to interact 
with thin actin filaments, a process that underlies contraction in muscle cells. Therefore, 
loss of MYLK likely disrupts this fundamental mechanism, and cause MMIHS in these 
patients. Data from a published smooth muscle-specific Mylk-KO mouse model show a 
similar phenotype shared between mouse and human, supporting our hypothesis that 
MYLK is indeed another gene that can cause a recessive form of MMIHS. These findings 
prove that MMIHS is a heterogeneous disease with multiple patterns of inheritance.    
Congenital Short Bowel Syndrome (CSBS) 
Patients who are diagnosed with CSBS are born with a short small intestine, which is 
approximately ≥75% shorter than the small intestinal length in normal neonates. Recently, 
our group identified two genes related to CSBS: coxsackie- and adenovirus receptor-
like membrane protein (CLMP) and filamin A (FLNA). CLMP is a membrane protein that 
has been suggested to play a role in the tight junction complex, while FLNA is known to 
regulate the cross link of actin filaments in the cytoplasm. In chapter 5, we provide an 
overview of the literature on CSBS, including the latest clinical and genetic findings. We 
speculate on how the recent genetic data could influence our understanding towards the 
CSBS pathogenesis. 
Since the original publication of CLMP as the CSBS gene, no publications have reported 
other CLMP variants in CSBS patients. We describe the identification of three novel variants 
in three CSBS patients in chapter 6. In two siblings, a homozygous nonsense variant in 
exon 4 was identified [c.508C>T; p.(R170*)]. Meanwhile, compound heterozygous variants 
consisting of a missense variant in exon 4 [c.410G>A; p.(C137Y)] and a splice variant in 
intron 2 (c.29-2A>G) were identified in another patient. Functional studies using Chinese 
hamster ovary (CHO-K1) cells shows that the missense variant impairs the expression of 
CLMP in the tight junction complex. 
To further understand how the identified FLNA variant in CSBS patients lead to the 
shortened intestine, we generated and characterised a transgenic zebrafish with an 
out of frame mutation, a mutation comparable to the mutations found in CSBC, in flna. 
The findings are described in chapter 7. Even though the shortening of the flna mutant 
zebrafish intestine is not as dramatic as found in CSBS patients, the shortening remains 
significant, suggesting a conserved function of FLNA in the elongation of the intestine. 
Furthermore, results from gastrointestinal transit (GIT) assay shows that mutant flna fish 
require a longer GIT time, indicating that the intestine is not only shortened, but also less 
motile in these mutant fishes.
174
Appendix
Hereditary multiple intestinal atresia (HMIA)
HMIA is a familial form of multiple intestinal atresia that often comorbids with 
immunodeficiency. To date, death is an almost certain outcome in patients who are 
diagnosed with this disease. Similar to findings of other groups, we identified a variant 
in Tetratricopeptide-7A (TTC7A) in 2 siblings who were diagnosed with HMIA and 
immunodeficiency. To further investigate the effect of TTC7A loss in the intestinal phenotype, 
we generated and characterized a transgenic ttc7a mutant zebrafish and described our 
findings in chapter 8. Despite macroscopically similar with wildtype zebrafish, the histology 
of the tt7a mutants shows dramatic narrowing of the intestinal lumen, suggesting the loss 
of ttc7a in zebrafish disrupts intestinal lumen formation. Furthermore, GIT time in mutant 
fishes is longer than in WT fish indicating that the narrowing of the lumen affects motility. 
Altogether, our data suggest that the ttc7a mutant zebrafish is a good model to further 
study the pathogenesis of HMIA and of intestinal lumen formation.  
Lastly, in chapter 8, we discuss how all of the above-mentioned findings affect our 
understanding towards the disease pathogenesis and physiology of the intestine. 
Furthermore, we speculate on how further research might be directed to improve our 
understanding of these diseases.   
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SAMENVATTING 
Voor een kinderchirurg is intestinale obstructie de meest geziene aandoening bij 
pasgeborenen. Ondanks het feit dat de prognose voor deze patiëntjes steeds beter 
wordt is de kans op overleven vrijwel nihil voor baby’s met het ‘Megacystis Microcolon 
Intestinale Hypoperistalsis Syndroom’ (MMIHS), met aangeboren korte darmsyndroom 
(gemeenschappelijke basisbeginselen) of met erfelijke meerdere intestinale atresieën 
(HMIA). Omdat bij deze drie ziektebeelden familiale gevallen voorkomen wordt al langere tijd 
gesuggereerd dat de ziekte aangeboren moet zijn, dus erfelijk. Het werk zoals beschreven 
in dit proefschrift bestaat uit genetische studies, gevolgd door functionele studies, die 
allemaal tot doel hebben de etiologie van deze drie ziekten (MMIHS, gemeenschappelijke 
basisbeginselen en HMIA) beter te leren begrijpen.
In hoofdstuk één vatten we samen wat al bekend was over deze drie ziekten toen 
we in 2012 aan onze studies begonnen. We bespreken de klinische symptomen, de 
histopathologie, de behandeling, de prognose en de genetica.
 
Megacystis Microcolon Intestinale Hypoperistalse Syndroom (MMIHS) 
Hoofdstuk twee beschrijft een aantal (functionele) onderzoeken die we hebben gedaan 
naar de gevonden aminozuurveranderingen (missense varianten) in het ACTG2 gen. 
Deze mutaties werden gevonden in sporadische MMIHS patiënten. Zoals de naam al 
impliceert hebben patiënten met MMIHS een uitzetting van de blaas, in combinatie met 
een verminderde of afwezige darmperistaltiek, en een microcolon. Al deze symptomen 
kunnen worden geïdentificeerd in de neonatale periode. In lijn met de bevindingen van 
een aantal andere groepen, identificeerden we heterozygote varianten in het ACTG2 gen 
in acht sporadische MMIHS patiënten. Immunohistochemie toont aan dat het ACTG2 
gen tot expressie komt in alle ontwikkelingsstadia van de menselijke darm die we 
hebben onderzocht. Het gen lijkt dus cruciaal voor de ontwikkelende darm. Interessant 
is dat er geen zichtbare afwijkingen konden worden waargenomen in de darmbiopsies 
van de onderzochte MMIHS patiënten. De resultaten van moleculaire dynamica en de 
uitgevoerde in vitro testen tonen aan dat de mutaties in het ACTG2 gen resulteren in het 
minder goed binden van het afwijkende ACTG2 eiwit aan actine filamenten. Ook konden 
we laten zien dat de mutaties zorgen voor minder contractiliteit. Dit bevestigt ons idee dat 
deze veranderingen ten grondslag liggen aan het MMIHS fenotype.
Aangezien we geen ACTG2 varianten konden vinden in de familiale MMIHS patiënten, 
veronderstelden wij dat er naast het ACTG2 gen nog een ander gen of andere genen 
verantwoordelijk moeten zijn voor het optreden van familiale MMIHS. Daarom voerden we 
‘exoom sequencing’ en ‘homozygosity mapping’ uit in familiale MMIHS patiënten, meer 
specifiek in families waarin bloedverwantschap voorkomt. In hoofdstuk drie beschrijven 
we de identificatie van een homozygote stop mutatie in het Leiomodin-1 (LMOD1) gen. Het 
LMOD1 gen codeert voor een eiwit dat functioneert als een ‘actine filament nucleator’ in 
gladde spiercellen. Om te bewijzen dat LMOD1 het ziekteverwekkende gen voor familiale 
176
Appendix
MMIHS is, genereerden wij een LMOD1-KO muis en konden we laten zien dat deze muizen 
een aandoening hebben die opvallend veel lijkt op MMIHS. Mechanistisch onderzoek met 
menselijke intestinale gladde spiercellen en het jejunum van de LMOD1 KO muizen toont 
aan dat het verlies van LMOD1 de vorming van actine filamenten vermindert wat leidt tot 
een verminderde contractiliteit wat weer een verklaring kan zijn voor het onvermogen van 
de blaas en de darm om goed te functioneren.
Naast het LMOD1 gen identificeerden we ook homozygote varianten in het MYLK gen. 
We vonden een verdubbeling van zeven basenparen in exon 22 binnen één gezin, en een 
splice variant in intron 22 in een andere familie. Deze bevindingen worden beschreven 
in hoofdstuk 4. Het MYLK gen codeert voor een eiwit dat de ‘myosine lichte keten’ 
fosforyleert. Deze fosforyleringsreactie veroorzaakt een interactie tussen de ‘dikke 
myosine filamenten’ met de ‘dunne actine filamenten’, het proces dat ten grondslag ligt 
aan spiercontractiliteit. Daarom is het verlies van MYLK waarschijnlijk de oorzaak van 
MMIHS bij deze patiënten. Gegevens van een reeds beschreven ‘gladde spier-specifieke 
MYLK-KO’ muismodel met een vergelijkbaar fenotype ondersteunt onze hypothese dat 
verlies van functiemutaties in MYLK inderdaad een recessieve vorm van MMIHS kan 
veroorzaken. Deze bevindingen bewijzen verder dat MMIHS een heterogene ziekte is met 
meerdere patronen van overerving.
 
Aangeboren korte dunne darm syndroom (CSBS)
Patiënten die gediagnosticeerd zijn met CSBS worden geboren met een veel te korte 
dunne darm, en wel een dunne darm die ongeveer ≥75% korter is dan de dunne darm van 
gezonde pasgeborenen. Onlangs heeft onze groep mutaties in twee genen geïdentificeerd 
die CSBS verklaren: coxsackie- en adenovirus receptor-achtig membraaneiwit (CLMP) en 
filamin A (FLNA). CLMP is een membraaneiwit dat een rol speelt in het ‘tight junction 
complex’. FLNA is betrokken bij het verbinden van actine filamenten in het cytoplasma. In 
hoofdstuk vijf geven we een overzicht van de literatuur over CSBS, we bespreken onder 
andere de nieuwste klinische en genetische bevindingen.
Sinds de eerste publicatie over CLMP als het gen voor CSBS, zijn er geen andere 
publicaties meer verschenen over CLMP varianten in CSBS. In hoofdstuk zes 
beschrijven we de identificatie van drie nieuwe varianten in drie CSBS patiënten. We 
identificeerden een homozygote stop variant in exon 4 in één familie en we hebben 
twee heterozygote varianten gevonden in een andere patiënt (familie), te weten een 
aminozuur verandering en een splice site variant. Dat de aminozuur variant echt de 
ziekte zou kunnen veroorzaken werd bevestigd door functioneel werk in Chinese hamster 
ovarium (CHO-K1) cellen. Hieruit blijkt dat de aminozuur verandering de expressie van 
CLMP in het tight junction complex vermindert.Behalve CLMP hebben we ook mutaties 
gevonden in FLNA. Om te begrijpen hoe de geïdentificeerde FLNA variant CSBS 
veroorzaakt, hebben we een transgene zebravis gemaakt en onderzocht. Deze vis heeft 
een uit-frame mutatie, een mutatie die vergelijkbaar is met de mutaties die gevonden 
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zijn in CSBS patiënten. De resultaten van ons onderzoek zijn beschreven in hoofdstuk 
zeven. De mutante zebravis heeft net als de patiënten een verkorte darm, maar de 
verkorting is niet zo dramatisch als in CSBS. Wel laat het zien dat de functie van FLNA 
geconserveerd is tot in de zebravis. Behalve dat de darm iets korter is konden we ook 
aantonen dat de tijd dat voedsel nodig heeft om de gehele darm te passeren langer is. 
 
Erfelijke meerdere intestinale atresieën (HMIA)
HMIA is een erfelijke vorm van multiple intestinale atresie, een ziekte die vaak samen 
voorkomt met een immunodeficiëntie. Tot op heden overleden alle patiënten met 
een dergelijk ziektebeeld. Vergelijkbaar met de bevindingen van andere groepen, 
identificeerden we een variant in tetratricopeptide-7A (TTC7A) in twee kinderen uit één 
gezin die beiden met HMIA en immunodeficiëntie werden gediagnosticeerd. Om het effect 
van TTC7A verlies te onderzoeken, genereerden we een transgene TTC7A zebravis. We 
beschrijven onze bevindingen over deze zebravis in hoofdstuk acht. Ondanks dat de vis 
er macroscopisch vergelijkbaar uitziet als de wildtype zebravis, laat de histologie van de 
TTC7A mutanten een dramatische vernauwing van het darmlumen zien. Dit suggereert 
dat het verlies van TTC7A in de zebravis de intestinale lumen vorming sterk beïnvloed. 
Bovendien is de tijd die voedsel nodig heeft de darm te passeren veel langer dan die van de 
wild type vis. Dit geeft aan dat de vernauwing van het lumen de motiliteit beïnvloedt. Onze 
data suggereren dat de TTC7A mutante zebravis een goed model is voor de pathogenese 
van HMIA en voor de intestinale lumen vorming. 
Tenslotte, in hoofdstuk negen bespreken we hoe alle bovengenoemde bevindingen ons 
begrip met betrekking tot de pathogenese van de drie genoemde ziektebeelden en van de 
darm heeft veranderd. Verder speculeren we over de richting van vervolgonderzoek om 
onze kennis met betrekking tot deze ziekten nog verder te verbeteren.
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RINGKASAN
Obstruksi usus adalah masalah kesehatan yang paling sering dihadapi dalam kasus 
kegawatdaruratan pada bayi baru lahir. Meskipun prognosis pasien penderita obstruksi 
usus terus meningkat, pada kasus-kasus yang disebabkan oleh sindrom megasistis 
mikrokolon intestinal hipoperistalsis (MMIHS), sindrom kelainan kongenital usus pendek 
(CSBS), ataupun kelainan bawaan atresia usus multipel (HMIA), kematian seringkali 
menjadi hasil akhir yang sulit dihindari pada kebanyakan kasus. Berdasarkan laporan 
yang ada tentang prevalensi kasus familial dari penyakit-penyakit diatas, kelainan genetik 
telah lama diduga sebagai penyebab utama dari kondisi ini. Thesis ini memaparkan 
hasil penelitian genetik pada pasien yang didiagnosis dengan penyakit-penyakit diatas, 
yang dilanjutkan dengan investigasi mengenai fungsi dari gen-gen yang terlibat, demi 
mengungkap mekanisme terjadinya penyakit-penyakit tersebut pada pasien.   
Bab 1 memaparkan tentang hal-hal yang telah diketahui tentang ketiga penyakit bawaan 
ini sebelum dimulainya penelitian kami pada tahun 2012. Penjelasan ini mencakup tentang 
gejala klinis, hasil pemeriksaaan histopatologi, metode pengobatan yang telah ada, serta 
prognosis dan pengetahuan tentang latar belakang genetik dari ketiga penyakit ini. 
Sindrom Megasistis Mikrokolon Intestinal Hipoperistalsis (MMIHS) 
Bab 2 memaparkan tentang hasil uji fungsi mutasi missense pada gen actin otot polos 
usus γ-2 (ACTG2) yang menyebabkan kasus MMIHS sporadik. Seperti yang telah tersirat 
dalam nama sindrom ini, pasien yang didiagnosis dengan MMIHS menunjukkan gejala 
klinis yang khas, seperti distensi kandung kemih, yang disertai dengan berkurangnya 
atau hilangnya gerakan peristalsis usus, serta mikrokolon, yang kesemuanya dapat 
diidentifikasi pada masa bayi baru lahir. Sejalan dengan hasil penemuan beberapa 
grup peneliti lainnya, kami menemukan varian heterozigot pada gen ACTG2 di delapan 
kasus sporadik MMIHS. Hasil pemeriksaan immunohistochemistry menunjukkan bahwa 
ACTG2 diekspresikan di setiap tahap perkembangan usus manusia yang diikutsertakan 
dalam penelitian ini. Menariknya, kami tidak dapat mendeteksi adanya kelainan dari hasil 
pemeriksaan histopatologi usus pasien MMIHS dengan mutasi di gen ACTG2. Hasil 
pemeriksaan molekuler dinamik dan eksperimen in vitro mengindikasikan bahwa mutasi di 
gen ACTG2 yang ditemukan pada pasien MMIHS mengakibatkan penurunan kemampuan 
protein mutan ACTG2 untuk berikatan dengan filamen aktin, sehingga menurunkan 
kontraktilitas. Oleh karena itu, kami berspekulasi bahwa rentetan mekanisme inilah yang 
mengakibatkan terjadinya MMIHS pada pasien.
Mengingat kami tidak menemukan varian ACTG2 pada kasus familial MMIHS, kami 
membuat hipotesis tentang kemungkinan adanya lokus lain yang bertanggungjawab 
atas terjadinya kasus familial MMIHS. Untuk itu, kami menerapkan metode pemeriksaan 
genetika terbaru, yaitu exome sequencing dan pemetaan homozigot, pada beberapa 
pasien MMIHS dari orangtua yang berkerabat.
Dalam bab 3, kami mempresentasikan penemuan mutasi nonsense homozigot di gen 
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Leiomodin-1 (LMOD1). Penelitian pada protein LMOD1 sebelumnya menganjurkan bahwa 
protein ini berfungsi sebagai nukleator filamen aktin di sel otot polos. Untuk membuktikan 
bahwa LMOD1 adalah gen yang menjadi penyebab kasus familial MMIHS, kami membuat 
model tikus transgenik yang memiliki mutasi pada gen LMOD1, sehingga tidak dapat 
mengekspresikan protein LMOD1. Kami menemukan bahwa fenotipe yang dimiliki tikus 
transgenik ini sangat mirip dengan fenotipe yang diidentifikasi pada pasien MMIHS. 
Investigasi lebih lanjut tentang bagaimana mutasi di gen LMOD1 dapat menyebabkan 
MMIHS dilakukan dengan menggunakan sel otot polos usus manusia dan jejunum tikus 
transgenik tanpa ekspresi gen Lmod1. Hasil dari berbagai eksperimen menunjukkan bahwa 
berkurangnya atau hilangnya protein LMOD1 mengakibatkan turunnya pembentukan 
filamen aktin. Selanjutnya, hal ini berakibat pada menurunnya kontraktilitas, dan berujung 
pada ketidakmampuan kandung kemih dan usus untuk mengekskresikan sisa produk 
metabolisme tubuh.
 Meski kami telah menemukan mutasi di gen LMOD1 sebagai penyebab kasus 
familial MMIHS, kelainan genetika pada tiga pasien MMIHS dari dua pasang orangtua 
yang berkerabat masih belum ditemukan. Oleh karena itu, kami menganalisis hasil 
exome sequencing dan pemetaan homozigot dari ketiga pasien ini. Di ketiga pasien ini, 
kami mengidentifikasi mutasi homozigot di gen myosin light chain kinase (MYLK) yang 
mengganggu ekspresi dari gen tersebut. Pada satu keluarga, mutasi yang kami temukan 
adalah duplikasi tujuh pasang basa nukleotida di ekson 22. Di satu keluarga lainnya, kami 
menemukan varian pada splice site yang terletak di intron 22. Kesemuanya ini dijabarkan 
dalam bab 4. Protein MYLK diketahui berfungsi untuk memfosforilasi regulatory myosin 
light chain. Proses fosforilasi ini mengakibatkan rantai tebal miosin berinteraksi dengan 
rantai tipis aktin, dan menyebabkan sel otot berkontraksi. Oleh karena itu, hilangnya 
ekspresi gen MYLK dapat mengakibatkan terganggunya proses fundamental ini, dan 
berujung pada didapatkannya MMIHS di ketiga pasien ini. Dari informasi yang telah ada 
tentang tikus transgenik yang kehilangan ekspresi gen Mylk, kami mengetahui bahwa tikus 
yang kehilangan ekspresi gen ini memiliki fenotipe yang menyerupai MMIHS pada pasien. 
Berdasarkan hal ini, maka kami menyimpulkan bahwa selain LMOD1, MYLK adalah 
gen yang juga berkaitan dengan terjadinya MMIHS pada pasien, dan diturunkan secara 
resesif. Penemuan ini juga membuktikan bahwa MMIHS adalah penyakit heterogen yang 
diturunkan dengan pola genetika yang beragam.     
Sindrom Kelainan Kongenital Usus Pendek (CSBS)
Pasien yang didiagnosis dengan CSBS dilahirkan dengan panjang usus halus yang jauh 
lebih pendek dibandingkan panjangnya usus halus pada bayi normal, yaitu sekitar ≥75% 
lebih pendek. Baru-baru ini, grup kami mempublikasikan penemuan dua gen yang terkait 
dengan CSBS, yaitu coxsackie- and adenovirus receptor-like membrane protein (CLMP) 
dan filamin A (FLNA). CLMP adalah protein yang berperan dalam pembentukan struktur 
sambungan erat (tight junction) antar sel, sedangkan FLNA telah diketahui memiliki 
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fungsi dalam mengatur pola filamen aktin yang saling bersilangan di sitoplasma sel. 
Dalam bab 5, kami menyajikan studi pustaka yang telah ada mengenai CSBS, termasuk 
perkembangan terkini dalam bidang klinis dan penemuan genetika. Kami berspekulasi 
tentang bagaimana penemuan genetika terbaru ini akan mempengaruhi pemahaman kita 
mengenai mekanisme terjadinya CSBS pada pasien. 
Di tahun 2012, sejak dipublikasikannya CLMP sebagai gen yang bertanggungjawab atas 
terjadinya CSBS pada pasien, belum ada publikasi yang melaporkan varian lainnya di gen 
CLMP dari pasien CSBS. Dalam bab 6, kami memaparkan penemuan tiga varian baru 
di gen CLMP pada tiga pasien yang didiagnosis dengan CSBS. Pada dua pasien yang 
merupakan saudara kandung, kami mengidentifikasi satu varian homozigot nonsense di 
exon 4 [c.508C>T; p.(R170*)]. Selain itu, kami juga menemukan 2 varian CLMP lainnya 
pada seorang pasien CSBS, termasuk varian missense di exon 4 [c.410G>A; p.(C137Y)], 
dan varian pada splice site di intron 2 (c.29-2A>G). Uji fungsi dari varian missense dengan 
menggunakan sel ovarium hamster China (CHO-K1) menunjukkan bahwa varian ini 
merusak ekspresi protein CLMP pada struktur sambungan erat.  
Untuk memahami lebih jauh tentang mekanisme yang menjelaskan bagaimana varian 
FLNA pada pasien CSBS menyebabkan pemendekan usus, kami membuat dan 
mengkarakterisasi model ikan zebra transgenik dengan mutasi out-of-frame di gen flna. 
Hasil dari proyek penelitian ini kami presentasikan dalam bab 7. Meskipun hasil yang 
ada menunjukkan bahwa pemendekan usus pada ikan zebra transgenik tidak sebesar 
pemendekan usus pada pasien CSBS, secara statistik, pemendekan usus pada ikan 
zebra transgenik ini masih signifikan. Hal ini menandakan adanya kemiripan fungsi protein 
FLNA pada proses pemanjangan usus di manusia dan ikan zebra. Lebih lanjut, hasil 
dari uji transit usus menunjukkan bahwa ikan yang memiliki mutasi di gen flna memiliki 
waktu transit usus yang lebih lama dibandingkan dengan waktu transit usus pada ikan 
normal, mengindikasikan bahwa hilangnya protein flna pada ikan zebra bukan hanya 
mengakibatkan pemendekan usus, namun juga mengurangi motilitas usus.   
Kelainan Bawaan Atresia Usus Multipel (HMIA)
HMIA adalah tipe familial dari kasus atresia usus multipel yang seringkali disertai dengan 
defisiensi fungsi imunitas. Hingga saat ini, kematian adalah hasil akhir yang hampir pasti 
didapat pada pasien HMIA. Sejalan dengan hasil penemuan yang telah dipublikasikan 
oleh grup penelitian lainnya, kami menemukan sebuah varian di gen Tetratricopeptide-
7A (TTC7A) pada dua orang saudara kandung yang didiagnosis dengan HMIA dan 
defisiensi fungsi imunitas. Demi melakukan penyelidikan yang lebih mendalam tentang 
mekanisme terjadinya kelainan usus yang ditemukan pada pasien HMIA, kami membuat 
dan mengkarakterisasi ikan zebra transgenik yang memiliki mutasi pada gen ttc7a. Hasil 
yang kami dapatkan dalam proyek penelitian ini dipaparkan di bab 8. Meskipun secara 
kasat mata ikan mutan ttc7a tidak memiliki perbedaan signifikan dibandingkan dengan 
ikan normal, namun pemeriksaan histologi menunjukkan adanya penyempitan lumen 
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usus yang signifikan pada ikan mutan ttc7a. Penyelidikan lebih jauh terhadap fungsi usus 
dari ikan mutan ttc7a menunjukkan bahwa waktu transit usus pada ikan mutan ttc7a lebih 
lama dibandingkan dengan waktu transit usus pada ikan normal. Hal ini mengindikasikan 
bahwa hilangnya ekspresi gen ttc7a pada ikan zebra mengganggu proses pembentukan 
lumen dan motilitas usus. Berdasarkan seluruh hasil penelitian ini, kami menyimpulkan 
bahwa ikan mutan ttc7a yang kami buat adalah modalitas yang baik untuk digunakan 
dalam studi lebih lanjut tentang patogenesis HMIA dan proses pembentukan lumen usus.
    
Sebagai penutup, kami mendiskusikan bagaimana seluruh penemuan kami mempengaruhi 
pemahaman ilmiah yang ada tentang patogenesis and fisiologi usus. Lebih lanjut, kami 
berspekulasi tentang bagaimana penelitian ketiga penyakit ini di masa depan harus 
diarahkan. 

A
pp
en
di
x
183
List of Affiliations
Erasmus University Medical Center, Rotterdam, The Netherlands:
- Alan J. Burns  - Alice S. Brooks  - Bianca M. de Graaf 
- Danny Halim  - Dick Tibboel  - Erwin Brosens
- Gert-Jan Kremers - Hans J. Stoop  - Herma C. van der Linde
- Jasper Saris  - Luca Signorile  - Maria M. Alves  
- Michail Doukas   - Niels Galjart  - Rene M.H. Wijnen 
- Rhiana Garritsen - Rob M. Verdijk  - Robert M.W. Hofstra 
- Rutger W.W. Brouwer - Wilfred F.J. van IJcken - William Cheng  
- Yolande van Bever - Zakia Azmani
University Medical Center Groningen, Groningen, The Netherlands:
- Christine van der Werf - Joke B.G.M. Verheij
Hôpital Universitaire Robert Debré, Paris, France:
- Françoise Muller  - Clarisse Baumann - Jean-François Oury 
- Jonathan Rosenblatt
University of Rochester, Rochester, New York, United States:
- Christine K. Christie - Daniel Oliver  - Gen-Zheng Jin  
- Orazio J. Slivano - Joseph M. Miano - Michael Wilson  
- Vivek Nanda  - Suowen Xu  - Wei Yan 
- Yu Han
Baylor College of Medicine, Houston, Texas, United States:
- Arthur Beaudet  - Michael F. Wangler 
Stanford University, Palo Alto, California, United States:
- John Kerner
University of Washington, Seattle, Washington, United States:
- Raj Kapur
Emory University, Atlanta, Georgia, United States:
- Iain Shepherd   - Jackie Glodener
184
Appendix
Universitas Padjadjaran, Bandung, West Java, Indonesia
- Tono Djuwantono - Yunia Sribudiani
University of Padua, Padua, Italy:
- Mariagiulia Dal Cero
Uppsala University, Uppsala, Sweden:
- Niklas Dahl
University of Exeter Medical School, Exeter, United Kingdom:
- Andrew H. Crosby - Barry A. Chioza  - Emma L. Baple
- Reza Maroofian
University Hospital of Antwerp, Antwerp, Belgium:
- Els van de Vijver - Raoul Rooman  
Shahid Sadoughi University of Medical Sciences, Yazd, Iran:
- Majid Aflatoonian - Mohammadreza Dehghani 
- Mohammad YV Mehrjardi 
A
pp
en
di
x
185
List of Publications
Alves M.M., Halim D.*, Maroofian R.*, de Graaf B.M., Rooman R., van der Werf C.S., Van 
de Vijver E., Mehrjardi M.Y., Aflatoonian M., Chioza B.A., Baple E.L., Dehghani M., Crosby 
A.H., Hofstra R.M. 'Genetic screening of Congenital Short Bowel Syndrome patients 
confirms CLMP as the major gene involved in the recessive form of this disorder', Eur J 
Hum Genet. 2016 Jun. doi: 10.1038/ejhg.2016.58.
Halim D., Hofstra R.M., Signorile L., Verdijk R.M., van der Werf C.S., Sribudiani Y., 
Brouwer R.W., van IJcken W.F., Dahl N., Verheij J.B., Baumann C., Kerner J., van Bever 
Y., Galjart N., Wijnen R.M., Tibboel D., Burns A.J., Muller F., Brooks A.S., Alves M.M., 
'ACTG2 variants impair actin polymerization in sporadic Megacystis Microcolon Intestinal 
Hypoperistalsis Syndrome', Hum Mol Genet. 2016 Feb;25(3):571-83. doi: 10.1093/hmg/
ddv497.
van der Werf C.S., Halim D., Verheij JB, Alves MM, Hofstra RM. 'Congenital Short Bowel 
Syndrome: from clinical and genetic diagnosis to the molecular mechanisms involved in 
intestinal elongation', Biochim Biophys Acta. 2015 Nov;1852(11):2352-61. doi: 10.1016/j.
bbadis.2015.08.007.
Chhipa R.R.*, Halim D.*, Cheng J., Zhang H.Y., Mohler J.L., Ip C., Wu Y. 'The Direct 
Inhibitory Effect of Dutasteride or Finasteride on Androgen Receptor Activity is Cell Line 
Specific'. Prostate. 2013 Oct;73(14):1483-94. doi: 10.1002/pros.22696.
Djuwantono T., Wirakusumah F.F., Achmad T.H., Sandra F., Halim D., Faried A. 'A 
Comparison of Cryopreservation Methods: Slow Cooling vs Rapid Cooling Based 
on Cell Viability, Oxidative Stress, Apoptosis and CD34+ Enumeration of Human 
Umbilical Cord Blood Mononucleated Cells', BMC Res Notes. 2011 Sep;4:371. doi: 
10.1186/1756-0500-4-371.
186
Appendix
Curriculum Vitae
Danny Halim
Pasirluyu VI No.11
Bandung 40254
Indonesia
Phone : +62-22-5223364
dannyhalim@gmail.com
Date of Birth: June 25, 1983
Place of Birth: Bandung, West Java, Indonesia
  
Educations
 2012 - Present: Erasmus Medical Center, Rotterdam, the Netherlands 
•	 PhD student at the Department of Clinical Genetics.
2006 – 2008: Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
•	 Clinical Clerkship
2001 – 2006: Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
•	 Bachelor in Medical Sciences.
•	 Thesis-research in Department of Pharmacy: “The Effect of Ethanol 
Extract of Phaleria macrocarpa on Viability of Leukemia Cell Line 
L1210”, under the supervision of Dr. Ajeng Diantini.
Professional experiences
May 2012-December 2016: Erasmus Medical Center, Rotterdam, The Netherlands
•	 PhD Study in the Department of Clinical Genetics, research project: Genetics 
and Pathogenesis of Congenital Diseases of The Intestine, under the 
supervision of Prof. dr. Robert MW Hofstra ; Prof. dr. Dick Tibboel ; Dr. Alan 
J. Burns.
2011-2012: Roswell Park Cancer Institute, Buffalo, New York, United States
•	 Postgraduate Training in the Department of Cancer Prevention and Control, 
research project: Translational Research of Finasteride and Dutasteride on 
the Prevention of Prostate Cancer, under the supervision of Prof. dr. Clement 
Ip and Dr. Yue Wu.
2009-2010: Stem Cell Research Working Group, Faculty of Medicine, Universitas 
Padjadjaran, Bandung, Indonesia 
•	 As a research staff in collaboration with Stem Cell and Cancer Institute, 
Jakarta, Indonesia, working on “A Comparison of Cryopreservation 
Methods: Slow-Cooling vs Rapid-Cooling Based on Cell Viability, Oxidative 
Stress, Apoptosis and CD34+ Enumeration of Human Umbilical Cord Blood 
A
pp
en
di
x
187
Curriculum Vitae
Mononucleated Cells”, (8 months) under the supervision of Dr. Ferry Sandra 
and Dr. Tono Djuwantono.  
2007-2008: Promedika (Healthcare Management Consulting and Training Services, 
Bandung, Indonesia
•	 As a junior consultant in the project to formulate a strategic plan on how to 
transform RSPI Sulianti Saroso, Jakarta to become The Indonesian Institute 
of Infectious Diseases
2004-2006: Health Research Unit,Universitas Padjadjaran, Bandung, Indonesia
•	 As an assistant in Tissue Culture laboratory in research on: 1)“The Protective 
Effect of Sargassum sp. on Ultraviolet A & B Irradiation-Mediated Oxidative 
Damage in Fibroblast Cells”, 2005-2006, under the supervision of Dr. Savitri 
Restu Wardhani and Prof. dr. Tri Hanggono Achmad; 2) “Optimation on 
Primary Culture of Fibroblast Cells Isolated from Chick Embryo and Human 
Preputium”, 2004-2005, under the supervision of Prof. dr. Tri Hanggono 
Achmad.
2004: Sanbe Farma Ltd, Bandung, Indonesia 
•	 As a research apprentice in molecular biology laboratory of Biotech and 
Research Division, research on “Mutation of P53 Gene in Patients with History 
of Familial Breast Cancer”, (3 months) under supervision of Dr. Joseph H.M. 
Hilgers, Dr. Kadarsyah and Dr. Eng. Sukma Nuswantara.
Additional Medical Training
•	 Department of Digestive Surgery, Lund Medical School, Lund University, 
Lund, Sweden, July - August 2006. 
•	 Department of Transplantation Surgery, Graz Medical University, Graz, 
Austria, October 2005.
•	 Pius Branzeu Center for Laparoscopic and Microsurgery, Timisoara, 
Romania, September 2005.
188
Appendix
PhD Portfolio
Summary of PhD training and teaching activities
Name PhD student: Danny Halim
Erasmus MC Department: Clinical Genetics
Research School: MGC
PhD period: 2012 - 2016
Promotor(s): 
Prof.dr. R.M.W Hofstra; 
Prof.dr. D. Tibboel; 
Dr. A.J. Burns 
Supervisor: Prof.dr. R.M.W Hofstra
1. PhD training
Year Workload
(ECTS)
General courses 
- Safely Working in the Laboratory
- Genetics
- Laboratory animal science
- Biochemistry and Biophysics
- Literature Course
- Cell and Developmental Biology
- Biomedical English Writing and Communication
- Research Integrity
- Statistics
2012
2012
2012
2013
2014
2014
2015
2015
2015
0,5 
3 
3 
3  
2 
3 
2 
0,5 
2 
Specific courses 
- Next Generation Sequence Data Analysis 2013 2 
Seminars and workshops
- 20th MGC PhD Workshop, Luxembourg
- 21st MGC PhD Workshop, Mϋnster
2013
2014
1 
1 
Presentations
- Oral presentation 26th International Symposium on 
Paediatric Surgical Research, Cape Town
- Oral presentation MGC PhD Workshop, Mϋnster
- Oral presentation Bandung International Biomedical 
Conference, Bandung
- Poster presentation International Enteric Nervous 
System Meeting, Rotterdam 
- Poster presentation European Society of Human 
Genetics Conference, Glasgow
- Oral presentation MGC Annual Symposium, Leiden 
2013
2014
2014
2015
2015
2016
0,5
0,5
0,5
0,25
0,25
0,5
A
pp
en
di
x
189
PhD Portfolio
(Inter)national conferences
- 26th International Symposium on Paediatric 
Surgical Research, Cape Town
- Bandung International Biomedical Conference, 
Bandung
- International Enteric Nervous System Meeting, 
Rotterdam
- European Society of Human Genetics 
Conference, Glasgow
2013
2014
2015
2015
1
1
1
1
Other
- Organizing committee 20th MGC PhD Workshop, 
Luxembourg
2013 2 
2. Teaching Year Workload (ECTS)
- Supervising international medical student 
(Mariagiulia Dal Cero from Bologna, Italy)
2014 2
- Supervising BSc student (Noor Vermeij from 
Hogeschool Rotterdam)
2014 - 
2015
2
         TOTAL ECTS: 35,5
190
Appendix
Dankwoord
First of all, thank God I will finally get this! This PhD study has been nothing less than a 
journey to me. Through countless ups and downs, lucks and challenges, happiness and 
disappointments, and hardships, this moment is finally here. And through this journey, I 
have been blessed with the presences and kindness of special people whom I would like 
to express my sincere gratitude to.
Dear Prof.dr. Hofstra, dear Robert, you have no idea how much your constant support 
and guidance meant to me. Through hours of discussions, you taught me so many things: 
not only science-related matters, but also politics and personal life. More than a good sci-
entist, you are also a wonderful human being. So many times, I and my family talked about 
how thankful we were for your help and kindness. Robert, truly, I am forever in your debt. 
I hope one day I can make you proud, Sir! Thank you!
Dear Prof.dr. Tibboel, dear Dick, thank you for being such a good mentor and a role 
model for me. Your passion and knowledge in both, clinical and research, have been an 
inspiration. You are the type of medical doctor I have been dreaming to be - excel in both 
research and clinics. I am truly honoured to be one of your students. I hope we can stay in 
touch and collaborate in the future.
Dear Dr. Burns, dear Alan, knowing you and having you as my co-promotor have been 
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dear Jean-Marie, thank you so much for every help, discussion, lesson, everything! You 
are just the best mentor! I truly learned a lot. I hope we can keep in touch, meet again 
somehow bro. All the best! Dear Dr. McCann, dear Conor, many thanks for all the help 
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I would also like to express my sincere gratitude to my good friend, Tom de Vries Lentsch. 
Tom, many thanks for your countless help in preparing the layout of this thesis. I truly en-
joyed every discussion that we had. I wish you many happiness and success, and I hope 
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Dear Mr. Lassche, dear Job, my pal, thanks for every help and for being a great friend. I 
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are very grateful to know you all, and I wish you three all the best. I hope we can stay in 
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